<SEC-DOCUMENT>0001193125-22-213583.txt : 20220805
<SEC-HEADER>0001193125-22-213583.hdr.sgml : 20220805
<ACCEPTANCE-DATETIME>20220805160607
ACCESSION NUMBER:		0001193125-22-213583
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20220915
FILED AS OF DATE:		20220805
DATE AS OF CHANGE:		20220805

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Spero Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001701108
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38266
		FILM NUMBER:		221140774

	BUSINESS ADDRESS:	
		STREET 1:		675 MASSACHUSETTS AVENUE
		STREET 2:		14TH FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		857-242-1600

	MAIL ADDRESS:	
		STREET 1:		675 MASSACHUSETTS AVENUE
		STREET 2:		14TH FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Spero Therapeutics, LLC
		DATE OF NAME CHANGE:	20170316
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>d341851ddef14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<HTML><HEAD>
<TITLE>DEF 14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Proxy
Statement Pursuant to Section&nbsp;14(a) of the </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Amendment No.&nbsp;&nbsp;&nbsp;&nbsp;) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by the
Registrant&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Filed by a Party other than the
Registrant&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="95%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Preliminary Proxy Statement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Definitive Proxy Statement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Definitive Additional Materials</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Soliciting Material Under &#167;240.14a-12</TD></TR></TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>Spero
Therapeutics, Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Registrant as Specified in its Charter) </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Person(s) Filing Proxy Statement, if other than the Registrant) </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of Filing Fee (Check the appropriate box all boxes that apply): </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">No fee required.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Fee paid previously with preliminary materials.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-1.</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g341851g50v17.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>675 Massachusetts Avenue, 14th Floor </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Cambridge, Massachusetts 02139 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">August&nbsp;5, 2022 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To Our
Stockholders: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">You are cordially invited to attend the 2022 annual meeting of stockholders of Spero Therapeutics, Inc. to
be held at 9:00 a.m. Eastern Time on Thursday, September&nbsp;15, 2022. This year&#146;s annual meeting will be conducted solely via live audio webcast on the Internet. You will be able to attend the annual meeting, vote and submit your questions
during the annual meeting by visiting www.virtualshareholdermeeting.com/SPRO2022. You will not be able to attend the annual meeting in person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Details regarding the meeting, the business to be conducted at the meeting, and information about Spero Therapeutics, Inc.
that you should consider when you vote your shares are described in this proxy statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At the annual meeting, we will
ask stockholders to (i)&nbsp;elect two people to our board of directors; (ii)&nbsp;ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December&nbsp;31, 2022; and
(iii)&nbsp;approve an amendment to our 2017 Stock Incentive Plan, as amended, to increase the total number of shares of common stock authorized for issuance thereunder by 2,000,000 shares. The board of directors recommends the approval of each of
the proposals. Such other business will be transacted as may properly come before the annual meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under Securities
and Exchange Commission rules that allow companies to furnish proxy materials to stockholders over the Internet, we have elected to deliver our proxy materials to the majority of our stockholders over the Internet. This delivery process allows us to
provide stockholders with the information they need, while at the same time conserving natural resources and lowering the cost of delivery. On or about August&nbsp;5, 2022 we intend to begin sending to our stockholders a Notice of Internet
Availability of Proxy Materials (the &#147;Notice&#148;) containing instructions on how to access our proxy statement for our 2022 annual meeting of stockholders and our 2021 annual report to stockholders. The Notice also provides instructions on
how to vote online or by telephone, how to access the virtual annual meeting and how to receive a paper copy of the proxy materials by mail. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We hope you will be able to attend the annual meeting. Whether you plan to attend the annual meeting or not, it is important
that you cast your vote either in person or by proxy. You may vote over the Internet as well as by telephone or by mail. When you have finished reading the proxy statement, you are urged to vote in accordance with the instructions set forth in this
proxy statement. We encourage you to vote by proxy so that your shares will be represented and voted at the meeting, whether or not you can attend. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Thank you for your continued support of Spero Therapeutics, Inc. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:55%; text-indent:-2%">


<IMG SRC="g341851g46n24.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Ankit Mahadevia, M.D. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">President and Chief Executive Officer </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>675 Massachusetts Avenue, 14th Floor </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Cambridge, Massachusetts 02139 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>August&nbsp;5, 2022 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF 2022 ANNUAL MEETING OF STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TIME: 9:00 a.m. Eastern Time </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DATE: Thursday, September&nbsp;15,
2022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">ACCESS: www.virtualshareholdermeeting.com/SPRO2022 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This year&#146;s annual meeting will be a virtual meeting via live audio webcast on the Internet. You will be able to attend the annual
meeting, vote and submit your questions during the meeting by visiting www.virtualshareholdermeeting.com/SPRO2022 and entering the <FONT STYLE="white-space:nowrap">16-digit</FONT> control number included in the Notice of Internet Availability or
proxy card that you receive. For further information about the virtual annual meeting, please see the Questions and Answers about the Annual Meeting beginning on page 4. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">PURPOSES: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">To elect two directors to serve three-year terms expiring in 2025; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">To ratify the appointment of PricewaterhouseCoopers LLP as the Company&#146;s independent registered public
accounting firm for the fiscal year ending December&nbsp;31, 2022; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">To approve an amendment to our 2017 Stock Incentive Plan, as amended, to increase the total number of shares
of common stock authorized for issuance thereunder by 2,000,000 shares; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">To transact such other business that is properly presented at the annual meeting and any adjournments or
postponements thereof. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">WHO MAY VOTE: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">You may vote if you were the record owner of Spero Therapeutics, Inc. common stock at the close of business on July&nbsp;20, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A list of stockholders of record will be available at the annual meeting, and during the 10 days prior to the annual meeting at our principal
executive offices located at 675 Massachusetts Avenue, 14th Floor, Cambridge, Massachusetts 02139. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">All stockholders are cordially invited
to attend the annual meeting. <B>Whether you plan to attend the annual meeting or not, we urge you to vote and submit your proxy by the Internet, telephone or mail by following the instructions in the Notice of Internet Availability of Proxy
Materials that you previously received and as described in this proxy statement in order to ensure the presence of a quorum. </B>You may change or revoke your proxy at any time before it is voted at the meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">BY ORDER OF THE BOARD OF DIRECTORS </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:55%; text-indent:-2%">


<IMG SRC="g341851g46n24.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Ankit Mahadevia, M.D. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">President and Chief Executive Officer </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U><A NAME="toc"></A>TABLE OF CONTENTS </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom341851_1">IMPORTANT INFORMATION ABOUT THE ANNUAL MEETING AND VOTING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom341851_2">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
MANAGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom341851_3">MANAGEMENT AND CORPORATE GOVERNANCE MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom341851_4">EXECUTIVE OFFICER AND DIRECTOR COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom341851_5">EQUITY COMPENSATION PLANS AND OTHER BENEFIT PLANS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom341851_6">REPORT OF AUDIT COMMITTEE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom341851_7">CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom341851_8">PROPOSAL 1: ELECTION OF DIRECTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom341851_9">PROPOSAL 2: INDEPENDENT PUBLIC ACCOUNTANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom341851_10">PROPOSAL 3: APPROVE AMENDMENT TO 2017 STOCK INCENTIVE PLAN</A></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom341851_11">CODE OF CONDUCT AND ETHICS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom341851_12">OTHER MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom341851_13">STOCKHOLDER PROPOSALS AND NOMINATIONS FOR DIRECTOR</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom341851_14">APPENDIX A - SPERO THERAPEUTICS, INC. AMENDED AND RESTATED 2017 EQUITY INCENTIVE
 PLAN, AS AMENDED</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>675 Massachusetts Avenue, 14th Floor </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Cambridge, Massachusetts 02139 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROXY STATEMENT FOR SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2022 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON SEPTEMBER&nbsp;15, 2022 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This proxy statement, along with the accompanying Notice of 2022 Annual Meeting of Stockholders, contains information about
the 2022 annual meeting of stockholders of Spero Therapeutics, Inc. (&#147;Annual Meeting&#148;), including any adjournments or postponements of the Annual Meeting. We are holding the Annual Meeting at 9:00 a.m. Eastern Time on Thursday,
September&nbsp;15, 2022. This year&#146;s annual meeting will be conducted solely via live audio webcast on the Internet. You will be able to attend the annual meeting, vote and submit your questions during the annual meeting by visiting
www.virtualshareholdermeeting.com/SPRO2022. You will not be able to attend the annual meeting in person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In this proxy
statement, we refer to Spero Therapeutics, Inc. as &#147;Spero,&#148; &#147;the Company,&#148; &#147;we&#148; and &#147;us.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This proxy statement relates to the solicitation of proxies by our board of directors (&#147;Board of Directors&#148;) for use
at the Annual Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On or about August&nbsp;5, 2022, we intend to begin sending to our stockholders a Notice of
Internet Availability of Proxy Materials (the &#147;Notice&#148;) containing instructions on how to access our proxy statement for our 2022 Annual Meeting of stockholders and our 2021 annual report to stockholders. The Notice also provides
instructions on how to vote online or by telephone, how to access the virtual annual meeting and how to receive a paper copy of the proxy materials by mail. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SHAREHOLDER MEETING TO BE HELD ON SEPTEMBER&nbsp;15, 2022 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>This proxy statement, the Notice of Annual Meeting of Stockholders, our form of proxy card and our 2021 Annual Report on
Form <FONT STYLE="white-space:nowrap">10-K</FONT> are available for viewing, printing and downloading at www.proxyvote.com</B><B><I>.</I></B><B> To view these materials, please have your <FONT STYLE="white-space:nowrap">16-digit</FONT> control
number available that appears on your Notice or proxy card. On this website, you can also elect to receive future distributions of our proxy statements and annual reports to stockholders by electronic delivery. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Additionally, you can find a copy of our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> which includes
our financial statements, for the fiscal year ended December&nbsp;31, 2021 on the website of the Securities and Exchange Commission (the &#147;SEC&#148;), at </B><B><I>www.sec.gov</I></B><B>, or in the &#147;SEC Filings&#148; section of the
&#147;Investors&nbsp;&amp; Media&#148; section of our website at www.sperotherapeutics.com</B><B><I>.</I></B><B> You may also obtain a printed copy of our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> including our financial
statements, free of charge, from us by sending a written request to: Spero Therapeutics, Inc., Attn: Investor Relations, 675 Massachusetts Avenue, 14th Floor, Cambridge, Massachusetts 02139. Exhibits will be provided upon written request and payment
of an appropriate processing fee. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom341851_1"></A>IMPORTANT INFORMATION ABOUT THE ANNUAL MEETING AND VOTING
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Why is the Company Soliciting My Proxy? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Board of Directors of Spero Therapeutics, Inc. is soliciting your proxy to vote at the 2022 Annual Meeting of stockholders
to be held on Thursday, September&nbsp;15, 2022 at 9:00 a.m. Eastern Time. This year&#146;s annual meeting and any adjournments of the meeting will be conducted solely via live audio webcast on the Internet. You will be able to attend the annual
meeting, vote and submit your questions during the annual meeting by visiting www.virtualshareholdermeeting.com/SPRO2022. You will not be able to attend the annual meeting in person. The proxy statement along with the accompanying Notice of Annual
Meeting of Stockholders summarizes the purposes of the meeting and the information you need to know to vote at the Annual Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have made available to you on the Internet or have sent you this proxy statement, the Notice of Annual Meeting of
Stockholders, the proxy card and a copy of our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2021 because you owned shares of Spero Therapeutics, Inc. common stock on the record date.
The Company intends to commence distribution to stockholders of the Notice of Internet Availability of Proxy Materials, which we refer to throughout this proxy statement as the &#147;Notice&#148;, and, if applicable, the proxy materials on or about
August&nbsp;5, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Why Did I Receive a Notice in the Mail Regarding the Internet Availability of Proxy Materials Instead of a Full Set of Proxy
Materials? </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As permitted by the rules of the U.S. Securities and Exchange Commission (the &#147;SEC&#148;), we may
furnish our proxy materials to our stockholders by providing access to such documents on the Internet, rather than mailing printed copies of these materials to each stockholder. Most stockholders will not receive printed copies of the proxy
materials unless they request them. We believe that this process should expedite stockholders&#146; receipt of proxy materials, lower the costs of the annual meeting and help to conserve natural resources. If you received the Notice by mail or
electronically, you will not receive a printed or email copy of the proxy materials, unless you request one by following the instructions included in the Notice. Instead, the Notice instructs you as to how you may access and review all of the proxy
materials and submit your proxy on the Internet. If you requested a paper copy of the proxy materials, you may authorize the voting of your shares by following the instructions on the proxy card, in addition to the other methods of voting described
in this proxy statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Why Are you Holding a Virtual Annual Meeting? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This year&#146;s Annual Meeting will be held in a virtual meeting format only. We have designed our virtual format to enhance,
rather than constrain, stockholder access, participation and communication. For example, the virtual format allows stockholders to communicate with us in advance of, and during, the Annual Meeting so they can ask questions of our Board of Directors
or management, as time permits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How can I attend the Annual Meeting? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Annual Meeting will be a completely virtual meeting of stockholders, which will be conducted exclusively by webcast. You
are entitled to participate in the Annual Meeting only if you were a stockholder of the Company as of the close of business on the Record Date, or if you hold a valid proxy for the Annual Meeting. No physical meeting will be held. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">You will be able to attend the Annual Meeting online and submit your questions during the meeting by visiting
www.virtualshareholdermeeting.com/SPRO2022. You also will be able to vote your shares online by attending the Annual Meeting by webcast. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To participate in the Annual Meeting, you will need to review the
information included in the Notice on your proxy card or on the instructions that accompanied your proxy materials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If
you hold your shares through an intermediary, such as a bank or broker, you must register in advance using the instructions below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The online meeting will begin promptly 9:00 a.m. Eastern Time. We encourage you to access the meeting prior to the start time
leaving ample time for the check in. Please follow the registration instructions as outlined in this proxy statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How do I register to attend the
Annual Meeting virtually on the Internet? </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If you are a registered shareholder (i.e., you hold your shares through our
transfer agent, Computershare), you do not need to register to attend the Annual Meeting virtually on the Internet. Please follow the instructions on the proxy card that you received. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If you are not a stockholder of record but hold shares as a beneficial owner in street name, you may be required to provide
proof of beneficial ownership, such as your most recent account statement as of the Record Date, a copy of the voting instruction form provided by your broker, bank, trustee, or nominee, or other similar evidence of ownership. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What Happens if There Are Technical Difficulties during the Annual Meeting? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We will have technicians ready to assist you with any technical difficulties you may have accessing the virtual Annual
Meeting, voting at the Annual Meeting or submitting questions at the Annual Meeting. If you encounter any difficulties accessing the virtual Annual Meeting during the <FONT STYLE="white-space:nowrap">check-in</FONT> or meeting time, please visit the
shareholder <FONT STYLE="white-space:nowrap">log-in</FONT> page for technical support. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Who Can Vote? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Only stockholders who owned our common stock at the close of business on July&nbsp;20, 2022 are entitled to vote at the Annual
Meeting. On this record date, there were 35,067,477 shares of our common stock outstanding and entitled to vote. Our common stock is our only class of voting stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">You do not need to attend the Annual Meeting to vote your shares. Shares represented by valid proxies, received in time for
the Annual Meeting and not revoked prior to the Annual Meeting, will be voted at the Annual Meeting. For instructions on how to change or revoke your proxy, see &#147;May I Change or Revoke My Proxy?&#148; below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How Many Votes Do I Have? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each share of our common stock that you own entitles you to one vote. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How Do I Vote? </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Whether
you plan to attend the Annual Meeting or not, we urge you to vote by proxy. All shares represented by valid proxies that we receive through this solicitation, and that are not revoked, will be voted in accordance with your instructions on the proxy
card or as instructed via Internet or telephone. You may specify whether your shares should be voted for or withheld for each nominee for director, whether your shares should be voted for, against or abstain with respect to the ratification of the
appointment of PricewaterhouseCoopers LLP </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
as the Company&#146;s independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2022 and whether your shares should be voted for, against or abstain with respect
to the increase in shares authorized for issuance under our 2017 Stock Incentive Plan, as amended. If you properly submit a proxy without giving specific voting instructions, your shares will be voted in accordance with the Board of Directors&#146;
recommendations as noted below. Voting by proxy will not affect your right to attend the Annual Meeting. If your shares are registered directly in your name through our stock transfer agent, Computershare Trust Company, N.A., or you have stock
certificates registered in your name, you may vote: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>By Internet or by telephone. </B>Follow the instructions included in the Notice or, if you received printed
materials, in the proxy card to vote by Internet or telephone. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>By mail.</B> If you received a proxy card by mail, you can vote by mail by completing, signing, dating and
returning the proxy card as instructed on the card. If you sign the proxy card but do not specify how you want your shares voted, they will be voted in accordance with the Board of Directors&#146; recommendations as noted below.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>At the meeting.</B> If you attend the meeting, you may vote by completing an electronic ballot, which will
be available at the meeting. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If you are a registered shareholder (i.e., you hold your shares through
our transfer agent, Computershare), you do not need to register to attend the Annual Meeting virtually on the Internet. Please follow the instructions on the proxy card that you received. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Telephone and Internet voting facilities for stockholders of record will be available 24 hours a day until the Annual Meeting
begins at 9:00 a.m. Eastern Time on Thursday, September&nbsp;15, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If your shares are held in &#147;street name&#148;
(held in the name of a bank, broker or other holder of record), you will receive instructions from the holder of record. You must follow the instructions of the holder of record in order for your shares to be voted. Telephone and Internet voting
also will be offered to stockholders owning shares through certain banks and brokers. If your shares are not registered in your own name and you plan to vote your shares in person at the Annual Meeting, you should contact your broker or agent to
obtain a legal proxy or broker&#146;s proxy card in order to vote. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How Does the Board of Directors Recommend That I Vote on the Proposals? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Board of Directors recommends that you vote as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>&#147;FOR&#148; </B>the election of the nominees for director; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>&#147;FOR&#148;</B> the ratification of the selection of PricewaterhouseCoopers LLP as our independent
registered public accounting firm for our fiscal year ending December&nbsp;31, 2022; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>&#147;FOR&#148;</B> the approval of an amendment to our 2017 Stock Incentive Plan, as amended, to increase
the total number of shares of common stock authorized for issuance thereunder by 2,000,000 shares. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If
any other matter is presented at the Annual Meeting, your proxy provides that your shares will be voted by the proxy holder listed in the proxy in accordance with his best judgment. At the time this proxy statement was first made available, we knew
of no matters that needed to be acted on at the Annual Meeting, other than those discussed in this proxy statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>May I Change or Revoke My Proxy? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If you give us your proxy, you may change or revoke it at any time before the Annual Meeting. You may change or revoke your proxy in any one
of the following ways: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if you received a proxy card, by signing a new proxy card with a date later than your previously delivered
proxy and submitting it as instructed above; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by <FONT STYLE="white-space:nowrap">re-voting</FONT> by Internet or by telephone as instructed above;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by notifying the Company&#146;s Secretary in writing before the Annual Meeting that you have revoked your
proxy; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by attending the Annual Meeting and voting at the meeting. Attending the Annual Meeting will not in and of
itself revoke a previously submitted proxy. You must specifically request at the Annual Meeting that it be revoked. Your most current vote, whether by telephone, Internet or proxy card is the one that will be counted. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What if I Receive More Than One Notice or Proxy Card? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">You may receive more than one Notice or proxy card if you hold shares of our common stock in more than one account, which may
be in registered form or held in street name. Please vote in the manner described above under &#147;How Do I Vote?&#148; for each account to ensure that all of your shares are voted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Will My Shares be Voted if I Do Not Vote? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If your shares are registered in your name or if you have stock certificates, they will not be counted if you do not vote as
described above under &#147;How Do I Vote?&#148; If your shares are held in street name and you do not provide voting instructions to the bank, broker or other nominee that holds your shares as described above, the bank, broker or other nominee that
holds your shares has the authority to vote your unvoted shares only on certain of the proposals set forth in this proxy statement without receiving instructions from you. Therefore, we encourage you to provide voting instructions to your bank,
broker or other nominee. This ensures your shares will be voted at the Annual Meeting and in the manner you desire. A &#147;broker <FONT STYLE="white-space:nowrap">non-vote&#148;</FONT> will occur if your broker cannot vote your shares on a
particular matter because it has not received instructions from you and does not have discretionary voting authority on that matter or because your broker chooses not to vote on a matter for which it does have discretionary voting authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What Vote is Required to Approve Each Proposal and How are Votes Counted? </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="63%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Proposal 1: Elect Directors</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The nominees for director who receive the most votes (also known as a &#147;plurality&#148; of the votes cast) will be
elected. You may vote either FOR each of the nominees, WITHHOLD your vote from each of the nominees or WITHHOLD your vote from any of the nominees. Votes that are withheld will not be included in the vote tally for the election of the directors.<B>
Brokerage firms do not have authority to vote customers&#146; unvoted shares held by the firms in street name for the election of the directors.</B> As a result, any shares not voted by a customer will be treated as a broker <FONT
STYLE="white-space:nowrap">non-vote.</FONT> Such broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will have no effect on the results of this vote.</P></TD></TR></TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
<DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="63%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Proposal 2: Ratify Selection of Independent Registered Public Accounting Firm</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The affirmative vote of the holders of a majority in voting power of the votes cast by the holders of the shares of our
common stock present or represented at the meeting and voting affirmatively or negatively for this proposal is required to ratify the selection of our independent registered public accounting firm. Abstentions will have no effect on the results of
this vote. <B>Brokerage firms have authority to vote customers&#146; unvoted shares held by the firms in street name on this proposal.</B> If a broker does not exercise this authority, such broker <FONT STYLE="white-space:nowrap">non-votes</FONT>
will have no effect on the results of this vote. We are not required to obtain the approval of our stockholders to select our independent registered public accounting firm. However, if our stockholders do not ratify the selection of
PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2022, our Audit Committee of our Board of Directors will reconsider its selection.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Proposal 3: Approve Amendment to 2017 Stock Incentive Plan, as amended</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The affirmative vote of the holders of a majority in voting power of the votes cast by the holders of the shares of our
common stock present or represented at the meeting and voting affirmatively or negatively for this proposal is required to approve the amendment to our 2017 Stock Incentive Plan, as amended, to increase the total number of shares of common stock
authorized for issuance thereunder by 2,000,000 shares. Abstentions will have no effect on the results of this vote. <B>Brokerage firms do not have authority to vote customers&#146; unvoted shares held by the firms in street name for the approval of
the amendment to the 2017 Stock Incentive Plan, as amended.</B> As a result, any shares not voted by a customer will be treated as a broker <FONT STYLE="white-space:nowrap">non-vote.</FONT> Such broker
<FONT STYLE="white-space:nowrap">non-votes</FONT> will have no effect on the results of this vote.</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Is Voting Confidential? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We will keep all the proxies, ballots and voting tabulations private. We only let our Inspectors of Election, Satyavrat
Shukla, examine these documents. Management will not know how you voted on a specific proposal unless it is necessary to meet legal requirements. We will, however, forward to management any written comments you make on the proxy card or otherwise
provide. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Where Can I Find the Voting Results of the Annual Meeting? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The preliminary voting results will be announced at the Annual Meeting, and we will publish preliminary, or final results if
available, in a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> within four business days of the Annual Meeting. If final results are unavailable at the time, we file the Form <FONT STYLE="white-space:nowrap">8-K,</FONT> then we
will file an amended report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> to disclose the final voting results within four business days after the final voting results are known. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What Are the Costs of Soliciting these Proxies? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We will pay all of the costs of soliciting these proxies. Our directors and employees may solicit proxies in person or by
telephone, fax or email. We will pay these employees and directors no additional compensation for these services. We will ask banks, brokers and other institutions, nominees and fiduciaries to forward these proxy materials to their principals and to
obtain authority to execute proxies. We will then reimburse them for their expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have engaged Alliance Advisors LLC to assist in the solicitation of
proxies and provide related advice and informational support, for a services fee and the reimbursement of customary disbursements, which are not expected to exceed $20,000 in total. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What Constitutes a Quorum for the Annual Meeting? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The presence, in person or by proxy, of the holders of a majority of the voting power of all outstanding shares of our capital
stock entitled to vote at the Annual Meeting is necessary to constitute a quorum at the Annual Meeting. Votes of stockholders of record who are present at the Annual Meeting in person or by proxy, abstentions, and broker <FONT
STYLE="white-space:nowrap">non-votes</FONT> are counted for purposes of determining whether a quorum exists. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Attending the Annual Meeting </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Annual Meeting will be held at 9:00 a.m. Eastern Time on Thursday, September&nbsp;15, 2022. This year, our Annual Meeting
will be held in a virtual meeting format only. To attend the virtual Annual Meeting, go to www.virtualshareholdermeeting.com/SPRO2022 shortly before the meeting time, and follow the instructions for downloading the webcast. You need not attend the
Annual Meeting in order to vote. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Householding of Annual Disclosure Documents </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The SEC has adopted rules that permit companies and intermediaries such as brokers to satisfy delivery requirements for proxy
statements and annual reports with respect to two or more stockholders sharing the same address by delivering a single proxy statement or annual report, as applicable, addressed to those stockholders. This process, which is commonly referred to as
&#147;householding,&#148; potentially provides extra convenience for stockholders and cost savings for companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Spero
has not instituted householding for stockholders of record. However, certain brokerage firms may have instituted householding for beneficial owners of shares of Spero&#146;s common stock held through brokerage firms. If your household has multiple
accounts holding shares of Spero&#146;s common stock, you may have already received householding notification from your broker. Please contact your broker directly if you have any questions or require additional copies of the Notice or proxy
materials. The broker will arrange for delivery of a separate copy of the Notice or proxy materials promptly upon your request. Spero stockholders may decide at any time to revoke a decision to household, and thereby receive multiple copies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Electronic Delivery of Company Stockholder Communications </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Most stockholders can elect to view or receive copies of future proxy materials over the Internet instead of receiving paper
copies in the mail. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This proxy statement, the Notice of Annual Meeting of Stockholders, our form of proxy card and our
2021 Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> are available for viewing, printing and downloading at www.proxyvote.com. To view these materials, please have your <FONT STYLE="white-space:nowrap">16-digit</FONT> control
number available that appears on your Notice or proxy card. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom341851_2"></A>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth certain information with respect to the beneficial ownership of our common stock as of
July&nbsp;20, 2022 for (a)&nbsp;the executive officers named in the Summary Compensation Table on page 21 of this proxy statement, (b)&nbsp;each of our directors and director nominees, (c)&nbsp;all of our current directors and executive officers as
a group and (d)&nbsp;each stockholder known by us to own beneficially more than 5% of our common stock. Beneficial ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to the
securities. We deem shares of common stock that may be acquired by an individual or group within 60 days of July&nbsp;20, 2022, including pursuant to the exercise of options, to be outstanding for the purpose of computing the percentage ownership of
such individual or group, but not outstanding for the purpose of computing the percentage ownership of any other person shown in the table. Except as indicated in footnotes to this table, we believe that the stockholders named in this table have
sole voting and investment power with respect to all shares of common stock shown to be beneficially owned by them based on information provided to us by these stockholders. Percentage of ownership is based on 35,067,477 shares of common stock
outstanding on July&nbsp;20, 2022. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD style="width:38pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:38pt"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD style="width:41pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:41pt"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:10pt; font-family:Times New Roman; "><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Number&nbsp;of&nbsp;Shares</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Beneficially</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:10pt; font-family:Times New Roman; " ALIGN="center"><B>Owned</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Percent&nbsp;of&nbsp;Shares</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:10pt; font-family:Times New Roman; " ALIGN="center"><B>Beneficially&nbsp;Owned</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><I>Principal Stockholders</I></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Aquilo Capital Management, LLC&nbsp;(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,021,536</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.32</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with BVF Inc. (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,411,520</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.73</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pfizer Inc. (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,362,348</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.74</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="5"></TD>
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><I>Named Executive Officers and Directors</I></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ankit Mahadevia, M.D. (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,049,490</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.91</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cristina Larkin (5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">273,598</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Satyavrat Shukla (6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,267</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Milind Deshpande, Ph.D. (7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,118</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scott Jackson (8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,833</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John C. Pottage, Jr., M.D. (9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,219</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cynthia Smith (10)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,848</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Frank E. Thomas (11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,786</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kathleen Tregoning (12)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,381</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick Vink, M.D. (13)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,489</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All current executive officers and directors as a group (11 persons) (14)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,619,892</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.36</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Indicates beneficial ownership of less than 1%. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Aquilo Capital Management, LLC is an investment advisor that serves as the general partner and investment
manager to each of Aquilo Capital, L.P. and Aquilo Capital LO, L.P. (previously known as Aquilo Capital II, L.P.), (collectively, the &#147;Aquilo Funds&#148;), and may be deemed to be the beneficial owner of all shares of common stock held by the
Aquilo Funds. Mr.&nbsp;Marc Schneidman, as Managing Member of Aquilo Capital Management, LLC, with the power to exercise investment and voting discretion, may be deemed to be the beneficial owner of all shares of common stock held by the Aquilo
Funds. Each of the Aquilo Funds and Mr.&nbsp;Schneidman expressly disclaims beneficial ownership over any of the shares of common stock held by the Aquilo Funds. The address for Aquilo Capital, L.P. and Aquilo Capital II, L.P. is One Letterman
Drive, Suite D4900, Building D, The Presidio, San Francisco, California 94129. This information is based solely on a Schedule 13G/A filed by Aquilo Capital, L.P. with the SEC on March&nbsp;9, 2022, which reported ownership as of January&nbsp;18,
2022. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Includes (i) 2,169,102 shares of common stock held by Biotechnology Value Fund, L.P. (&#147;BVF&#148;),
(ii)&nbsp;1,001,264 shares of common stock held by Biotechnology Value Fund II, L.P. (&#147;BVF II&#148;), and (iii)&nbsp;106,154 shares of common stock held by Biotechnology Value Trading Fund OS LP (&#147;Trading Fund OS&#148;). BVF I GP LLC
(&#147;BVF GP&#148;), as general partner of BVF, may be deemed to beneficially own 2,169,102 shares of common stock beneficially owned by BVF. BVF II GP LLC (&#147;BVF II GP&#148;), as general partner of BVF II, may be deemed to beneficially own
1,001,264 shares of common stock beneficially owned by BVF II. BVF Partners OS Ltd. (&#147;Partners OS&#148;), as general partner of Trading Fund OS, may be deemed to beneficially own 106,154 shares of common stock beneficially owned by Trading Fund
OS. BVF GP Holdings LLC (&#147;BVF GPH&#148;), as the sole member of BVF GP and BVF II GP, may be deemed to beneficially own 3,170,366 shares of common stock beneficially owned in the aggregate by BVF GP and BVF II GP. BVF Partners L.P.
(&#147;Partners&#148;), as investment manager of BVF, BVF II and Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the 3,411,520 shares of common stock beneficially owned in the aggregate by BVF, BVF II, Trading
Fund OS, and certain managed accounts of Partners (the &#147;Partners Managed Accounts&#148;), including 135,000 shares of common stock held in the Partners Managed Accounts. BVF Inc., as the general partner of Partners, may be deemed to
beneficially own the 3,411,520 shares of common stock owned by Partners. Mark N. Lampert is a director and officer of BVF Inc., and may be deemed to beneficially own the 3,411,520 shares of common stock beneficially owned by BVF, Inc. Together, BVF,
BVF II, BVF GP, BVF II GP, Trading Fund OS, BVF GPH, Partners OS, Partners, BVF Inc. and Mark N. Lampert (the &#147;BVF Entities&#148;) hold 938 shares of Series B Convertible Preferred Stock (&#147;Series B Preferred&#148;) convertible for an
aggregate of 938,000 shares of common stock. The Series B Preferred may not be converted if, after such conversion, the BVF Entities would beneficially own more than 9.99% of the common stock then issued and outstanding (the &#147;Series B
Blocker&#148;). As of December&nbsp;31, 2021, the Series B Blocker does not limit the conversion of Series B Preferred. As a result of the Series B Blocker, included in the percentage of shares beneficially owned as of December&nbsp;31, 2021 is the
maximum number of shares of common stock issuable upon conversion of Series B Preferred up to the limit imposed by the Series B Blocker, and excluded are the remaining shares of common stock issuable upon conversion of Series B Preferred that are
prevented from converting due to the Series B Blocker. Together the BVF Entities also hold 2,214 shares of Series C Convertible Preferred Stock (the &#147;Series C Preferred&#148;) convertible for an aggregate of 2.214,000 shares of common stock.
The Series C Preferred may not be converted if, after such conversion, the BVF Entities would beneficially own more than 9.99% of the common stock then issued and outstanding (the &#147;Series C Blocker&#148;). As of December&nbsp;31, 2021, the
Series C Blocker limits the aggregate conversion of Series C Preferred by the BVF Entities to 887,905 out of the 2,214,000 shares of common stock underlying the Series C Preferred. Together the BVF Entities also hold 3,215,000 shares of
Series&nbsp;D Convertible Preferred Stock (the &#147;Series D Preferred&#148;) convertible for an aggregate of 3,215,000 shares of common stock. The Series D Preferred may not be converted if, after such conversion, the BVF Entities would
beneficially own more than 9.99% of the common stock then issued and outstanding (the &#147;Series&nbsp;D Blocker&#148;). As of December&nbsp;31, 2021, the Series D Blocker limits the aggregate conversion of Series&nbsp;D Preferred by the BVF
Entities to 0 out of the 3,215,000 shares of common stock underlying the Series&nbsp;D Preferred. BVF GP disclaims beneficial ownership of the shares of common stock beneficially owned by BVF. BVF II GP disclaims beneficial ownership of the shares
of common stock beneficially owned by BVF II. Partners OS disclaims beneficial ownership of the shares of common stock beneficially owned by Trading Fund OS. BVF GPH disclaims beneficial ownership of the shares of common stock beneficially owned by
BVF GP and BVF II GP. Each of Partners, BVF Inc. and Mr.&nbsp;Lampert disclaims beneficial ownership of the shares of common stock beneficially owned by BVF, BVF II, Trading Fund OS, and the Partners Management Accounts. The address of the principal
business and office of BVF Inc. and certain of its affiliates is 1 Sansome Street, 30th Floor, San Francisco, California, 94194. This information is based solely on a Schedule 13G/A filed with the SEC on February&nbsp;14, 2022, which reported
ownership as of December&nbsp;31, 2021. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of 2,362,348 shares of common stock owned by Pfizer Inc. The address for Pfizer Inc. is 235 E. 42nd
Street, New York, NY 10017. This information is based solely on a Schedule 13G filed by Pfizer Inc. on July&nbsp;9, 2021, which reported ownership as of June&nbsp;30, 2021. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of (i) 65,817 shares of common stock held by Mahadevia-Mehta Family Trust, of which
Dr.&nbsp;Mahadevia is the trustee, and (ii) 983,673 shares of common stock underlying options that are exercisable as of July&nbsp;20, 2022 or will become exercisable within 60 days after such date held by Dr.&nbsp;Mahadevia. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of (i) 1,500 shares of common stock and (ii) 272,098 shares of common stock underlying options that
are exercisable as of July&nbsp;20, 2022 or will become exercisable within 60 days after such date held by Ms.&nbsp;Larkin. Effective as of July&nbsp;2, 2022, Ms.&nbsp;Larkin separated from the Company as its Chief Operating Officer pursuant to the
Company&#146;s restructuring, as described further below under &#147;Management and Corporate Governance Matters &#150; Executive Officers&#148;. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of 37,267 shares of common stock underlying options that are exercisable as of July&nbsp;20, 2022
or will become exercisable within 60 days after such date held by Mr. Shukla. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of (i) 16,454 shares of common stock and (ii) 83,664 shares of common stock underlying options that
are exercisable as of July&nbsp;20, 2022 or will become exercisable within 60 days after such date held by Dr.&nbsp;Deshpande. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of 25,833 shares of common stock underlying options that are exercisable as July&nbsp;20, 2022 or
will become exercisable within 60 days after such date held by Mr.&nbsp;Jackson. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of 33,219 shares of common stock underlying options that are exercisable as of July&nbsp;20, 2022
or will become exercisable within 60 days after such date held by Dr.&nbsp;Pottage. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of 35,848 shares of common stock underlying options that are exercisable as of July&nbsp;20, 2022
or will become exercisable within 60 days after such date held by Ms.&nbsp;Smith. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of 62,786 shares of common stock underlying options that are exercisable as of July&nbsp;20, 2022
or will become exercisable within 60 days after such date held by Mr.&nbsp;Thomas. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of 6,381 shares of common stock underlying options that are exercisable as of July&nbsp;20, 2022 or
will become exercisable within 60 days after such date held by Ms.&nbsp;Tregoning. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of 65,489 shares of common stock underlying options that are exercisable as of July&nbsp;20, 2022
or will become exercisable within 60 days after such date held by Dr.&nbsp;Vink. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">See 4 through 13 above; also includes Tamara Joseph and Timothy Keutzer, who are executive officers but not
named executive officers. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom341851_3"></A>MANAGEMENT AND CORPORATE GOVERNANCE MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Board of Directors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated <FONT STYLE="white-space:nowrap">By-Laws</FONT> provide that our business is to be managed by or
under the direction of our Board of Directors. Our Board of Directors is divided into three classes for purposes of election. One class is elected at each annual meeting of stockholders to serve for a three-year term. Our Board of Directors
currently consists of eight members, classified into three classes as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Patrick Vink, M.D. and Frank E. Thomas constitute our Class&nbsp;II directors with a term ending at the
upcoming 2022 Annual Meeting; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Milind Deshpande, Ph.D., Ankit Mahadevia, M.D. and Kathleen Tregoning constitute our Class&nbsp;III
directors with a term ending at the 2023 annual meeting; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Cynthia Smith, Scott Jackson and John C. Pottage, Jr., M.D. constitute our Class&nbsp;I directors with a
term ending at the 2024 annual meeting. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On July&nbsp;20, 2022, our Board of Directors accepted the
recommendation of the Nominating and Corporate Governance Committee and voted to nominate Patrick Vink, M.D. and Frank E. Thomas for election at the Annual Meeting for a term of three years to serve until the 2025 annual meeting of stockholders, and
until their respective successors have been elected and qualified or subject to their earlier death, resignation or removal. Set forth below are the names of the persons nominated as directors and directors whose terms do not expire this year, their
ages, their offices in the Company, if any, their principal occupations or employment for at least the past five years, the length of their tenure as directors and the names of other public companies in which such persons hold or have held
directorships during the past five years. Additionally, information about the specific experience, qualifications, attributes or skills that led to our Board of Directors&#146; conclusion at the time of filing of this proxy statement that each
person listed below should serve as a director is set forth below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="55%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:10pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Position with the Company</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Milind&nbsp;Deshpande,&nbsp;Ph.D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">66</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chairman of the Board of Directors</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scott Jackson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">57</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ankit Mahadevia, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">41</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer, President and Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John C. Pottage, Jr., M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">69</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cynthia Smith</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">53</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Frank E. Thomas</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">52</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kathleen Tregoning</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">51</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick Vink, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">59</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our Board of Directors has reviewed the materiality of any relationship that each of our
directors has with Spero Therapeutics, Inc., either directly or indirectly. Based upon this review, our Board of Directors has determined that the following members of the Board of Directors are &#147;independent directors&#148; as defined by The
Nasdaq Stock Market: Milind Deshpande, Ph.D., Scott Jackson, John C. Pottage, Jr., M.D., Cynthia Smith, Frank E. Thomas, Kathleen Tregoning and Patrick Vink, M.D. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following Board Diversity Matrix presents our Board of Directors&#146;
diversity statistics in accordance with Nasdaq Rule 5606, as self-disclosed by our directors. While the Board satisfies the minimum objectives of Nasdaq Rule&nbsp;5605(f)(2) by having at least one director who identifies as female and at least one
director who identifies as&nbsp;a member of an Underrepresented Minority (as defined by Nasdaq Rules), we will continue to consider the diversity of the Board of Directors in the selection of director nominees<I>.</I> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" COLSPAN="13" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="12" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><B>Board Diversity Matrix (As of August&nbsp;5, 2022)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt" BGCOLOR="#d8d8d8">
<TD HEIGHT="1" COLSPAN="13" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD></TR>
<TR BGCOLOR="#d8d8d8" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="12" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Number of Directors</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8</P></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;Female&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;Male&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Binary</FONT></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Did Not<BR>Disclose<BR>Gender</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt" BGCOLOR="#d8d8d8">
<TD HEIGHT="1" COLSPAN="13" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD></TR>
<TR BGCOLOR="#d8d8d8" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="12" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Gender:</B></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Directors</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">2</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">6</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt" BGCOLOR="#d8d8d8">
<TD HEIGHT="1" COLSPAN="13" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD></TR>
<TR BGCOLOR="#d8d8d8" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="12" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Number of Directors Who Identify in Any of the Categories Below:</B></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">African
American or Black</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alaskan
Native or Native American</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Asian
(other than South Asian)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">South
Asian</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">2</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hispanic
or Latinx</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Native
Hawaiian or Pacific Islander</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">White</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">2</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">4</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Two or
More Races or Ethnicities</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="12" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LGBTQ+</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="10" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="12" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Persons
with Disabilities</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="10" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Milind Deshpande, Ph.D. </I></B>has served on our Board of Directors since January 2014
and currently serves as chairman of our Board of Directors. Dr.&nbsp;Deshpande is the President and Chief Executive Officer at Nayan Therapeutics since February 2019, and President and Chief Executive Officer of Avilar Therapeutics since January
2020. He is also a Venture Partner at RA Capital, where he has served since October 2018. Dr.&nbsp;Deshpande served as President and Chief Executive Officer of Achillion Pharmaceuticals, Inc. and served on the board of directors from May 2013 until
May 2018. He joined Achillion in September 2001 as Vice President of Chemistry, was named Head of Drug Discovery in April 2002, Senior Vice President of Drug Discovery in December 2002, Senior Vice President and Chief Scientific Officer in December
2004, Executive Vice President of Research and Chief Scientific Officer in June 2007 and President of Research and Development in October 2010. Prior to joining Achillion, Dr.&nbsp;Deshpande was Associate Director of Lead Discovery and Early
Discovery Chemistry at the Pharmaceutical Research Institute at Bristol-Myers Squibb Co. from 1991 to 2001, where he managed the identification of new clinical candidates to treat infectious and neurological diseases. From 1988 to 1991, he held a
faculty position at Boston University Medical School. Dr.&nbsp;Deshpande received his Ph.D. in Organic Chemistry from Ohio University, following his undergraduate education in India. We believe that Dr.&nbsp;Deshpande is qualified to serve on our
Board of Directors due to his extensive experience in the life sciences industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Scott Jackson </I></B>has served
on our Board of Directors since April 2020. Mr.&nbsp;Jackson served as Chief Executive Officer and as a member of the board of directors of Celator Pharmaceuticals, Inc. from April 2008 until July 2016, when the company was acquired by Jazz
Pharmaceuticals plc. Mr.&nbsp;Jackson has more than thirty </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
years of corporate leadership experience in the pharmaceutical and biotechnology industry and has held positions of increasing responsibility in sales, marketing and commercial development at Eli
Lilly&nbsp;&amp; Company, SmithKline Beecham plc, ImClone Systems Incorporated, Centocor Inc., a division of Johnson&nbsp;&amp; Johnson, Eximias Pharmaceutical Corporation and YM BioSciences Inc. Mr.&nbsp;Jackson presently serves on the boards of
MacroGenics, Inc. and GlycoMimetics, Inc. Mr.&nbsp;Jackson holds a B.S. in pharmacy from the Philadelphia College of Pharmacy and Science and an M.B.A. from the University of Notre Dame. We believe that Mr.&nbsp;Jackson&#146;s extensive executive
leadership experience in the pharmaceutical industry and his experience as a member of the board of directors of other publicly traded biotechnology companies, as well as his broad life sciences industry knowledge qualifies him to serve on our Board
of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Ankit Mahadevia, M.D. </I></B>has served as our Chief Executive Officer and President since March
2015 and has been a member of our Board of Directors since September 2013. He was formerly a Venture Partner in the life sciences group at Atlas Venture, located in Cambridge, Massachusetts. In that capacity he supported the formation of eight
companies focused on novel drug discovery platforms and therapeutic products, including Nimbus Therapeutics, Arteaus Therapeutics (acquired by Lilly), and Translate Bio (Nasdaq: TBIO). He led three of these companies as acting CEO, including
Synlogic (Nasdaq: SYBX). Prior to joining Atlas Venture in 2008, Dr.&nbsp;Mahadevia worked on product and business development with the founding team at Arcion Therapeutics, Inc. He has also held positions in business development both at Genentech,
Inc. and at Vanda Pharmaceuticals Inc. Previously, he worked in the health care groups of McKinsey&nbsp;&amp; Company and Monitor Group. Dr.&nbsp;Mahadevia began his career in health care policy, with roles in the U.S. Senate Health, Education,
Labor, and Pensions committees, the U.S. Government Accountability Office and the Mexican Institute of Social Security. He has spoken widely on entrepreneurship, including at Harvard University, Columbia University, Northwestern University, and the
Berkeley Forum. Dr.&nbsp;Mahadevia has also been active in the policy of life science innovation, including service on the Advisory Council at the NIH National Center for Advancing Translational Sciences. Dr.&nbsp;Mahadevia holds an M.D. from the
Johns Hopkins School of Medicine, an M.B.A. from the Wharton School at the University of Pennsylvania and a B.A. in Economics and Biology from Northwestern University. We believe that Dr.&nbsp;Mahadevia is qualified to serve on our Board of
Directors due to his experience serving as our Chief Executive Officer and President and his extensive experience in the life sciences industry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>John C. Pottage, Jr., M.D.</I></B> has served on our Board of Directors since September 2018. Dr.&nbsp;Pottage served as
Senior Vice President and Chief Scientific and Medical Officer of ViiV Healthcare from November 2009 to October 2019. From September 2008 to November 2009, Dr.&nbsp;Pottage served as Senior Vice President, Head of Infectious Disease Medicine
Development Center and, from June 2007 to September 2008, as the Vice President, Global Clinical Development of Antivirals, at GlaxoSmithKline. Prior to joining GlaxoSmithKline, Dr.&nbsp;Pottage served as Chief Medical Officer and Senior Vice
President of Drug Development of Achillion Pharmaceuticals from May 2002 to May 2007. From July 1998 to May 2002, Dr.&nbsp;Pottage served as Medical Director of Vertex Pharmaceuticals. We believe that Dr.&nbsp;Pottage&#146;s extensive industry and
executive experience, his broad experience within the biopharmaceutical sector and his knowledge of the life sciences industry qualifies him to serve on our Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Cynthia Smith </I></B>has served on our Board of Directors since March 2019. Ms.&nbsp;Smith was Chief Commercial Officer
of ZS Pharma, from June 2013 to December 2016. ZS Pharma became a subsidiary of AstraZeneca after its acquisition in December 2015. Prior to joining ZS Pharma, Ms.&nbsp;Smith was Vice President, Market Access&nbsp;&amp; Commercial Development at
Affymax, Inc., a biotechnology company focused on the development and commercialization of novel renal therapies, including a new anemia drug for chronic kidney disease patients. Ms.&nbsp;Smith was employed at Affymax from October 2008 to March
2013. Prior to Affymax, Ms.&nbsp;Smith was Executive Director of Healthcare Systems and Medicare Strategy at Merck. During her tenure at Merck from June 2000 to October 2008, she also held various leadership positions in corporate strategy, public
policy, and external affairs, including global crisis management for the Vioxx recall. Before joining the pharmaceutical industry, she served in the White House Office of Management and Budget (OMB) in the Clinton Administration. Ms.&nbsp;Smith
earned an M.B.A. from the Wharton School of the University of Pennsylvania, an MS in public policy from the Eagleton Institute of Politics at Rutgers University, and a BA from the University of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
North Carolina at Chapel Hill. Ms.&nbsp;Smith also serves on the boards of directors of Dicerna Pharmaceuticals, Akebia Therapeutics and Protara Therapeutics, Inc. We believe that
Ms.&nbsp;Smith&#146;s extensive management experience in the healthcare industry and her experience as a member of the board of directors of other publicly traded biotechnology companies, as well as her broad life sciences industry knowledge,
qualifies her to serve on our Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Frank E. Thomas</I></B> has served on our Board of Directors
since July 2017. Mr.&nbsp;Thomas is currently President and Chief Operating Officer of Orchard Therapeutics, a development-stage biotechnology company based in the United Kingdom, where he served as Chief Financial Officer and Chief Business Officer
from January 2018 to December 2019. Prior to Orchard, Mr.&nbsp;Thomas served as the President and Chief Operating Officer of AMAG Pharmaceuticals, Inc., a publicly traded commercial-stage pharmaceutical company, from April 2015 to April 2017, as
AMAG&#146;s Executive Vice President and Chief Operating Officer from May 2012 through April 2015 and as Executive Vice President, Chief Financial Officer and Treasurer from August 2011 through May 2012. Prior to AMAG, he served as Senior Vice
President, Chief Operating Officer and Chief Financial Officer for Molecular Biometrics, Inc., a commercial-stage medical diagnostics company, from October 2008 to July 2011. Prior to Molecular Biometrics, Mr.&nbsp;Thomas spent four years at
Critical Therapeutics, Inc., a public biopharmaceutical company, from April 2004 to March 2008, where he was promoted to President in June 2006 and Chief Executive Officer in December 2006 from the position of Senior Vice President and Chief
Financial Officer. He also served on the board of directors of Critical Therapeutics from 2006 to 2008. Prior to 2004, Mr.&nbsp;Thomas served as the Chief Financial Officer and Vice President of Finance and Investor Relations at Esperion
Therapeutics, Inc., a public biopharmaceutical company. Mr.&nbsp;Thomas was a member of the board of directors of the Massachusetts Biotechnology Council from 2007 to 2015 and currently serves as a member of the board of directors of Zafgen, Inc., a
public biopharmaceutical company, which he joined in June 2014 and Larimar Therapeutics Inc, which he joined in May 2020. Mr.&nbsp;Thomas holds a B.B.A. from the University of Michigan, Ann Arbor. We believe that Mr.&nbsp;Thomas&#146; extensive
commercial and operational management experience at biopharmaceutical companies and with financial matters qualifies him to serve on our Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Kathleen Tregoning</I></B> has served on our Board of Directors since October 2021. Ms.&nbsp;Tregoning has served as
Chief Corporate Affairs Officer of Cerevel Therapeutics Holdings, Inc. since July 2020. Previously, from February 2017 to March 2020, Ms.&nbsp;Tregoning served as Executive Vice President for External Affairs at Sanofi S.A., a French multinational
pharmaceutical company, where she was responsible for leading an integrated organization that brought together market access, communications, public policy, government affairs, patient advocacy and corporate social responsibility. Prior to joining
Sanofi, Ms.&nbsp;Tregoning spent more than a decade at Biogen Inc., a multinational biotechnology company, first as Vice President, Public Policy&nbsp;&amp; Government Affairs, from 2006 to 2015, and then as Senior Vice President, Corporate Affairs,
from December 2015 to February 2017. Previously, Ms.&nbsp;Tregoning served as a professional staff member in the United States Congress, where she held health policy roles with the Senate Budget Committee, the House Energy&nbsp;&amp; Commerce
Committee, and the House Ways&nbsp;&amp; Means Committee. Ms.&nbsp;Tregoning began her career with Andersen Consulting, where she developed business strategies and processes for clients in a range of industries, and later served as an Assistant
Deputy Mayor for Policy&nbsp;&amp; Budget in the office of the Mayor of Los Angeles. Ms.&nbsp;Tregoning graduated from Stanford University with a B.A. in International Relations and holds an M.A. in Public Policy from the Kennedy School of
Government at Harvard University. We believe that Ms.&nbsp;Tregoning is qualified to serve on our Board of Directors because of her senior and executive leadership experience in several biopharmaceutical companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Patrick Vink, M.D.</I></B> has served on our Board of Directors since September 2015. Dr.&nbsp;Vink has been an advisor
to the pharmaceutical industry since 2015 and board member of several companies. Previously, Dr.&nbsp;Vink was employed at Cubist Pharmaceuticals, Inc. Most recently, he served as Executive Vice-President and Chief Operating Officer, overseeing all
worldwide commercial and technical operations as well as global alliance management and managing the company&#146;s profit and loss. He joined Cubist in 2012 as Senior Vice President and Head of all International Business Operations. In this role,
he was responsible for the business activities in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
International markets outside USA. Prior to joining Cubist, Dr.&nbsp;Vink served as Senior Vice President, Global Head of Hospital Business and Global Head of Biologics for Mylan Inc. In this
role, Dr.&nbsp;Vink managed the global hospital business of the company. He joined Mylan in 2008 and established a number of global functions for the company in Switzerland. Before joining Mylan, Dr.&nbsp;Vink held several leadership positions
across the industry, including Head of Global Business Franchise Biopharmaceuticals for Novartis Sandoz; Vice President International Business for Biogen, Inc.; and Head of Worldwide Marketing, Cardiovascular and Thrombosis for
Sanofi-Synth&eacute;labo SA. Dr.&nbsp;Vink served as a member of the Executive Committee of the European Federation of Pharmaceutical Industries and Associations (EFPIA) between 2013 and 2015. Dr.&nbsp;Vink graduated as a medical doctor from the
University of Leiden, Netherlands in 1988 and obtained his M.B.A. in 1992 from the University of Rochester. Dr.&nbsp;Vink serves on the boards of directors of Santhera Pharmaceuticals AG, Amryt Pharma PLC., and is Chairman of the board of directors
of two privately held companies. We believe that Dr.&nbsp;Vink is qualified to serve on our Board of Directors because of his extensive operational business experience, significant knowledge of the activities of our company, and diverse background
serving on the board of directors of various public and private life science companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Committees of the Board of Directors and Meetings </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Meeting Attendance.</I></B><I> </I>During the fiscal year ended December&nbsp;31, 2021, there were seven meetings of our
Board of Directors, and the various committees of the Board of Directors met a total of 13 times. No director attended fewer than 75% of the total number of meetings of the Board of Directors and of committees of the Board of Directors on which such
director served during the fiscal year ended December&nbsp;31, 2021. The Board of Directors has adopted a policy under which each member of the Board of Directors makes every effort to but is not required to attend each annual meeting of our
stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Audit Committee.</I></B> Our Audit Committee met four times during the fiscal year ended
December&nbsp;31, 2021. This committee currently has four members, Frank E. Thomas (Chairman), Scott Jackson, John C. Pottage, Jr., M.D., and Patrick Vink, M.D. Our Audit Committee&#146;s role and responsibilities are set forth in the Audit
Committee&#146;s written charter and include the authority to retain and terminate the services of our independent registered public accounting firm. In addition, the Audit Committee reviews annual financial statements, considers matters relating to
accounting policy and internal controls and reviews the scope of annual audits. All members of the Audit Committee satisfy the current independence standards promulgated by the SEC and by The Nasdaq Stock Market, as such standards apply specifically
to members of audit committees. The Board of Directors has determined that Mr.&nbsp;Thomas is an &#147;audit committee financial expert,&#148; as the SEC has defined that term in Item 407 of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT>
Please also see the report of the Audit Committee set forth elsewhere in this proxy statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A copy of the Audit
Committee&#146;s written charter is publicly available on our website at www.sperotherapeutics.com. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Compensation
Committee. </I></B>Our Human Capital Management Committee (the &#147;Compensation Committee&#148;) met five times during the fiscal year ended December&nbsp;31, 2021. This committee currently has four members, Patrick Vink, M.D. (Chairman), Milind
Deshpande, Ph.D., Cynthia Smith and Kathleen Tregoning. During the period of January&nbsp;1, 2021 through October&nbsp;11, 2021, our Compensation Committee was comprised of Patrick Vink, M.D. (Chairman), Jean-Fran&ccedil;ois Formela, M.D., Milind
Deshpande, Ph.D., and Cynthia Smith. On October&nbsp;11, 2021, Ms.&nbsp;Tregoning joined as a member of our Compensation Committee and Dr.&nbsp;Formela notified the Board of Directors of his resignation from the Board and the Compensation Committee
and Nominating and Corporate Governance Committee of the Board, effective as of October&nbsp;11, 2021. Our Compensation Committee&#146;s role and responsibilities are set forth in the Compensation Committee&#146;s written charter and include
reviewing, approving and making recommendations regarding our compensation policies, practices and procedures to ensure that legal and fiduciary responsibilities of the Board of Directors are carried out and that such policies, practices and
procedures contribute to our success. Our Compensation Committee also administers the Spero Therapeutics, Inc. 2017 Stock Incentive Plan, as amended, and our 2019 Inducement Equity Incentive </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Plan, as amended. The Compensation Committee is responsible for the determination of the compensation of our chief executive officer and shall conduct its decision-making process with respect to
that issue without the chief executive officer present. All members of the Compensation Committee qualify as independent under the definition promulgated by The Nasdaq Stock Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In July 2019, the Compensation Committee retained Meridian Compensation Partners, LLC (&#147;Meridian&#148;) as an independent
advisor to the Compensation Committee to provide executive compensation consulting services. Meridian did not provide any services to us other than executive compensation consulting services during the fiscal year ended December&nbsp;31, 2021. In
compliance with the SEC and the corporate governance rules of The Nasdaq Stock Market, Meridian provided the Compensation Committee with a letter addressing each of the six independence factors. Their responses affirm the independence of Meridian
and the partners, consultants, and employees who service the Compensation Committee on executive compensation matters and governance issues. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A copy of the Compensation Committee&#146;s written charter is publicly available on our website at www.sperotherapeutics.com.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Nominating and Corporate Governance Committee</I></B><I>. </I>Our Nominating and Corporate Governance Committee
(&#147;Nominating Committee&#148;) met three times during the fiscal year ended December&nbsp;31, 2021 and has three members, Milind Deshpande, Ph.D. (Chairman), Scott Jackson and Frank E. Thomas. During the period of January&nbsp;1, 2021 through
October&nbsp;11, 2021, our Nominating and Corporate Governance Committee was comprised of Milind Deshpande, Ph.D. (Chairman), Jean-Fran&ccedil;ois Formela, M.D., and Frank E. Thomas. On October&nbsp;11, 2021, Mr.&nbsp;Jackson joined the Committee
and Dr.&nbsp;Formela notified the Board of Directors of his resignation from the Board and the Compensation Committee and Nominating and Corporate Governance Committee of the Board, effective as of October&nbsp;11, 2021. Our Board of Directors has
determined that all members of the Nominating Committee qualify as independent under the definition promulgated by The Nasdaq Stock Market. The Nominating Committee&#146;s responsibilities are set forth in the Nominating Committee&#146;s written
charter and include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying and recommending candidates for membership on our Board of Directors; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recommending directors to serve on board committees; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and recommending our corporate governance guidelines and policies; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing proposed waivers of the code of conduct for directors and executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating, and overseeing the process of evaluating, the performance of our Board of Directors and individual
directors; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assisting our Board of Directors on corporate governance matters. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Generally, our Nominating Committee considers candidates recommended by stockholders as well as from other sources such as
other directors or officers, third party search firms or other appropriate sources. Once identified, the Nominating Committee will evaluate a candidate&#146;s qualifications in accordance with the criteria set forth in our Corporate Governance
Guidelines. Our Nominating Committee has not adopted a formal diversity policy in connection with the consideration of director nominations or the selection of nominees. However, the Nominating Committee will consider issues of diversity among its
members in identifying and considering nominees for director, and strive where appropriate to achieve a diverse balance of backgrounds, perspectives, experience, age, gender, and ethnicity on the Board of Directors and its committees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If a stockholder wishes to propose a candidate for consideration as a nominee for election to the Board of Directors, it must
follow the procedures described in our amended and restated <FONT STYLE="white-space:nowrap">By-Laws</FONT> and in &#147;Stockholder </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Proposals and Nominations For Director&#148; at the end of this proxy statement. Any such recommendation should be made in writing to the Nominating and Governance Committee, care of our
Secretary at our principal office, and should be accompanied by the following information concerning each recommending stockholder and the beneficial owner, if any, on whose behalf the nomination is made: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all information relating to such person that would be required to be disclosed in a proxy statement;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain biographical and share ownership information about the stockholder and any other proponent, including
a description of any derivative transactions in our securities; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a description of certain arrangements and understandings between the proposing stockholder and any beneficial
owner and any other person in connection with such stockholder nomination; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a statement whether or not either such stockholder or beneficial owner intends to deliver a proxy statement
and form of proxy to holders of voting shares sufficient to carry the proposal. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The recommendation must
also be accompanied by the following information concerning the proposed nominee: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain biographical information concerning the proposed nominee; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all information concerning the proposed nominee required to be disclosed in solicitations of proxies for
election of directors; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain information about any other security holder who supports the proposed nominee; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a description of all relationships between the proposed nominee and the recommending stockholder or any
beneficial owner, including any agreements or understandings regarding the nomination; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additional disclosures relating to stockholder nominees for directors, including completed questionnaires and
disclosures required by our amended and restated <FONT STYLE="white-space:nowrap">By-Laws.</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Corporate Governance Guidelines.</B> Our Board of Directors has adopted corporate governance guidelines, which apply to our
principal executive officer, our principal financial and accounting officer and all of our other employees, to assist in the exercise of its duties and responsibilities and to serve the best interests of us and our stockholders. The guidelines
provide that: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Board of Directors&#146; principal responsibility is to oversee our management; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">except as required by Nasdaq rules, a majority of the members of our Board of Directors must be independent
directors; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the independent directors meet in executive session at least twice a year; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">directors have full and free access to management and, as necessary, independent advisors; and
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our nominating and corporate governance committee will oversee periodic self-evaluations of the Board of
Directors to determine whether it and its committees are functioning effectively. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While we have no
formal policy regarding diversity of our board members, our Corporate Governance Guidelines provide that the background and qualifications of the members of our Board of Directors considered as a group should provide a significant breadth of
experience, knowledge, and ability to assist our Board of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Directors in fulfilling its responsibilities. Our priority in selection of board members is the identification of members who will further the interests of our stockholders through their
established records of professional accomplishment, the ability to contribute positively to the collaborative culture among our board members, knowledge of our business, understanding of the competitive landscape in which we operate and adherence to
high ethical standards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Copies of the Nominating Committee&#146;s written charter and our Corporate Governance Guidelines
are publicly available on our website at www.sperotherapeutics.com. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Compensation Committee Interlocks and Insider
Participation.</B> None of the members of our Compensation Committee has at any time during the prior three years been one of our officers or employees. None of our executive officers currently serves, or in the past fiscal year has served, as a
member of our Board of Directors or Compensation Committee of any entity that has one or more executive officers serving on our Board of Directors or Compensation Committee. For a description of any transactions between us and members of our
Compensation Committee and affiliates of such members, see &#147;Certain Relationships and Related Person Transactions.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Leadership
Structure and Role in Risk Oversight </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our Board of Directors is currently chaired by Milind Deshpande, Ph.D. As a
general policy, our Board of Directors believes that separation of the positions of chairman and chief executive officer reinforces the independence of our Board of Directors from management, creates an environment that encourages objective
oversight of management&#146;s performance and enhances the effectiveness of our Board of Directors as a whole. As such, Dr.&nbsp;Mahadevia serves as our Chief Executive Officer while Dr.&nbsp;Deshpande serves as the chairman of our Board of
Directors but is not an officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our Board of Directors oversees the management of risks inherent in the operation of our
business and the implementation of our business strategies. Our Board of Directors performs this oversight role by using several different levels of review. In connection with its reviews of our operations and corporate functions, our Board of
Directors addresses the primary risks associated with those operations and corporate functions. In addition, our Board of Directors reviews the risks associated with our business strategies periodically throughout the year as part of its
consideration of undertaking any such business strategies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each of our board committees also oversees the management of
our risk that falls within the committee&#146;s areas of responsibility. In performing this function, each committee has full access to management, as well as the ability to engage advisors. Our Chief Executive Officer reports to the Audit Committee
and is responsible for identifying, evaluating and implementing risk management controls and methodologies to address any identified risks. In connection with its risk management role, our Audit Committee meets privately with representatives from
our independent registered public accounting firm and our Chief Executive Officer. The Audit Committee oversees the operation of our risk management program, including the identification of the primary risks associated with our business and periodic
updates to such risks, and reports to our Board of Directors regarding these activities.<B> </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Policy Prohibiting Hedging </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We maintain an Insider Trading Policy that prohibits our officers, directors, and employees from, among other things, engaging
in speculative transactions in our securities, including by way of the purchase or sale of a put option, a call option or a short sale (including a short sale &#147;against the box&#148;), or engaging in hedging transactions, including prepaid
variable forward contracts, equity swaps, collars and exchange funds. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stockholder Communications to the Board of Directors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Generally, stockholders who have questions or concerns should contact our Investor Relations department at <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">857-242-1547</FONT></FONT> or ir@sperotherapeutics.com. However, any stockholders who wish to address </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
questions regarding our business directly with the Board of Directors, or any individual director, should direct his or her questions in writing to the Chairman of the Board of Directors at Spero
Therapeutics, Inc., 675 Massachusetts Avenue, 14th Floor, Cambridge, Massachusetts 02139. Communications will be distributed to the Board of Directors, or to any individual director or directors as appropriate, depending on the facts and
circumstances outlined in the communications. Items that are unrelated to the duties and responsibilities of the Board of Directors may be excluded, such as: junk mail and mass mailings; resumes and other forms of job inquiries; surveys; and
solicitations or advertisements. In addition, any material that is unduly hostile, threatening, or illegal in nature may be excluded, provided that any communication that is filtered out will be made available to any outside director upon request.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth certain information regarding our executive officers who are not also directors. We have
employment agreements with each of our executive officers. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD WIDTH="40%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:10pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Position</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tamara&nbsp;Joseph</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief&nbsp;Legal&nbsp;Officer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Timothy&nbsp;Keutzer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief&nbsp;Development&nbsp;Officer</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Satyavrat Shukla</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On May&nbsp;3, 2022, the Company implemented a strategic restructuring initiative and
corresponding reduction in workforce, designed to reduce costs and reallocate resources towards its clinical development programs for SPR720 and SPR206, while maintaining key personnel needed to help preserve the value of the Company&#146;s
tebipenem HBr program (the &#147;Restructuring&#148;). Effective as of July&nbsp;2, 2022, Cristina Larkin separated from the Company as its Chief Operating Officer and David Melnick, M.D. separated from the Company as its Chief Medical Officer
pursuant to the Restructuring. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Tamara Joseph</I></B><I> </I>has served as our Chief Legal Officer since December
2020. She has over 20 years of leadership roles in the biotechnology sector, overseeing legal, public and government affairs, compliance and risk management. Ms.&nbsp;Joseph most recently served as Chief Legal Officer at Millendo Therapeutics, Inc.
and previously served as General Counsel at Enzyvant Therapeutics Ltd., InVivo Therapeutics Holdings Corp., Cubist Pharmaceuticals, Inc., Mayne Pharma Ltd., and Transkaryotic Therapies, Inc. Her experience also includes establishing and leading the
international legal and public affairs departments of Biogen Idec Inc. Ms.&nbsp;Joseph received her B.A. in economics from Duke University, her J.D. from the University of Michigan Law School and her L.L.M. degrees from the College of Europe in
Belgium and the University of Paris. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Timothy Keutzer </I></B>has served as our Chief Development Officer since June
2019. He has over 20 years&#146; experience in the pharmaceutical industry, spanning multiple functional and therapeutic areas. Prior to joining Spero, Mr.&nbsp;Keutzer served in various roles at Cubist Pharmaceuticals, including Vice President of
Program and Portfolio Management from May 2014 to July 2015. At Cubist Mr.&nbsp;Keutzer was the program leader for ceftolozane/tazobactam, which progressed rapidly from Phase 1 to Phase 3, and was approved in the FDA in December of 2014. Prior to
that role, he also led several of Cubist&#146;s <FONT STYLE="white-space:nowrap">in-licensed</FONT> development programs and also led the commercial supply chain for Cubicin. His experience before Cubist spans multiple drug classes and includes
preclinical PK/PD and clinical operations at Genetics Institute, as well as global strategic marketing and program management at Wyeth. Tim began his career in contract toxicology labs. Mr.&nbsp;Keutzer earned his bachelor&#146;s degree from the
University of Kentucky. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Satyavrat Shukla</I></B> has served as our Chief Financial Officer since January 2021. He
has over 20 years of strategic and financial leadership experience. He was most recently Chief Financial Officer at Ziopharm Oncology, Inc. from July 2019 to December 2020, where he directed all of Ziopharm&#146;s financial aspects, including
financial planning, analysis and reporting, treasury and tax functions, capital strategy and investor relations. Prior to Ziopharm, Mr.&nbsp;Shukla was Vice President and Global Head of Corporate Finance for Vertex
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Pharmaceuticals, Inc. from July 2012 to July 2019, where he managed financial planning, analysis and budgeting, and led the annual long-range planning process encompassing Vertex&#146;s entire
portfolio and operations across more than 30 countries. Previously, Mr.&nbsp;Shukla was a Principal at Cornerstone Research, where he led teams providing consulting services for life science clients ranging from
<FONT STYLE="white-space:nowrap">start-ups</FONT> to multi-billion-dollar corporations. Prior to Cornerstone, he worked for finance consulting firms LECG Corporation and Putnam, Hayes&nbsp;&amp; Bartlett, Inc. Mr.&nbsp;Shukla earned a B.A. in
Economics from Harvard University and an M.B.A. in Finance and Strategy from Yale University. He also holds the Chartered Financial Analyst designation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom341851_4"></A>EXECUTIVE OFFICER AND DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary Compensation Table </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table shows the total compensation paid or accrued during the last two fiscal years ended December&nbsp;31, 2021
and 2020 to our President and Chief Executive Officer and our two next most highly compensated executive officers who earned more than $100,000 during the fiscal year ended December&nbsp;31, 2021 and were serving as executive officers as of such
date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name and Principal</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus</B><br><B>($)(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock</B><br><B>Awards</B><br><B>($)(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>Awards</B><br><B>($)(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT></B><br><B>Incentive Plan</B><br><B>Compensation</B><br><B>($)(4)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All other</B><br><B>Compensation</B><br><B>($)(5)(6)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Ankit Mahadevia, M.D.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">590,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,650,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">327,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,875,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>&nbsp;&nbsp;&nbsp;&nbsp;Chief Executive Officer</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">536,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,153,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">424,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,120,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Satyavrat Shukla</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">440,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">399,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,039,433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175,660</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,228,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>&nbsp;&nbsp;&nbsp;&nbsp;Chief Financial Officer</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Cristina Larkin (7)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">460,406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">399,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">848,983</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185,107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,903,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><I>Former Chief Operating Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">404,052</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">352,600</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">225,968</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">9,342</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">991,962</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of a <FONT STYLE="white-space:nowrap">sign-on</FONT> bonus to Mr.&nbsp;Shukla in connection with
his commencement of employment in January 2021. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">These amounts represent the aggregate grant date fair value for RSU awards computed in accordance with
Financial Accounting Standards Board Accounting Standards Codification Topic 718 (&#147;ASC 718&#148;). A discussion of the assumptions used in determining grant date fair value may be found in Note 9 to our consolidated financial statements for the
year ended December&nbsp;31, 2021. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">These amounts represent the aggregate grant date fair value for option awards computed in accordance with
ASC 718. A discussion of the assumptions used in determining grant date fair value may be found in Note 9 to our consolidated financial statements for the year ended December&nbsp;31, 2021. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Amounts represent annual cash bonuses earned for the applicable fiscal year. The annual cash bonuses are
paid in the first quarter of the calendar year following the year to which the cash bonus relates. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Amounts in this column include for the year ended December&nbsp;31, 2021 (i) in the case of
Dr.&nbsp;Mahadevia, $740 consists of the dollar value of life insurance premiums we paid with respect to term life insurance and $5,505 in a matching contribution under our 401(k) plan, (ii)&nbsp;in the case of Mr.&nbsp;Shukla, $740 consists of the
dollar value of life insurance premiums we paid with respect to term life insurance and $7,555 in a matching contribution under our 401(k) plan and (iii)&nbsp;in the case of Ms.&nbsp;Larkin, $740 consists of the dollar value of life insurance
premiums we paid with respect to term life insurance and $8,701 in a matching contribution under our 401(k) plan. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Amounts in this column for the year ended December&nbsp;31, 2020 include (i)&nbsp;in the case of
Dr.&nbsp;Mahadevia, $792 consists of the dollar value of life insurance premiums we paid with respect to term life insurance and $5,318 in a matching contribution under our 401(k) plan and (ii)&nbsp;in the case of Ms.&nbsp;Larkin, $792 consists of
the dollar value of life insurance premiums we paid with respect to term life insurance and $8,550 in a matching contribution under our 401(k) plan. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Effective as of July&nbsp;2, 2022, Cristina Larkin separated from the Company as its Chief Operating Officer
pursuant to the Restructuring. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Narrative Disclosure to Summary Compensation Table </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our employment arrangements with our named executive officers are described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ankit Mahadevia, M.D. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On March&nbsp;2, 2015, Dr.&nbsp;Mahadevia executed an offer letter with respect to his employment as our Chief Executive
Officer beginning on the same date. Under the terms of the offer letter, Dr.&nbsp;Mahadevia&#146;s annual base salary was $360,500 in 2016 and $400,000 effective on May&nbsp;19, 2017. Under the offer letter, he was eligible to receive an annual
incentive bonus determined at the discretion of our Board of Directors or Compensation Committee, with a target bonus opportunity of 30% of his then-current base salary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dr.&nbsp;Mahadevia entered into a new employment agreement on October&nbsp;20, 2017. This agreement provides for the following
increased severance payments upon termination by us without Cause (as defined below) or by Dr.&nbsp;Mahadevia for Good Reason (as defined below): (i) payment of his then current base salary for a period of 12 months following termination;
(ii)&nbsp;a <FONT STYLE="white-space:nowrap">pro-rated</FONT> target bonus for the period during which Dr.&nbsp;Mahadevia was employed in the year of termination; and (iii)&nbsp;continued coverage under our group health insurance plan until the
earlier of 12 months from termination or the date Dr.&nbsp;Mahadevia becomes eligible for medical benefits with another employer. Further, the new agreement provides that upon termination by us without Cause or by Dr.&nbsp;Mahadevia for Good Reason
within 90 days prior to the earlier to occur of a Change of Control (as defined below) or the execution of a definitive agreement the consummation of which would result in a Change of Control or one year following a Change of Control (a &#147;Change
of Control Termination&#148;), Dr.&nbsp;Mahadevia will be entitled to receive (i)&nbsp;a lump sum payment equal to 12 months of his then-current base salary plus a <FONT STYLE="white-space:nowrap">pro-rated</FONT> target bonus for the period during
which Dr.&nbsp;Mahadevia was employed in the year of termination; (ii)&nbsp;acceleration of all unvested equity awards as of the date of termination; and (iii)&nbsp;continued coverage under our group health insurance plan until the earlier of 12
months from termination or the date Dr.&nbsp;Mahadevia becomes eligible for medical benefits with another employer. Payment in each case is subject to Dr.&nbsp;Mahadevia&#146;s execution of a release satisfactory to us following such termination.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, if Dr.&nbsp;Mahadevia&#146;s employment terminates as a result of disability or death, he shall be entitled
to receive a <FONT STYLE="white-space:nowrap">pro-rated</FONT> target bonus for the period during which Dr.&nbsp;Mahadevia was employed in the year of termination. The new agreement also provides that Dr.&nbsp;Mahadevia shall serve as a member of
our Board of Directors during his employment with us until the term of his directorship expires and he is not <FONT STYLE="white-space:nowrap">re-elected</FONT> or his earlier resignation or removal from our Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In December 2017, Dr.&nbsp;Mahadevia&#146;s base salary was increased, effective January&nbsp;1, 2018, to $465,000 with a
target bonus opportunity of 50% of base salary. In December 2018, Dr.&nbsp;Mahadevia&#146;s base salary was increased, effective February&nbsp;1, 2019, to $500,000 with a target bonus opportunity of 50% of his base salary. In December 2019,
Dr.&nbsp;Mahadevia&#146;s base salary was increased, effective February&nbsp;1, 2020, to $540,000, with a target bonus opportunity of 50% of his base salary. In December 2020, Dr.&nbsp;Mahadevia&#146;s base salary was increased, effective
February&nbsp;1, 2021, to $565,000, with a target bonus opportunity of 50% of his base salary. As of July&nbsp;1, 2021, Dr.&nbsp;Mahadevia&#146;s base salary was increased to $620,000, with a target bonus opportunity of 60% of his base salary. In
December 2021, Dr.&nbsp;Mahadevia&#146;s base salary was increased, effective February&nbsp;1, 2022, to $635,000, with a target bonus opportunity of 60% of his base salary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Satyavrat Shukla </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On December&nbsp;9, 2020, we entered into an agreement with Mr.&nbsp;Shukla with respect to his employment as our Chief
Financial Officer commencing on January&nbsp;4, 2021. The terms of Mr.&nbsp;Shukla&#146;s agreement provided for an annual base salary of $425,000 prorated for fiscal year 2021, and eligibility for an annual incentive bonus, with a target bonus
opportunity of 40% of his then-current base salary.<B><I> </I></B>As of July&nbsp;1, 2021, Mr.&nbsp;Shukla&#146;s base salary was increased to $460,000, with a target bonus opportunity of 40% of his base salary. In December 2021,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Mr.&nbsp;Shukla&#146;s base salary was increased, effective February&nbsp;1, 2022, to $480,000 with a target bonus opportunity of 40% of his base salary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The agreement also provides for the following severance payments upon termination by us without Cause or by Mr.&nbsp;Shukla
for Good Reason: (i)&nbsp;payment of his then-current base salary for a period of nine months following termination; (ii)&nbsp;a <FONT STYLE="white-space:nowrap">pro-rated</FONT> target bonus for the period during which Mr.&nbsp;Shukla was employed
in the year of termination; and (iii)&nbsp;continued coverage under our group health insurance plan until the earlier of 12 months from termination or the date Mr.&nbsp;Shukla becomes eligible for medical benefits with another employer. Further, the
agreement provides that upon termination by us without Cause or by Mr.&nbsp;Shukla for Good Reason within 90 days prior to the earlier to occur of a Change of Control or a Change of Control Termination, Mr.&nbsp;Shukla will be entitled to receive:
(i)&nbsp;a lump sum payment equal to 12 months of his then-current base salary plus a <FONT STYLE="white-space:nowrap">pro-rated</FONT> target bonus for the period during which Mr.&nbsp;Shukla was employed in the year of termination;
(ii)&nbsp;acceleration of (A)&nbsp;all unvested equity awards as of the date of termination if Mr.&nbsp;Shukla&#146;s employment commenced at least 24 months prior to a Change of Control (B) 50% of all unvested equity awards as of the date of
termination if Mr.&nbsp;Shukla&#146;s employment commenced fewer than 24 months but at least 12 months prior to a Change of Control and (C) 25% of all unvested equity awards as of the date of termination if Mr.&nbsp;Shukla&#146;s employment
commenced fewer than 12 months prior to a Change of Control; and (iii)&nbsp;continued coverage under our group health insurance plan until the earlier of 12 months from termination or the date Mr.&nbsp;Shukla becomes eligible for medical benefits
with another employer. Payment in each case is subject to Mr.&nbsp;Shukla&#146;s execution of a release satisfactory to us following such termination. In addition, if Mr.&nbsp;Shukla&#146;s employment terminates as a result of disability or death,
he shall be entitled to receive a <FONT STYLE="white-space:nowrap">pro-rated</FONT> target bonus for the period during which Mr.&nbsp;Shukla was employed in the year of termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cristina Larkin </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In February 2016, Cristina Larkin, our then Chief Commercial Officer, executed an offer letter with respect to her employment
beginning on March&nbsp;7, 2016. In September 2017, Ms.&nbsp;Larkin was promoted to Chief Operating Officer, in connection with which her bonus target was increased from 25% to 30% of her then-current base salary. In October 2017, we entered into a
new employment agreement with Ms.&nbsp;Larkin, which provided for a base salary of $345,000 and eligibility for an annual incentive bonus, with a target bonus opportunity of 30% of her then-current base salary. In December 2017,
Ms.&nbsp;Larkin&#146;s base salary was increased, effective January&nbsp;1, 2018, to $385,000 with a target bonus opportunity of 35% of base salary. In December 2018, Ms.&nbsp;Larkin&#146;s base salary was increased, effective February&nbsp;1, 2019,
to $395,000 with a target bonus opportunity of 40% of base salary. In December 2019, Ms.&nbsp;Larkin&#146;s base salary was increased, effective February&nbsp;1, 2020, to $404,875 with a target bonus opportunity of 40% of her base salary. In
December 2020, Ms.&nbsp;Larkin&#146;s base salary was increased, effective February&nbsp;1, 2021, to $430,000 with a target bonus opportunity of 40% of her base salary. As of July&nbsp;1, 2021, Ms.&nbsp;Larkin&#146;s base salary was increased to
$495,000, with a target bonus opportunity of 40% of her base salary. In December 2021, Ms.&nbsp;Larkin&#146;s base salary was increased, effective February&nbsp;1, 2022, to $515,000 with a target bonus opportunity of 40% of her base salary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The agreement also provided for the following severance payments upon termination by us without Cause or by Ms.&nbsp;Larkin
for Good Reason: (i)&nbsp;payment of her then-current base salary for a period of nine months following termination; (ii)&nbsp;a <FONT STYLE="white-space:nowrap">pro-rated</FONT> target bonus for the period during which Ms.&nbsp;Larkin was employed
in the year of termination; and (iii)&nbsp;continued coverage under our group health insurance plan until the earlier of 12 months from termination or the date Ms.&nbsp;Larkin becomes eligible for medical benefits with another employer. Further, the
agreement provided that upon termination by us without Cause or by Ms.&nbsp;Larkin for Good Reason within 90 days prior to the earlier to occur of a Change of Control or a Change of Control Termination, Ms.&nbsp;Larkin would be entitled to receive:
(i)&nbsp;a lump sum payment equal to 12 months of her then-current base salary plus a <FONT STYLE="white-space:nowrap">pro-rated</FONT> target bonus for the period during which Ms.&nbsp;Larkin was employed in the year of termination;
(ii)&nbsp;acceleration of (A)&nbsp;all unvested equity awards as of the date of termination if Ms.&nbsp;Larkin&#146;s employment commenced at least 24 months prior to a Change of Control (B) 50% of all unvested equity awards as of the date of
termination if Ms.&nbsp;Larkin&#146;s employment commenced fewer than 24 months but at least 12 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
months prior to a Change of Control or (C) 25% of all unvested equity awards as of the date of termination if Ms.&nbsp;Larkin&#146;s employment commenced fewer than 12 months prior to a Change of
Control; and (iii)&nbsp;continued coverage under our group health insurance plan until the earlier of 12 months from termination or the date Ms.&nbsp;Larkin becomes eligible for medical benefits with another employer. Payment in each case was
subject to Ms.&nbsp;Larkin&#146;s execution of a release satisfactory to us following such termination. In addition, if Ms.&nbsp;Larkin&#146;s employment terminated as a result of disability or death, she was entitled to receive a <FONT
STYLE="white-space:nowrap">pro-rated</FONT> target bonus for the period during which Ms.&nbsp;Larkin was employed in the year of termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Effective as of July&nbsp;2, 2022 (the &#147;Effective Date&#148;), Ms.&nbsp;Larkin separated from the Company as its Chief
Operating Officer pursuant to the Restructuring. In connection with Ms.&nbsp;Larkin&#146;s separation, the Company and Ms.&nbsp;Larkin entered into a separation agreement (the&nbsp;&#147;Larkin Separation Agreement&#148;), dated as of May&nbsp;3,
2022. The Larkin Separation Agreement provides that the Company will pay Ms.&nbsp;Larkin provided that Ms.&nbsp;Larkin complies with the terms of the Larkin Separation Agreement, including the release and waiver provided therein, (i)&nbsp;severance
as a continuation of payments in an amount equal to Ms.&nbsp;Larkin&#146;s current annual base salary for a nine-month period, which will total $386,249.94, payable as continued salary in accordance with the Company&#146;s regular payroll dates, and
(ii)&nbsp;a pro rated cash bonus equal to $103,282 for the year ending December&nbsp;31, 2022, which will be paid to Ms.&nbsp;Larkin when the Company pays the 2022 annual bonuses to its employees in 2023, but in any event no later than
March&nbsp;15, 2023; in each case less all required taxes and employment-related deductions. The Larkin Separation Agreement also includes other customary provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the Company and Ms.&nbsp;Larkin entered into a consulting agreement (the &#147;Larkin Consulting
Agreement&#148;), dated as of May&nbsp;3,&nbsp;2022 and effective as of the Effective Date, pursuant to which Ms.&nbsp;Larkin will provide consulting services to the Company for a term of ten months following the Effective Date at a rate of $300.00
per hour. In further consideration for Ms.&nbsp;Larkin&#146;s services as a consultant, (i)&nbsp;all of Ms.&nbsp;Larkin&#146;s options to purchase shares of the Company&#146;s common stock and restricted stock units (&#147;RSUs&#148;) shall continue
to vest during the term of the Larkin Consulting Agreement; and (ii)&nbsp;after the term of the Larkin Consulting Agreement ends, all of Ms.&nbsp;Larkin&#146;s vested options to purchase shares of the Company&#146;s common stock will continue to be
exercisable for three months in accordance with the terms of such options and the Company&#146;s 2017 Stock Incentive Plan, as amended (the &#147;2017 Plan&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under each of the employment agreements, Cause means (i)&nbsp;the executive&#146;s conviction of (A)&nbsp;a felony or
(B)&nbsp;any misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (ii)&nbsp;the executive&#146;s willful failure or refusal to comply with lawful directions of our Board of Directors, with respect to Dr.&nbsp;Mahadevia, our Chief
Executive Officer, with respect to Mr.&nbsp;Shukla and Ms.&nbsp;Larkin, which failure or refusal continues for more than thirty days after written notice is given to the executive by our Board of Directors, with respect to Dr.&nbsp;Mahadevia, or by
our Chief Executive Officer, with respect to Mr.&nbsp;Shukla and Ms.&nbsp;Larkin, which notice sets forth in reasonable detail the nature of such failure or refusal; (iii)&nbsp;willful and material breach by the executive of a written company policy
applicable to the executive or the executive&#146;s covenants and/or obligations under his or her employment agreement or the material breach of the executive&#146;s proprietary information and inventions assignment agreement; and/or
(iv)&nbsp;material misconduct by the executive that seriously discredits or damages us or any of our affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under
each of the employment agreements, Good Reason means (i)&nbsp;relocation of the executive&#146;s principal business location to a location more than thirty (30)&nbsp;miles from the executive&#146;s then-current business location; (ii)&nbsp;a
material diminution in the executive&#146;s duties, authority or responsibilities; (iii)&nbsp;a material reduction in the executive&#146;s base salary; (iv)&nbsp;willful and material breach by us of our covenants and/or obligations under the
executive&#146;s employment agreement; or (v)&nbsp;within one year following a Change of Control, the executive is not an executive of the parent company, provided that the executive&#146;s roles responsibilities and scope of authority within the
subsidiary is not comparable to the executive&#146;s roles, responsibilities and scope of authority with us prior to the Change of Control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under each of the employment agreements, Change of Control means (i)&nbsp;any person (as such term is used in Sections 13(d)
and 14(d) of the Exchange Act) becomes the beneficial owner, directly or indirectly, of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company&#146;s then outstanding voting securities (excluding for this purpose any
such voting securities held by the Company, or any affiliate, parent or subsidiary of the Company, or by any employee benefit plan of the Company) pursuant to a transaction or a series of related transactions; (ii)&nbsp;a merger or consolidation of
the Company other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities
of the surviving entity or the parent of such corporation) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or parent of such corporation, as the case may be,
outstanding immediately after such merger or consolidation; (iii)&nbsp;our stockholders approve an agreement for the sale or disposition by the Company of all or substantially all of our assets; or (iv)&nbsp;a change in the composition of our Board
of Directors, as a result of which fewer than a majority of the directors are incumbent directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">All of our executive
officers have entered into our standard proprietary information and inventions assignment agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at 2021 Fiscal <FONT
STYLE="white-space:nowrap">Year-End</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On June&nbsp;30, 2017, we completed a series of transactions pursuant to
which Spero Therapeutics, LLC merged with and into Spero Therapeutics, Inc., with Spero Therapeutics, Inc. continuing as the surviving corporation (the &#147;2017 Reorganization&#148;). As part of the 2017 Reorganization, each of the capital units
of Spero Therapeutics, LLC issued and outstanding prior to the 2017 Reorganization was cancelled and converted into and exchanged for one share of Spero Therapeutics, Inc. capital stock of the same class and/or series, and each of the incentive
units of Spero Therapeutics, LLC was terminated and cancelled. Promptly after the 2017 Reorganization, previous holders of incentive units who were still employed by us at the time of the Reorganization received stock options under the 2017 Plan.
Such stock options were granted for the same number of shares of our common stock as the number of incentive units cancelled, and the stock options were granted with continued vesting on the same terms and with similar rights and restrictions as the
incentive units. All such stock options have an exercise price of $5.90. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table shows grants of stock options and awards outstanding on
the last day of the fiscal year ended December&nbsp;31, 2021 to each of the executive officers named in the Summary Compensation Table. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number
of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Exercisable</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number
of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Unexercisable</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Option<BR>Exercise<BR>Price<BR>($)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Option<BR>Expiration<BR>Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of<BR>Shares or<BR>Units of<BR>Stock&nbsp;That<BR>Have not<BR>Vested (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Market<BR>Value
of<BR>Shares&nbsp;or<BR>Units of<BR>Stock&nbsp;that<BR>Have not<BR>Vested&nbsp;($)(1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Ankit Mahadevia, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/5/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$5.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/5/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$5.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/5/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">244,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$5.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/5/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$11.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/12/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$6.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/1/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$9.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/2/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">179,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$19.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/31/2031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Satyavrat Shukla</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/3/2031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">399,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cristina Larkin (14)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/5/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$5.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/5/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,779</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$5.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/5/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$11.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/12/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$6.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/1/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$9.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/2/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,432</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$19.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/31/2031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">399,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The market value of the stock awards is based on the closing price of our common stock of $16.01 per share
on December&nbsp;31, 2021. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">100% of these options vested on August&nbsp;24, 2019. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">As part of the 2017 Reorganization, Dr.&nbsp;Mahadevia was granted options to replace his previously awarded
incentive units in Spero Therapeutics, LLC. The options vest in accordance with the vesting terms of Dr.&nbsp;Mahadevia&#146;s previously held incentive units: 25% of the underlying shares were deemed vested April&nbsp;28, 2017, the first
anniversary of the vesting commencement date, with an additional 1/36th of the remaining shares vesting monthly thereafter until the option was fully vested. In addition, in the event of a Change of Control Termination, the vesting of these options
will accelerate in accordance with the terms of the option and his employment agreement. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">100% of these options vested on July&nbsp;6, 2017. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">100% of these options vested on July&nbsp;6, 2021. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">100% of these options vested on December&nbsp;13, 2021. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">25% of the options vested on January&nbsp;2, 2020 and an additional 1/36th of the remaining shares vest
monthly until the option is fully vested. In addition, in the event of a Change of Control Termination, the vesting of these options will accelerate in accordance with the terms of the option and his or her employment agreement.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">25% of the options vested on February&nbsp;3, 2021 and an additional 1/36th of the remaining shares vest
monthly until the option is fully vested. In addition, in the event of a Change of Control Termination, the vesting of these options will accelerate in accordance with the terms of the option and his or her employment agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">25% of the options vested on February&nbsp;1, 2022 and an additional 1/36th of the remaining shares vest
monthly until the option is fully vested. In addition, in the event of a Change of Control Termination, the vesting of these options will accelerate in accordance with the terms of the option and his or her employment agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of RSUs. Each RSU represents the right to receive one share of common stock upon vesting. The RSUs
vest in four equal annual installments beginning on August&nbsp;26, 2022. In addition, in the event of a Change of Control Termination, the vesting of these RSUs will accelerate in accordance with the terms of the RSU and his or her employment
agreement. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">As part of our 2017 Reorganization, Ms.&nbsp;Larkin was granted options to replace her previously awarded
incentive units in Spero Therapeutics, LLC. The options vest in accordance with the vesting terms of Ms.&nbsp;Larkin&#146;s previously held incentive units: 25% of the underlying shares were deemed vested on March&nbsp;7, 2017, the first anniversary
of the vesting commencement date, with an additional 1/36th of the remaining shares vesting monthly thereafter until the option was fully vested. In addition, in the event of a Change of Control Termination, the vesting of these options will
accelerate in accordance with the terms of the option and her employment agreement. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">As part of our 2017 Reorganization, Ms.&nbsp;Larkin was granted options to replace her previously awarded
incentive units in Spero Therapeutics, LLC. The options vest in accordance with the vesting terms of Ms.&nbsp;Larkin&#146;s previously held incentive units: 25% of the underlying shares were deemed vested April&nbsp;28, 2017, the first anniversary
of the vesting commencement date, with an additional 1/36th of the remaining shares vesting monthly thereafter until the option was fully vested. In addition, in the event of a Change of Control Termination, the vesting of these options will
accelerate in accordance with the terms of the option and her employment agreement. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">25% of the options vested on January&nbsp;4, 2022 and an additional 1/36th of the remaining shares vest
monthly until the option is fully vested. In addition, in the event of a Change of Control Termination, the vesting of these options will accelerate in accordance with the terms of the option and his or her employment agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Effective as of July&nbsp;2, 2022, Cristina Larkin separated from the Company as its Chief Operating Officer
pursuant to the Restructuring. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table shows the number of shares acquired and the value
realized upon exercises of share options during the fiscal year ended December&nbsp;31, 2021 by each of the executive officers named in the Summary Compensation Table. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Shares&nbsp;Acquired<BR>on Exercise (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value&nbsp;Realized</B><br><B>on Exercise</B><br><B>($)(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ankit Mahadevia, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Satyavrat Shukla</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cristina Larkin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The value realized on exercise is based on the market price of the shares at exercise less the applicable
option exercise price. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2019 Performance-Based Equity Incentive Awards </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Historically, we have generally granted stock options with time-based vesting to our executives at the time of hire and on an
annual basis thereafter. In March 2019, in addition to the foregoing, we granted an aggregate of 150,000 performance-based options and RSUs to our senior executives. These options and RSUs (the &#147;2019 Performance Awards&#148;) were subject to
performance-based vesting eligibility and a subsequent partial time-based vesting schedule. Specifically, the 2019 Performance Awards are eligible for vesting based on the achievement of performance criteria, each representing a 25% vesting
opportunity if achieved within a specified time during the performance period (the &#147;Performance Period&#148;), and relating to (i)&nbsp;the release of tebipenem HBr <FONT STYLE="white-space:nowrap">top-line</FONT> data; (ii)&nbsp;FDA acceptance
of a tebipenem HBr New Drug Application; <FONT STYLE="white-space:nowrap">(iii)&nbsp;non-dilutive</FONT> financing; and (iv)&nbsp;equity financing. Following the Performance Period, 2019 Performance Awards determined to be eligible for vesting as a
result of achievement of the performance criteria would vest as follows: (a) 50% of the eligible award would vest immediately, and (b)&nbsp;the remaining eligible award would vest (i)&nbsp;in the case of options, in equal monthly instalments ending
two years after the Performance Period expiration, and (ii)&nbsp;in the case of RSUs, on such <FONT STYLE="white-space:nowrap">two-year</FONT> anniversary. The 2019 Performance Awards were subject to provisions of the executives&#146; employment
agreements regarding acceleration of vesting in the event of certain termination events following a change in control only to the extent previously determined to be eligible for vesting as a result of achievement of the performance criteria. Awards
for which the performance criteria have not been achieved as specified during the Performance Period would lapse. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In
January 2021, the 2019 Performance Awards were cancelled due to the <FONT STYLE="white-space:nowrap">non-achievement</FONT> of the performance-based vesting criteria. None of the 2019 Performance Awards had vested as of the date of cancellation.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2022 Retention Cash Bonus and Performance Awards </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On July&nbsp;1, 2022, upon recommendation of the Compensation Committee, the Board of Directors approved a cash and RSU
retention award for the Company&#146;s executive officers, including awards to Dr.&nbsp;Mahadevia,&nbsp;M.D. and Mr.&nbsp;Shukla, consisting of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Subject to Dr.&nbsp;Mahadevia remaining actively employed with the Company through May&nbsp;31, 2023,
Dr.&nbsp;Mahadevia will receive: (i)&nbsp;a cash bonus of $254,000 payable on November&nbsp;30, 2022 and (ii)&nbsp;if certain performance criteria are achieved, a number of shares of common stock to be issued to him on May&nbsp;31, 2023 having a
value of $508,000 based on the common stock price at such time, subject to the discretion of the Board or the Compensation Committee to pay in cash or a combination of cash and stock. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Subject to Mr.&nbsp;Shukla remaining actively employed with the Company through May&nbsp;31, 2023,
Mr.&nbsp;Shukla shall receive: (i)&nbsp;a cash bonus of $168,000 payable on November&nbsp;30, 2022 and (ii)&nbsp;if certain performance criteria are achieved, a number of shares of common stock to be issued to him on May&nbsp;31, 2023 having a value
of $336,000 based on the common stock price at such time, subject to the discretion of the Board or the Compensation Committee to pay in cash or a combination of cash and stock. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The RSUs are eligible for vesting based on the achievement of certain performance criteria by May&nbsp;31, 2023 relating to
pipeline execution, business development, and financial stewardship. RSUs for which the performance criteria have not been achieved as specified by May&nbsp;31, 2023 will lapse and be forfeited. The RSUs will be subject to acceleration of vesting in
the event of termination of employment without cause by the Company or by the executive for good reason (each as defined in the executive&#146;s employment agreement). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Potential Payments upon Termination or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Change-In-Control</FONT></FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The employment agreements provide for the following severance payments upon termination by us without Cause or by the employee
for Good Reason: (i)&nbsp;payment of the employee&#146;s then-current base salary for a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
period of nine months following termination (12 months in the case of the Chief Executive Officer); (ii) a <FONT STYLE="white-space:nowrap">pro-rated</FONT> target bonus for the period during
which the employee was employed in the year of termination; and (iii)&nbsp;continued coverage under our group health insurance plan until the earlier of 12 months from termination or the date the employee becomes eligible for medical benefits with
another employer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Further, the agreements provide that upon termination by us without Cause or by the employee for Good
Reason within 90 days prior to or one year following the earlier to occur of a Change of Control (as defined in the executive&#146;s employment agreements) or the execution of a definitive agreement the consummation of which would result in a Change
of Control, the employee will be entitled to receive: (i)&nbsp;a lump sum payment equal to 12 months of the employee&#146;s then-current base salary plus a <FONT STYLE="white-space:nowrap">pro-rated</FONT> target bonus for the period during which
the employee was employed in the year of termination; (ii)&nbsp;acceleration of unvested equity awards as of the date of termination in accordance with the terms of the executive&#146;s employment agreement, as described above under &#147;Narrative
Disclosure to Summary Compensation Table;&#148; and (iii)&nbsp;continued coverage under our group health insurance plan until the earlier of 12 months from termination or the date the employee becomes eligible for medical benefits with another
employer. Payment in each case is subject to the employee&#146;s execution of a release satisfactory to us following such termination. In addition, if the employee&#146;s employment terminates as a result of disability or death, he or she shall be
entitled to receive a <FONT STYLE="white-space:nowrap">pro-rated</FONT> target bonus for the period during which the employee was employed in the year of termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Effective as of July&nbsp;2, 2022, Ms.&nbsp;Larkin separated from the Company as its Chief Operating Officer pursuant to the
Restructuring. In connection with Ms.&nbsp;Larkin&#146;s separation, the Company and Ms.&nbsp;Larkin entered into the&nbsp;Larkin Separation Agreement. The Larkin Separation Agreement provides that the Company will pay Ms.&nbsp;Larkin provided that
Ms.&nbsp;Larkin complies with the terms of the Larkin Separation Agreement, including the release and waiver provided therein, (i)&nbsp;severance as a continuation of payments in an amount equal to Ms.&nbsp;Larkin&#146;s current annual base salary
for a nine-month period, which will total $386,249.94, payable as continued salary in accordance with the Company&#146;s regular payroll dates, and (ii)&nbsp;a <FONT STYLE="white-space:nowrap">pro-rated</FONT> cash bonus equal to $103,282 for the
year ending December&nbsp;31, 2022, which will be paid to Ms.&nbsp;Larkin when the Company pays the 2022 annual bonuses to its employees in 2023, but in any event no later than March&nbsp;15, 2023; in each case less all required taxes and
employment-related deductions. The Larkin Separation Agreement also includes other customary provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Compensation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table shows the total compensation paid or accrued during the fiscal year ended December&nbsp;31, 2021 to each
of our current and former <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. On October&nbsp;11, 2021, Kathleen Tregoning joined our Board of Directors and Jean-Fran&ccedil;ois Formela, M.D. notified the Board of Directors of his
resignation from the Board of Directors, effective as of October&nbsp;11, 2021. Directors who are employed by us are not compensated for their service on our Board of Directors. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees&nbsp;Earned<BR>or&nbsp;Paid in<BR>Cash ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>Awards*<BR>($)(8)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Milind Deshpande, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108,392</TD>
<TD NOWRAP VALIGN="bottom">(3)(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jean-Fran&ccedil;ois Formela, M.D. (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,403</TD>
<TD NOWRAP VALIGN="bottom">(5)(7)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106,403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scott Jackson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,403</TD>
<TD NOWRAP VALIGN="bottom">(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John C. Pottage, Jr., M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,403</TD>
<TD NOWRAP VALIGN="bottom">(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cynthia Smith</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108,392</TD>
<TD NOWRAP VALIGN="bottom">(3)(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Frank E. Thomas</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90,891</TD>
<TD NOWRAP VALIGN="bottom">(4)(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">127,391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kathleen Tregoning (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175,439</TD>
<TD NOWRAP VALIGN="bottom">(6)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184,352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick Vink, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90,891</TD>
<TD NOWRAP VALIGN="bottom">(4)(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">These amounts represent the aggregate grant date fair value of options granted to each director in the
fiscal year ended December&nbsp;31, 2021, computed in accordance with FASB ASC Topic 718. A discussion of the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
assumptions used in determining grant date fair value may be found in Note 9 to our consolidated financial statements, included in our Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2021. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Dr.&nbsp;Formela resigned from our Board of Directors in October 2021. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Ms.&nbsp;Tregoning joined our Board of Directors in October 2021. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Represents an option to purchase 2,629 shares of common stock at an exercise price of $17.93. The shares
underlying the option award vest and became fully exercisable on December&nbsp;31, 2021, subject to the individual&#146;s continued service as of such date. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Represents an option to purchase 1,314 shares of common stock at an exercise price of $17.93. The shares
underlying the option award vest and became fully exercisable on December&nbsp;31, 2021, subject to the individual&#146;s continued service as of such date. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Represents an option to purchase 7,500 shares of common stock at an exercise price of $13.69. The shares
underlying the option award vest and became fully exercisable on August&nbsp;17, 2022, subject to the individual&#146;s continued service as of such date. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Represents an option to purchase 15,000 shares of common stock at an exercise price of $16.91. The shares
underlying the option award vest in <FONT STYLE="white-space:nowrap">thirty-six</FONT> equal monthly installments at the end of each successive month following November&nbsp;11, 2021, subject to the individual&#146;s continued service as of such
date. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Upon resignation from our Board of Directors in October 2021, none of Dr.&nbsp;Formela&#146;s options
granted during the year ended December&nbsp;31, 2021 had vested and the options were forfeited. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">As of December&nbsp;31, 2021, the aggregate number of options held by each of our current and former <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors was as follows (representing both exercisable and unexercisable option awards, none of which have been exercised): </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares</B><br><B>Underlying<BR>Outstanding</B><br><B>Stock&nbsp;Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Milind Deshpande, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jean Fran&ccedil;ois Formela, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scott Jackson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John C. Pottage, Jr., M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cynthia Smith</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Frank E. Thomas</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kathleen Tregoning</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick Vink, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under our <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy, each <FONT
STYLE="white-space:nowrap">non-employee</FONT> director is eligible to receive compensation for his or her service consisting of annual cash retainers and equity awards. Our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors received the
following annual retainers for their service as of December&nbsp;31, 2021: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Retainer</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Board Member</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Board Chairperson (additional retainer)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lead Director, if any (additional retainer)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Committee Chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation Committee Chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nominating and Governance Committee Chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Committee Member</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation Committee Member</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nominating and Governance Committee Member</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy provides
the following with respect to equity awards to <FONT STYLE="white-space:nowrap">non-employee</FONT> directors: (i)&nbsp;the initial equity award consisting of a <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock option to purchase shares of
our common stock upon first appointment to our Board of Directors and vesting in equal monthly installments until the third anniversary of the grant date subject to the <FONT STYLE="white-space:nowrap">non-employee</FONT> director&#146;s continued
service in the amount of 15,000 shares, and (ii)&nbsp;annual equity awards consisting of a <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock option to purchase shares of our common stock vesting on the first anniversary of the grant date
subject to the <FONT STYLE="white-space:nowrap">non-employee</FONT> director&#146;s continued service in the amount of 7,500 shares. The policy also provides that, prior to the beginning of each calendar year, a
<FONT STYLE="white-space:nowrap">non-employee</FONT> director may elect to receive all or a portion of his or her base annual fee for service on our Board of Directors in the form of a <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock
option to purchase a number of shares of our common stock based on the Black-Scholes value of such option, which option will be granted on the first business day of the calendar year. These options vest in four quarterly installments on the last day
of each calendar quarter during the calendar year, subject to the continued service of the <FONT STYLE="white-space:nowrap">non-employee</FONT> director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In July 2022, upon the recommendation of the Compensation Committee, the Board approved an RSU grant representing 15,000
shares of common stock to be issued to each <FONT STYLE="white-space:nowrap">non-employee</FONT> director on the date of the Annual Meeting in lieu of the annual equity award consisting of a <FONT STYLE="white-space:nowrap">non-qualified</FONT>
stock option to purchase 7,500 shares of our common stock as described in the current <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy. The RSUs will vest on the first anniversary of the grant date, subject to the <FONT
STYLE="white-space:nowrap">non-employee</FONT> director&#146;s continued service, and will be issued under, and subject to the terms of, our 2017 Stock Incentive Plan, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Directors may be reimbursed for travel, food, lodging and other expenses directly related to their service as directors.
Directors are also entitled to the protection provided by their indemnification agreements and the indemnification provisions in our amended and restated certificate of incorporation and amended and restated
<FONT STYLE="white-space:nowrap">By-Laws.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, in December 2021, we amended our <FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy to provide for the following annual retainers, effective as of January&nbsp;1, 2022: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Retainer</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Board Member</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Board Chairperson (additional retainer)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lead Director, if any (additional retainer)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Committee Chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation Committee Chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nominating and Governance Committee Chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Committee Member</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation Committee Member</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nominating and Governance Committee Member</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom341851_5"></A>EQUITY COMPENSATION PLANS AND OTHER BENEFIT PLANS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Equity Compensation Plan Information </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table provides certain aggregate information with respect to all of the Company&#146;s equity compensation plans
in effect as of December&nbsp;31, 2021. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD style="width:123pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:123pt"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD style="width:158pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:158pt"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD style="width:222pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:222pt"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Plan category</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of&nbsp;securities</B><br><B>to be issued upon<BR>exercise of<BR>outstanding options,</B><br><B>warrants and rights<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">Weighted-average</FONT><BR>exercise price
of<BR>outstanding&nbsp;options,<BR>warrants&nbsp;and&nbsp;rights</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of&nbsp;securities&nbsp;remaining<BR>for&nbsp;future&nbsp;issuance&nbsp;under&nbsp;equity<BR>compensation plan
(excluding<BR>securities&nbsp;reflected</B><br><B>in&nbsp;column&nbsp;(a)&nbsp;(#)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans Approved by stockholders (1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,893,605</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.02</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,685,972</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans not approved by stockholders (2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">997,111</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.60</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,252</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,890,716</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.75</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,695,224</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">This plan category consists of the Company&#146;s 2017 Stock Incentive Plan, as amended.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">This plan category consists of the Company&#146;s 2019 Inducement Equity Incentive Plan, as amended.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The table below provides the aggregate information with respect to all of the Company&#146;s equity
compensation plans in effect as of July&nbsp;20, 2022. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD style="width:80pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:80pt"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD style="width:158pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:158pt"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD style="width:222pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:222pt"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Plan category</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of&nbsp;securities</B><br><B>to&nbsp;be&nbsp;issued&nbsp;upon</B><br><B>exercise of<BR>outstanding options,</B><br><B>warrants and
rights<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">Weighted-average</FONT><BR>exercise price
of<BR>outstanding&nbsp;options,<BR>warrants&nbsp;and&nbsp;rights</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of&nbsp;securities&nbsp;remaining<BR>for&nbsp;future&nbsp;issuance&nbsp;under&nbsp;equity<BR>compensation plan
(excluding<BR>securities&nbsp;reflected</B><br><B>in&nbsp;column&nbsp;(a)&nbsp;(#)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans Approved by stockholders (1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,776,356</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.51</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,260,791</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans not approved by stockholders (2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">523,311</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.97</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">483,052</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,299,667</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.02</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,743,843</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">This plan category consists of the Company&#146;s 2017 Stock Incentive Plan, as amended.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">This plan category consists of the Company&#146;s 2019 Inducement Equity Incentive Plan, as amended.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Benefits Programs </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each named executive employee is eligible to participate in our benefits programs, which include health, life, disability and
dental insurance and a 401(k) retirement savings plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Spero Therapeutics, Inc.&#146;s 2017 Stock Incentive Plan </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We adopted the Spero Therapeutics, Inc. 2017 Stock Incentive Plan on June&nbsp;28, 2017, as amended on October&nbsp;18, 2017
and August&nbsp;17, 2021 (the &#147;2017 Plan&#148;). The 2017 Plan will expire on June&nbsp;30, 2027. Under the 2017 Plan, we may grant incentive stock options, <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options, restricted and
unrestricted stock awards and other stock-based awards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since its adoption, there have been 7,688,627 shares of our common stock
authorized for issuance under the 2017 Plan. As of July&nbsp;20, 2022, there were 4,776,356 shares outstanding and 2,260,791 shares available for grant under the 2017 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our Board of Directors is authorized to administer the 2017 Plan. In accordance with the provisions of the 2017 Plan, our
Board of Directors determines the terms of the options and other awards issued pursuant thereto, including the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">which employees, directors and consultants shall be granted awards; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares of common stock subject to options and other awards; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the exercise price of each option, which generally shall not be less than fair market value of the common
stock on the date of grant; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the termination or cancellation provisions applicable to the options; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and conditions of other awards, including conditions for repurchase, termination or cancellation,
issue price and repurchase price; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all other terms and conditions upon which each award may be granted in accordance with the 2017 Plan.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">No participant may receive awards for more than 1,000,000 shares of our common stock in any fiscal
year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, our Board of Directors or any committee to which our Board of Directors delegates authority may, with
the consent of the affected plan participants, amend outstanding awards consistent with the terms of the 2017 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon
a merger, consolidation, or sale of all or substantially all of our assets, our Board of Directors or any committee to which our Board of Directors delegates authority, or the Board of Directors of any corporation assuming our obligations, may, in
its sole discretion, take any one or more of the following actions pursuant to the 2017 Plan, as to some or all outstanding awards, to the extent not otherwise agreed under any individual agreement: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that outstanding options will be assumed or substituted for options of the successor corporation;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that the outstanding options must be exercised within a certain number of days, either to the extent
the options are then exercisable, or at our Board of Directors&#146; discretion, any such options being made partially or fully exercisable; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">terminate outstanding options in exchange for a cash payment of an amount equal to the difference between
(a)&nbsp;the consideration payable upon consummation of the corporate transaction to a holder of the number of shares into which such option would have been exercisable to the extent then exercisable, or in our Board of Directors&#146; discretion,
any such options being made partially or fully exercisable, and (b)&nbsp;the aggregate exercise price of those options; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that outstanding stock grants will be substituted for shares of the successor corporation or
consideration payable with respect to our outstanding stock in connection with the corporate transaction; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">terminate outstanding stock grants in exchange for payment of an amount equal to the consideration payable
upon consummation of the corporate transaction to a holder of the same number of shares comprising the stock grant, to the extent the stock grant is no longer subject to any forfeiture or repurchase rights, or at our Board of Directors&#146;
discretion, all forfeiture and repurchase rights being waived upon the corporate transaction. For purposes of determining such payments, in the case of a corporate transaction the consideration for which, in whole or in part, is other than cash, the
consideration other than cash shall be valued at the fair market value thereof as determined in good faith by our Board of Directors. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with our 2017 Reorganization, all outstanding incentive units issued under Spero Therapeutics, LLC&#146;s
operating agreement were cancelled. Any incentive unit holders who were our employees, directors or consultants at the time of the 2017 Reorganization were issued options under the 2017 Plan with continued vesting on the same schedule and the same
terms as such person&#146;s incentive units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Spero Therapeutics, Inc.&#146;s 2019 Inducement Equity Incentive Plan </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On March&nbsp;11, 2019, the Board of Directors adopted Spero Therapeutics, Inc.&#146;s 2019 Inducement Equity Incentive Plan,
as amended on June&nbsp;23, 2020 (the &#147;2019 Inducement Plan&#148;). The Board of Directors initially reserved 331,500 shares of our common stock under the 2019 Inducement Plan. As previously disclosed, in June 2020, the Board of Directors
reserved an additional 700,000 shares of our common stock under the 2019 Inducement Plan to be used exclusively for grants of awards to individuals that were not previously our employees or directors, as an inducement to the individual&#146;s entry
into employment with us within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. The 2019 Inducement Plan was adopted without stockholder approval pursuant to Rule 5635(c)(4). The 2019 Inducement Plan provides for the grant of equity-based
awards, including options, restricted and unrestricted stock awards, and other stock-based awards, and its terms are substantially similar to the 2017 Plan, but with such other terms and conditions intended to comply with the Nasdaq inducement award
exception. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of July&nbsp;20, 2022, there were 523,311 shares outstanding and 483,052 shares available for grant under
the 2019 Inducement Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Rule&nbsp;10b5-1&nbsp;Sales</FONT> Plans </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our directors and executive officers may adopt written plans, known as Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT>
plans, in which they will contract with a broker to buy or sell shares of our common stock on a periodic basis. Under a Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plan, a broker executes trades pursuant to parameters established by the
director or officer when entering into the plan, without further direction from the director or officer. The director or officer may amend or terminate the plan in limited circumstances. Our directors and executive officers may also buy or sell
additional shares of our common stock outside of a Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plan when they are not in possession of material, nonpublic information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom341851_6"></A>REPORT OF AUDIT COMMITTEE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Audit Committee of the Board of Directors, which consists entirely of directors who meet the independence and experience
requirements of The Nasdaq Stock Market has furnished the following report: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Audit Committee assists the Board of
Directors in overseeing and monitoring the integrity of our financial reporting process, compliance with regulatory requirements and the quality of internal and external audit processes. This committee&#146;s role and responsibilities are set forth
in our charter adopted by the Board of Directors, which is available on our website at www.sperotherapeutics.com. This committee reviews and reassesses our charter annually and recommends any changes to the Board of Directors for approval. The Audit
Committee is responsible for overseeing our overall financial reporting process, and for the appointment, compensation, retention, and oversight of the work of PricewaterhouseCoopers LLP. In fulfilling its responsibilities for the financial
statements for fiscal year ended December&nbsp;31, 2021, the Audit Committee took the following actions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Reviewed and discussed the audited financial statements for the fiscal year ended December&nbsp;31, 2021 with
management and PricewaterhouseCoopers LLP, our independent registered public accounting firm; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Discussed with PricewaterhouseCoopers LLP the matters required to be discussed by the Public Company
Accounting Oversight Board in accordance with Auditing Standard No.&nbsp;1301, Communications with Audit Committees; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Received written disclosures and the letter from PricewaterhouseCoopers LLP regarding its independence as
required by applicable requirements of the Public Company Accounting Oversight Board regarding PricewaterhouseCoopers LLP communications with the Audit Committee and the Audit Committee further discussed with PricewaterhouseCoopers LLP their
independence. The Audit Committee also considered the status of pending litigation, taxation matters and other areas of oversight relating to the financial reporting and audit process that the committee determined appropriate. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Based on the Audit Committee&#146;s review of the audited financial statements and discussions with management and
PricewaterhouseCoopers LLP, the Audit Committee recommended to the Board of Directors that the audited financial statements be included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended
December&nbsp;31, 2021 for filing with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:39%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Members of the Spero Therapeutics, Inc. Audit Committee </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:39%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Frank E. Thomas (Chairman) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:39%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Scott Jackson </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:39%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">John C. Pottage, Jr., M.D. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:39%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Patrick Vink, M.D. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom341851_7"></A>CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following is a description of transactions since January&nbsp;1, 2020, to which we have been a party, in which the amount
involved exceeds $120,000, and in which any of our directors, executive officers or holders of more than 5% of our capital stock, or an affiliate or immediate family member thereof, had or will have a direct or indirect material interest. We refer
to such transactions as &#147;related party transactions&#148; and such persons as &#147;related parties.&#148; With the approval of our Board of Directors, we have engaged in the related party transactions described below. We believe the terms
obtained or consideration that we paid or received, as applicable, in connection with the transactions described below were comparable to terms available or the amounts that would be paid or received, as applicable, from unaffiliated third parties.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investors&#146; Rights Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We entered into an investors&#146; rights agreement at the time of our initial public offering with the purchasers of our
outstanding preferred stock, including entities with which certain of our directors are affiliated. The investors&#146; rights agreement contains piggyback registration rights that are applicable in certain circumstances and expire on the 5th
anniversary of our initial public offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pfizer 2021 Share Purchase Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On June&nbsp;30, 2021, we sold 2,362,348 shares of our common stock to Pfizer Inc., which beneficially owns more than 5% of
our outstanding common stock, pursuant to a Share Purchase Agreement at a price of $16.93 per share, for an aggregate purchase price of $40&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Participation in Our March 2020 Rights Offering </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On March&nbsp;5, 2020, we completed a rights offering of (i) 1,046,249 shares of our common stock and (ii) 2,287 shares of our
<FONT STYLE="white-space:nowrap">non-voting</FONT> Series C Convertible Preferred Stock (the &#147;Series C Preferred Stock&#148;), with each share of Series C Preferred Stock convertible into 1,000 shares of our common stock, subject to certain
ownership restrictions. Entities affiliated with BVF, which beneficially owns more than 5% of our outstanding common stock, purchased all 2,287 shares of Series C Preferred Stock for a total purchase price of $20,583,000, before deducting expenses
related to the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Participation in Our September 2020 Public Offering </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On September&nbsp;15, 2020, we completed an underwritten public offering of (i) 4,785,000 shares of our common stock and (ii)
3,215,000 shares of our <FONT STYLE="white-space:nowrap">non-voting</FONT> Series D Convertible Preferred Stock (the &#147;Series D Preferred Stock&#148;), each at a price to the public of $10.00 per share, with the shares of Series D Preferred
Stock convertible on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-to-one</FONT></FONT> basis into shares of our common stock, subject to certain ownership restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Certain of our existing stockholders and their affiliated entities purchased an aggregate of approximately $60&nbsp;million of
shares of our common stock and Series D Preferred Stock in our September 2020 offering at the public offering price. The table below sets forth the aggregate number of shares of our common stock and Series D Preferred Stock issued to our holders of
more than 5% of our capital stock, or an affiliate thereof, at the time of the transaction: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;of<BR>Common<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;of&nbsp;Series&nbsp;D</B><br><B>Preferred&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Purchase&nbsp;Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with Aquilo Capital Management, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with BVF Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">285,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,215,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification Agreements with Officers and Directors and Directors&#146; and Officers&#146; Liability
Insurance </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have entered into indemnification agreements with each of our executive officers and directors. The
indemnification agreements, our amended and restated certificate of incorporation and our amended and restated <FONT STYLE="white-space:nowrap">By-Laws</FONT> require us to indemnify our directors to the fullest extent not prohibited by Delaware
law. Subject to certain limitations, our amended and restated certificate of incorporation also requires us to advance expenses incurred by our directors and officers, subject to limited exceptions. We also maintain a general liability insurance
policy which covers certain liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Policies and Procedures for Related Party Transactions </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have adopted a written policy that requires all future transactions between us and any director, executive officer, holder
of 5% or more of any class of our capital stock or any member of the immediate family of, or entities affiliated with, any of them, or any other related persons, as defined in Item 404 of Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT> or
their affiliates, in which the amount involved is equal to or greater than the threshold amount proscribed by Item 404 of Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT> be approved in advance by our Audit Committee. Any request for such a
transaction must first be presented to our Audit Committee for review, consideration and approval. In approving or rejecting any such proposal, our Audit Committee is to consider the relevant facts and circumstances available and deemed relevant to
the Audit Committee, including, but not limited to, the extent of the related party&#146;s interest in the transaction, and whether the transaction is on terms no less favorable to us than terms we could have generally obtained from an unaffiliated
third party under the same or similar circumstances. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom341851_8"></A>PROPOSAL 1: ELECTION OF DIRECTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Board of Directors has nominated Patrick Vink, M.D. and Frank E. Thomas for
<FONT STYLE="white-space:nowrap">re-election</FONT> at the Annual Meeting. The Board of Directors currently consists of eight members, classified into three classes as follows: (i)&nbsp;Patrick Vink, M.D. and Frank E. Thomas constitute our
Class&nbsp;II directors with a term ending at the upcoming 2022 Annual Meeting; (ii)&nbsp;Cynthia Smith, Scott Jackson and John C. Pottage, Jr., M.D. constitute our Class&nbsp;I directors with a term ending at the at the 2024 annual meeting; and
(iii)&nbsp;Milind Deshpande, Ph.D., Kathleen Tregoning and Ankit Mahadevia, M.D. constitute our Class&nbsp;III directors with a term ending at the 2023 annual meeting. At each annual meeting of stockholders, directors are elected for a full term of
three years to succeed those directors whose terms are expiring. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Board of Directors has voted to nominate Patrick
Vink, M.D. and Frank E. Thomas for election at the Annual Meeting as Class&nbsp;II directors for a term of three years to serve until the 2025 annual meeting of stockholders, and until their respective successors are elected and qualified. The
Class&nbsp;I directors (Cynthia Smith, John C. Pottage, Jr., M.D. and Scott Jackson) and the Class&nbsp;III directors (Milind Deshpande, Ph.D., Ankit Mahadevia, M.D. and Kathleen Tregoning) will serve until the annual meeting of stockholders to be
held in 2024 and 2023, respectively, and until their respective successors have been elected and qualified. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unless
authority to vote for any of these nominees is withheld, the shares represented by the enclosed proxy will be voted <B>FOR</B> the election as directors of Patrick Vink, M.D. and Frank E. Thomas. In the event that either nominee becomes unable or
unwilling to serve, the shares represented by the enclosed proxy will be voted for the election of such other person as the Board of Directors may recommend in that nominee&#146;s place. We have no reason to believe that any nominee will be unable
or unwilling to serve as a director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A plurality of the votes cast <B>FOR</B> each nominee at the Annual Meeting is
required to elect each nominee as a director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While we have no formal policy regarding diversity of our board members,
our Corporate Governance Guidelines provide that the background and qualifications of the members of our Board of Directors considered as a group should provide a significant breadth of experience, knowledge, and ability to assist our Board of
Directors in fulfilling its responsibilities. Our priority in selection of board members is the identification of members who will further the interests of our stockholders through their established records of professional accomplishment, the
ability to contribute positively to the collaborative culture among our board members, knowledge of our business, understanding of the competitive landscape in which we operate and adherence to high ethical standards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>THE BOARD OF DIRECTORS RECOMMENDS THE ELECTION OF PATRICK VINK M.D. AND FRANK E. THOMAS AS DIRECTORS, AND PROXIES SOLICITED
BY THE BOARD OF DIRECTORS WILL BE VOTED IN FAVOR THEREOF UNLESS A STOCKHOLDER HAS INDICATED OTHERWISE ON THE PROXY. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom341851_9"></A>PROPOSAL 2: INDEPENDENT PUBLIC ACCOUNTANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Audit Committee has appointed PricewaterhouseCoopers LLP, or PwC, as our independent registered public accounting firm, to
audit our financial statements for the fiscal year ending December&nbsp;31, 2022. PricewaterhouseCoopers LLP was our independent registered public accounting firm for the fiscal years ended December&nbsp;31, 2021 and 2020. The Board of Directors
proposes that the stockholders ratify this appointment. We expect that representatives of PricewaterhouseCoopers LLP will be present at the Annual Meeting, will be able to make a statement if they so desire, and will be available to respond to
appropriate questions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In deciding to appoint PricewaterhouseCoopers LLP, the Audit Committee reviewed auditor
independence issues and existing commercial relationships with PricewaterhouseCoopers LLP and concluded that PricewaterhouseCoopers LLP has no commercial relationship with the Company that would impair its independence for the fiscal year ending
December&nbsp;31, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table presents fees for professional audit services and other services rendered by
PricewaterhouseCoopers LLP to the Company for the fiscal years ended December&nbsp;31, 2021 and December&nbsp;31, 2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal&nbsp;Year<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal&nbsp;Year<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Fees (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">902,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">777,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit-Related Fees (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax Fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All Other Fees (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">958,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">834,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Audit fees consisted of audit work performed in the preparation of financial statements, the review of the
interim consolidated financial statements, and related services that are normally provided in connection with registration statements. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Audit related fees consist of fees billed by PricewaterhouseCoopers LLP for assurance and related services
that are reasonably related to the performance of the audit or review of our consolidated financial statements. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">All other fees represent payment for access to the PricewaterhouseCoopers LLP online accounting research and
financial disclosure databases. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Policy on Audit Committee <FONT STYLE="white-space:nowrap">Pre-Approval</FONT> of Services </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Consistent with SEC policies regarding auditor independence, the Audit Committee has responsibility for appointing, setting
compensation and overseeing the work of our independent registered public accounting firm. In recognition of this responsibility, the Audit Committee reviews and <FONT STYLE="white-space:nowrap">pre-approves</FONT> all audit and permissible <FONT
STYLE="white-space:nowrap">non-audit</FONT> services provided by our independent registered public accounting firm; provided, however, that de minimis <FONT STYLE="white-space:nowrap">non-audit</FONT> services may instead be approved in accordance
with applicable SEC rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event the stockholders do not ratify the appointment of PricewaterhouseCoopers LLP as
our independent registered public accounting firm, the Audit Committee will reconsider its appointment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The affirmative
vote of the holders of a majority in voting power of the votes cast by the holders of the shares of our common stock present or represented at the Annual Meeting and voting affirmatively or negatively is required to ratify the appointment of the
independent registered public accounting firm. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>THE BOARD OF DIRECTORS RECOMMENDS A VOTE TO RATIFY THE APPOINTMENT OF
PRICEWATERHOUSECOOPERS LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM, AND PROXIES SOLICITED BY THE BOARD OF DIRECTORS WILL BE VOTED IN FAVOR OF SUCH RATIFICATION UNLESS A STOCKHOLDER INDICATES OTHERWISE ON THE PROXY. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom341851_10"></A>PROPOSAL 3: APPROVE AMENDMENT TO 2017 STOCK INCENTIVE PLAN
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our Board of Directors is requesting that our stockholders approve an amendment to the Spero Therapeutics, Inc. 2017
Stock Incentive Plan, as amended (the &#147;Existing 2017 Plan&#148;) to increase the number of shares of common stock authorized for issuance by 2,000,000 shares. The complete text of the amendment is set forth in the Spero Therapeutics, Inc.
Amended and Restated Stock 2017 Stock Incentive Plan, a copy of which is attached as Appendix A to this proxy statement (the &#147;Amended 2017 Plan&#148;). We are seeking this amendment in order to reserve sufficient shares to provide equity
incentives that align the interests of our directors, executives and employees with those of our stockholders, while attracting and retaining talented personnel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Except for the proposed increase in the number of shares authorized for issuance, the terms of the Existing 2017 Plan as
previously approved by our stockholders shall remain in full force and effect. In determining the number of shares to request for approval under the Amended 2017 Plan, our Compensation Committee worked with management and an independent compensation
consultant to evaluate a number of factors, including our corporate strategy and compensation needs, our recent and projected share usage, share usage at companies of similar sector and size and the total potential dilution level. For the reasons
below, we believe that the size of the increase is reasonable to support our continued growth and success while being protective of stockholder dilution and consistent with market practice for a clinical-stage biopharmaceutical company of our size
and circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Key Considerations for Requesting Additional Shares </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our Board of Directors focused on the key considerations described below in adopting the amendment and requesting your
approval. Please note that the outstanding shares of common stock are based on 35,067,477 shares of common stock outstanding as of July&nbsp;20, 2022. This does <U>not</U> include an additional 4,487,000 shares of common stock underlying our
outstanding convertible preferred stock as of such date, which are held by funds affiliated with BVF, Inc. as described above in the table captioned &#147;<I>Security Ownership of Certain Beneficial Owners and Management</I>&#148;. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Inadequate Number of Shares Available for Granting</I></B>: As of July&nbsp;20, 2022, we had only
2,260,791 shares of our common stock available for issuance under the Existing 2017 Plan. While we have additional capacity under our 2019 Inducement Equity Incentive Plan, as amended (the &#147;2019 Inducement Plan&#148;) (i.e., 483,052 shares),
the overall number of shares available for granting is inadequate for our needs as we endeavor to retain talented personnel and attract employees in a very competitive labor market. Furthermore, grants under the 2019 Inducement Plan are of limited
utility because they (i)&nbsp;may be granted only to new hires and are subject to other Nasdaq Stock Market limitations and (ii)&nbsp;are ineligible to provide the recipient with the favorable tax treatment afforded by Section&nbsp;422 of the
Internal Revenue Code, as amended (the &#147;Code&#148;). We use the term &#147;equity plans&#148; when referring to both the Existing 2017 Plan and 2019 Inducement Plan. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We currently expect the additional share authorization under the amendment to the Amended 2017 Plan, together with the
remaining shares available for grant thereunder as of July&nbsp;20, 2022, and the remaining shares under the 2019 Inducement Plan (a combined total of 4,743,843 shares) to provide us with sufficient shares to address our anticipated retention and
recruiting activity through at least the 2023 annual meeting of stockholders, with such timing dependent on a variety of factors, as further described below under &#147;The Additional Shares and Future Needs.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe our future success continues to depend in part on our ability to attract, motivate and retain high quality
employees and directors; thus, our ability to provide equity-based and incentive-based awards under the Amended 2017 Plan is critical to achieving this success. Without adequate shares available for equity compensation, we might be compelled to
increase significantly the cash component of our employee compensation, which would consume cash needed to advance our clinical programs, which are the drivers of value for our stockholders. Replacing equity awards with
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
cash may not necessarily align employee and director compensation interests with the investment interests of our stockholders. Further, a lack of equity compensation to offer would put us at
competitive disadvantage to recruit and retain employees, and would hamper our ability to align our compensation with long-term stockholder value creation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unlike many biopharmaceutical companies of similar stage to us, our Existing 2017 Plan and 2019 Inducement Plan do not
contain any &#147;evergreen&#148; provisions that provide for automatic share reserve replenishments without additional shareholder approval when implemented. Instead, we have opted to provide stockholders with the ability to approve authorized
share increases. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Shares Subject to Outstanding Awards</I></B>: As of July&nbsp;20, 2022, the shares subject to
outstanding awards under the Existing 2017 Plan (4,776,356 shares) and 2019 Inducement Plan (523,311 shares), aggregate to 5,299,667 shares, or 15% of the common stock outstanding. Such outstanding awards included an aggregate of 4,537,020 stock
options under our equity plans with consolidated weighted average exercise price of $11.02 and a consolidated weighted average remaining term of approximately 5 years. Our share price has fallen significantly since the date of grant for almost all
of these awards, and they now provide very modest retention impact. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Overhang from Our Equity Plans</I></B>: As of July&nbsp;20, 2022, the equity overhang, represented by
(a)&nbsp;the sum of all outstanding awards under our equity plans, plus the number of shares available for issuance pursuant to future awards under such equity plans as a percentage of (b)&nbsp;the sum of (i)&nbsp;the number of shares of our common
stock outstanding as of July&nbsp;20, 2022, plus (ii)&nbsp;the number of shares described in clause (a)&nbsp;above, was 19%. If the amendment to the Existing 2017 Plan is approved by stockholders, the equity overhang would be 22% (or approximately
17% inclusive of the common stock underlying our outstanding convertible preferred stock). </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Burn Rate of Our Equity Plans</I></B>. For the fiscal years of 2021, 2020, and 2019, our burn rate was
8.04%, 5.43% and 6.15% respectively, on an &#147;option equivalent basis.&#148; These rates were calculated by dividing the number of shares subject to awards granted during the fiscal year by the weighted average number of shares outstanding during
the fiscal year. We multiplied full-value awards such as RSUs and performance shares by 1.5 to calculate &#147;option equivalents.&#148; Our average burn rate over this three-year period was 6.54%. We have been advised by our independent
compensation consultant that among pharmaceuticals and biotechnology companies not included in the Russell 3000 index the three-year average burn rate is 5.74%. Our own three-year average burn rate is in reasonable alignment with this broader
industry trend. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that we have demonstrated a commitment to sound equity compensation
practices. We recognize that equity compensation awards dilute shareholders&#146; equity, so we have carefully managed our equity incentive compensation. Our equity compensation practices are intended to be competitive, broad-based and consistent
with market practices, and we believe our historical share usage has been responsible and mindful of shareholder interests. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>The Additional Shares and Future Needs:</I></B> Our Compensation Committee considered our historic burn
rate levels and the impact of utilizing regular annual equity compensation grants in determining how long the additional share authorization could potentially last. We intend to utilize the shares authorized under the amendment to the Amended 2017
Plan to continue our practice of incentivizing key individuals through equity awards. We currently expect the additional share authorization under the amendment to the Amended 2017 Plan, together with the remaining shares available for grant
thereunder as of July&nbsp;20, 2022, and the remaining shares under the 2019 Inducement Plan (a combined total of 4,743,843 shares) to provide us with enough shares for awards to address our anticipated retention and recruiting activity through at
least the 2023 annual meeting of stockholders, with such timing dependent on a variety of factors, including the price of </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
our shares and hiring activity over the next year, forfeitures of outstanding awards, and noting that future circumstances may require us to change our current equity grant practices. We cannot
predict our future equity grant practices, the future price of our shares or future hiring activity with any degree of certainty at this time, and the share reserve under the Plan could last for a shorter or longer time. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following is a brief summary of the Amended 2017 Plan. This summary is qualified in its entirety by reference to the text
of the Amended 2017 Plan, a copy of which is attached as <B><U>Appendix A</U></B> to this proxy statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary of Material Features of the Amended
2017 Plan </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Eligibility</I></B><B>. </B>The Amended 2017 Plan allows us, under the direction of our Compensation
Committee, to make grants of stock options, restricted and unrestricted stock awards and other stock-based awards to employees, consultants and directors who, in the opinion of the Compensation Committee, are in a position to make a significant
contribution to our long-term success. All employees, directors and consultants of the Company and its affiliates are eligible to participate in the Amended 2017 Plan. As of July&nbsp;20, 2022, there were approximately 40 individuals eligible to
participate in the Existing 2017 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Corporate Governance Aspects of the Plan.</I></B><B> </B>The Amended 2017
Plan includes several provisions that we believe promote best practices by reinforcing alignment with stockholders&#146; interests. These provisions include, but are not limited to, the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>No Liberal Share Recycling:</I> Shares that are withheld to satisfy any tax withholding obligation related
to any stock award or for<I> </I>payment of the exercise price or purchase price of any stock award under the Amended 2017 Plan will not again become available for issuance under the Amended 2017 Plan. Shares repurchased by the Company with the
proceeds of option exercises will also not be available for reissuance. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>No Liberal
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Change-in-Control</FONT></FONT> Definition</I>: <FONT STYLE="white-space:nowrap">Non-double</FONT> trigger vesting may only be enacted in the event the Company is to be consolidated
with or acquired by another entity in a merger, consolidation, sale of all or substantially all of the Company&#146;s assets or the acquisition of all of the outstanding voting stock of the Company in a single transaction or a series of related
transactions other than a transaction to merely change the state of incorporation (a &#147;Corporate Transaction&#148;); such <FONT STYLE="white-space:nowrap">non-double</FONT> trigger vesting is not available in the absence of an actual <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">change-in-control.</FONT></FONT> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>No Discounted Options or Stock Appreciation Rights</I>: Stock options and stock appreciation rights may not
be granted with exercise prices lower than the fair market value of the underlying shares on the grant date except to replace equity awards due to a Corporate Transaction. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>No Repricing without Stockholder Approval</I>: Other than in connection with corporate reorganizations or
restructurings, at any time when the exercise price of a stock option is above the fair market value of a share, the Company will not, without stockholder approval, reduce the exercise price of such stock option and will not exchange such stock
option for a new award with a lower (or no) purchase price or for cash. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>No Transferability</I>: Equity awards generally may not be transferred, except by will or the laws of
descent and distribution, unless approved by the Compensation Committee. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>No Dividends</I>: The Amended 2017 Plan prohibits, for all award types, the payment of dividends or
dividend equivalents before the vesting of the underlying award but permits accrual of dividends or dividend equivalents to be paid upon vesting. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>No Evergreen: </I>The Amended 2017 Plan does not contain any &#147;evergreen&#148; provisions to increase
shares available for issuance as equity awards. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Shares Available for Issuance; </I></B>The Existing 2017 Plan provides
for the issuance of up to 2,260,791 shares of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Generally, shares of common stock reserved for awards
under the Amended 2017 Plan that lapse or are canceled (other than by exercise) will be added back to the share reserve available for future awards. However, shares of common stock tendered in payment for an award or shares of common stock withheld
for taxes are not available again for future awards.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>In addition, shares repurchased by the Company with the proceeds of the option exercise price may not be reissued under the Amended 2017 Plan.<SUP
STYLE="font-size:75%; vertical-align:top"> </SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The aggregate grant date fair value of shares granted to any <FONT
STYLE="white-space:nowrap">non-employee</FONT> director under the Amended 2017 Plan in any calendar year may not exceed $750,000; provided however that the foregoing limitation shall not apply to stock rights made pursuant to an election to receive
the stock right in lieu of cash for all or a portion of fees received for service on the Board of Directors or any committee thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Stock Options.</I></B> Stock options granted under the Amended 2017 Plan may either be incentive stock options, which
are intended to satisfy the requirements of Section&nbsp;422 of the Code, or <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options, which are not intended to meet those requirements. Incentive stock options may be granted to employees
of the Company and its affiliates. <FONT STYLE="white-space:nowrap">Non-qualified</FONT> options may be granted to employees, directors and consultants of the Company and its affiliates. The exercise price of a stock option may not be less than 100%
of the fair market value of our common stock on the date of grant and the term of the option may not be longer than ten years. If an incentive stock option is granted to an individual who owns more than 10% of the combined voting power of all
classes of our capital stock, the exercise price may not be less than 110% of the fair market value of our common stock on the date of grant and the term of the option may not be longer than five years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Award agreements for stock options include rules for exercise of the stock options after termination of service. Options may
not be exercised unless they are vested, and no option may be exercised after the end of the term set forth in the award agreement. Generally, stock options will be exercisable for three months after termination of service for any reason other than
death or total and permanent disability, and for 12 months after termination of service on account of death or total and permanent disability but will not be exercisable if the termination of service was due to cause. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Restricted Stock.</I></B><I> </I>Restricted stock is common stock that is subject to restrictions, including a
prohibition against transfer and a substantial risk of forfeiture, until the end of a &#147;restricted period&#148; during which the grantee must satisfy certain time or performance-based vesting conditions. If the grantee does not satisfy the
vesting conditions by the end of the restricted period, the restricted stock is forfeited. During the restricted period, the holder of restricted stock has the rights and privileges of a regular stockholder, except that the holder of such restricted
stock is not entitled to receive dividends during the restricted period and the restrictions set forth in the applicable award agreement apply. For example, the holder of restricted stock may vote the restricted shares; but he or she may not sell
the shares until the restrictions are lifted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Restricted Stock Units</I></B><B>. </B>Restricted stock units are
phantom shares that vest in accordance with terms and conditions established by the Compensation Committee and when the applicable restrictions lapse, the grantee shall be entitled to receive a payout in shares, cash or a combination thereof based
on the number of restricted stock units as specified in the award agreement. Dividend equivalents may accrue but shall not be paid prior to and only to the extent that, the restricted stock unit award vests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Other Stock-Based Awards.</I></B> The Amended 2017 Plan also authorizes the grant of other types of stock-based
compensation including, but not limited to stock appreciation rights and phantom stock awards. Our Board of Directors or Compensation Committee may award such stock-based awards subject to such conditions and restrictions as it may determine. These
conditions and restrictions may include continued employment with us through a specified restricted period or achievement of one or more performance goals. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Plan Administration.</I></B> In accordance with the terms of the
Amended 2017 Plan, our Board of Directors has authorized our Compensation Committee to administer the Amended 2017 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Administration</I></B>. The Amended 2017 Plan authorizes the Board of Directors or a committee of the board to grant
incentive stock options, <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options, restricted and unrestricted stock awards and other stock-based awards. The Amended 2017 Plan affords the Compensation Committee the ability to design
compensatory awards that are responsive to the Company&#146;s needs and authorizes a variety of award types designed to advance the interests and long-term success of the Company by encouraging stock ownership among employees (including officers), <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors and certain consultants or other service providers of the Company and its subsidiaries. By its terms, the Amended 2017 Plan may be amended by the Compensation Committee provided that any
amendment that the Compensation Committee determines requires stockholder approval is subject to receiving such stockholder approval. Our Compensation Committee continues to retain full discretion under the Amended 2017 Plan to determine the number
and amount of awards to be granted under the Amended 2017 Plan, subject to the terms of the Amended 2017 Plan. Future benefits that may be received by participants under the Amended 2017 Plan are not determinable at this time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Compensation Committee may delegate part of its authority and powers under the Amended 2017 Plan to one or more of our
directors and/or officers, but only the Compensation Committee can make awards to participants who are subject to the reporting and other requirements of Section&nbsp;16 of the Securities Exchange Act of 1934. In accordance with the provisions of
the Amended 2017 Plan, our Compensation Committee determines the terms of awards, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">which employees, directors and consultants will be granted awards; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares subject to each award; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the vesting provisions of each award; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the termination or cancellation provisions applicable to awards; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all other terms and conditions upon which each award may be granted in accordance with the Amended 2017 Plan.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, our Compensation Committee may, in its discretion, amend any term or condition of an
outstanding award provided (i)&nbsp;such term or condition as amended is permitted by the Amended 2017 Plan, and (ii)&nbsp;any such amendment shall be made only with the consent of the participant to whom such award was made, if the amendment is
adverse to the participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Stock Dividends and Stock Splits</I></B><B>.</B> If our common stock shall be
subdivided or combined into a greater or smaller number of shares or if we issue any shares of common stock as a stock dividend, the number of shares of our common stock deliverable upon exercise of an option issued or upon issuance of an award
shall be appropriately increased or decreased proportionately, and appropriate adjustments shall be made in the exercise price per share of stock options or purchase price, if any, to reflect such subdivision, combination or stock dividend. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Corporate Transactions.</I></B> Upon a merger or other reorganization event, our Board of Directors, may, in its sole
discretion, take any one or more of the following actions pursuant to the Amended 2017 Plan, as to some or all outstanding awards: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that all outstanding options shall be assumed or substituted by the successor corporation;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon written notice to a participant provide that the participant&#146;s options must be exercised (either to
the extent then exercisable or at the discretion of the Board of Directors, any such options being made partially or fully exercisable) and unexercised options will terminate immediately prior to the consummation of such transaction unless exercised
by the participant; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the event of a merger pursuant to which holders of our common stock will receive a cash payment for each
share surrendered in the merger, make or provide for a cash payment to the participants equal to the difference between the merger price times the number of shares of our common stock subject to such outstanding options (either to the extent then
exercisable or at the discretion of the Board of Directors, any such options being made partially or fully exercisable), and the aggregate exercise price of all such outstanding options, in exchange for the termination of such options;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that outstanding awards shall be assumed or substituted by the successor corporation, become
realizable or deliverable, or restrictions applicable to an award will lapse, in whole or in part, prior to or upon the merger or reorganization event; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">with respect to stock grants and in lieu of any of the foregoing, our Board of Directors or an authorized
committee may provide that, upon consummation of the transaction, each outstanding stock grant shall be terminated in exchange for payment of an amount equal to the consideration payable upon consummation of such transaction to a holder of the
number of shares of common stock comprising such award (to the extent such stock grant is no longer subject to any forfeiture or repurchase rights then in effect or, at the discretion of our Board of Directors or an authorized committee, all
forfeiture and repurchase rights being waived upon such transaction). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Amendment and
Termination</I></B><B>. </B>The Amended 2017 Plan may be amended by our stockholders. It may also be amended by our Board of Directors or our Compensation Committee, provided that any amendment approved by our Board of Directors or Compensation
Committee which is of a scope that requires stockholder approval as required by (i)&nbsp;the rules of the Nasdaq Stock Market, (ii)&nbsp;in order to ensure favorable federal income tax treatment for any incentive stock options under Section&nbsp;422
of the Code, or (iii)&nbsp;for any other reason, is subject to obtaining such stockholder approval. No such amendment may adversely affect any rights under any outstanding award without the holder&#146;s consent unless such amendment is required by
applicable law or necessary to preserve the economic value of such award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Duration of Plan</I></B><I>.</I> The
Amended 2017 Plan will expire by its terms on June&nbsp;30, 2027. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Federal Income Tax Considerations </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The material federal income tax consequences of the issuance and exercise of stock options and other awards under the Amended
2017 Plan, based on the current provisions of the Code and regulations, are as follows. Changes to these laws could alter the tax consequences described below. This summary assumes that all awards granted under the Amended 2017 Plan are exempt from
or comply with, the rules under Section&nbsp;409A of the Code related to nonqualified deferred compensation. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="63%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Incentive Stock Options:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Incentive stock options are intended to qualify for treatment under Section&nbsp;422 of the Code. An incentive stock option
does not result in taxable income to the optionee or deduction to us at the time it is granted or exercised, provided that no disposition is made by the optionee of the shares acquired pursuant to the option within two years after the date of grant
of the option nor within one year after the date of issuance of shares to the optionee (referred to as the &#147;ISO holding period&#148;). However, the difference between the</P></TD></TR></TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
<DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="63%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fair market value of the shares on the date of exercise and the option price will be an item of tax preference includible
in &#147;alternative minimum taxable income&#148; of the optionee. Upon disposition of the shares after the expiration of the ISO holding period, the optionee will generally recognize long term capital gain or loss based on the difference between
the disposition proceeds and the option price paid for the shares. If the shares are disposed of prior to the expiration of the ISO holding period, the optionee generally will recognize taxable compensation, and we will have a corresponding
deduction, in the year of the disposition, equal to the excess of the fair market value of the shares on the date of exercise of the option over the option price. Any additional gain realized on the disposition will normally constitute capital gain.
If the amount realized upon such a disqualifying disposition is less than fair market value of the shares on the date of exercise, the amount of compensation income will be limited to the excess of the amount realized over the optionee&#146;s
adjusted basis in the shares.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Options:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>Options otherwise qualifying as incentive stock options, to the extent the aggregate fair market value of shares
with respect to which such options are first exercisable by an individual in any calendar year exceeds $100,000, and options designated as <FONT STYLE="white-space:nowrap">non-qualified</FONT> options will be treated as options that are not
incentive stock options.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A <FONT STYLE="white-space:nowrap">non-qualified</FONT> option ordinarily will not result in income to the optionee or
deduction to us at the time of grant. The optionee will recognize compensation income at the time of exercise of such <FONT STYLE="white-space:nowrap">non-qualified</FONT> option in an amount equal to the excess of the then value of the shares over
the option price per share. Such compensation income of optionees may be subject to withholding taxes, and a deduction may then be allowable to us in an amount equal to the optionee&#146;s compensation income.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">An optionee&#146;s initial basis in shares so acquired will be the amount paid on exercise of the <FONT
STYLE="white-space:nowrap">non-qualified</FONT> option plus the amount of any corresponding compensation income. Any gain or loss as a result of a subsequent disposition of the shares so acquired will be capital gain or loss.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Stock Grants:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>With respect to stock grants under the Amended 2017 Plan that result in the issuance of shares that are either not
restricted as to transferability or not subject to a substantial risk of forfeiture, the grantee must generally recognize ordinary income equal to the fair market value of shares received. Thus, deferral of the time of issuance will generally result
in the deferral of the time the grantee will be liable for income taxes with respect to such issuance. We generally will be entitled to a deduction in an amount equal to the ordinary income recognized by the
grantee.</P></TD></TR></TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
<DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="63%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">With respect to stock grants involving the issuance of shares that are restricted as to transferability and subject to a
substantial risk of forfeiture, the grantee must generally recognize ordinary income equal to the fair market value of the shares received at the first time the shares become transferable or are not subject to a substantial risk of forfeiture,
whichever occurs earlier. A grantee may elect to be taxed at the time of receipt of shares rather than upon lapse of restrictions on transferability or substantial risk of forfeiture, but if the grantee subsequently forfeits such shares, the grantee
would not be entitled to any tax deduction, including as a capital loss, for the value of the shares on which he previously paid tax. The grantee must file such election with the Internal Revenue Service within 30 days of the receipt of the shares.
We generally will be entitled to a deduction in an amount equal to the ordinary income recognized by the grantee.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Stock Units:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The grantee recognizes no income until the issuance of the shares. At that time, the grantee must generally recognize
ordinary income equal to the fair market value of the shares received. We generally will be entitled to a deduction in an amount equal to the ordinary income recognized by the grantee.</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Plan Benefits </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since the adoption of the Existing 2017 Plan through July&nbsp;20, 2022, we have granted the following stock options and
restricted stock units under the Existing 2017 Plan to the individuals and groups listed below. In all cases, the securities underlying stock options were shares of our common stock. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Name and Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Stock<BR>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Restricted<BR>Stock<BR>Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Ankit Mahadevia, M.D.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,396,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">212,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Satyavrat Shukla</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,081</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>All Current Executive Officers as a group</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,774,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">398,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>All Current Directors who are not executive officers as a group</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">332,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>All Current Employees who are not current executive officers as a group</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">574,573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">183,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, subject to Dr.&nbsp;Mahadevia and Mr.&nbsp;Shukla remaining actively
employed with the Company through May&nbsp;31, 2023, if certain performance criteria are achieved,(i) Dr.&nbsp;Mahadevia will receive a number of shares of common stock to be issued to him on May&nbsp;31, 2023 having a value of $508,000 based on the
common stock price at such time, subject to the discretion of the Board or the Compensation Committee to pay in cash or a combination of cash and stock, and (ii)&nbsp;Mr.&nbsp;Shukla will receive a number of shares of common stock to be issued to
him on May&nbsp;31, 2023 having a value of $336,000 based on the common stock price at such time, subject to the discretion of the Board or the Compensation Committee to pay in cash or a combination of cash and stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Other than as provided above or by the terms of our <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation
Policy, as amended, the amounts of future grants under the Amended 2017 Plan are not determinable and will be granted at the sole discretion of the Compensation Committee or other delegated persons, and we cannot determine at this time either the
persons who will receive such awards under the Amended 2017 Plan or the amount or types of any such awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On
July&nbsp;20, 2022, the closing market price per share of our common stock was $0.77, as reported by The Nasdaq Stock Market. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The affirmative vote of the holders of a majority in voting power of the
votes cast by the holders of the shares of our common stock present or represented at the Annual Meeting and voting affirmatively or negatively is required to approve the Amended 2017 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the Amended 2017 Plan is approved, it will become effective immediately following the Annual Meeting, and we will have up
to 4,619,690 shares authorized for future awards thereunder (subject to adjustment in the event of stock splits and similar events). If the Amended 2017 Plan is not approved, then the Existing 2017 Plan shall remain in effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>THE BOARD OF DIRECTORS RECOMMENDS A VOTE TO APPROVE THE AMENDMENT TO THE 2017 STOCK INCENTIVE PLAN, AS AMENDED, AND PROXIES
SOLICITED BY THE BOARD OF DIRECTORS WILL BE VOTED IN FAVOR THEREOF UNLESS A STOCKHOLDER HAS INDICATED OTHERWISE ON THE PROXY. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom341851_11"></A>CODE OF CONDUCT AND ETHICS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have adopted a Code of Business Conduct and Ethics that applies to all of our employees, including our chief executive
officer and chief financial and accounting officers. The text of the Code of Business Conduct and Ethics is posted on our website at www.sperotherapeutics.com and will be made available to stockholders without charge, upon request, in writing to the
Secretary of the Company at Spero Therapeutics, Inc., 675 Massachusetts Avenue, 14th Floor, Cambridge, Massachusetts 02139. Disclosure regarding any amendments to, or waivers from, provisions of the Code of Business Conduct and Ethics that apply to
our directors, principal executive and financial officers will be included in a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> within four business days following the date of the amendment or waiver, unless website posting or the
issuance of a press release of such amendments or waivers is then permitted by the rules of The Nasdaq Stock Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom341851_12">
</A>OTHER MATTERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Board of Directors knows of no other business which will be presented to the Annual Meeting. If
any other business is properly brought before the Annual Meeting, proxies will be voted in accordance with the judgment of the persons named therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom341851_13"></A>STOCKHOLDER PROPOSALS AND NOMINATIONS FOR DIRECTOR </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To be considered for inclusion in the proxy statement relating to our 2023 annual meeting of stockholders (the &#147;2023
Annual Meeting&#148;), we must receive stockholder proposals (other than for director nominations) no later than May&nbsp;18, 2023. To be considered for presentation at the 2023 Annual Meeting, although not included in the proxy statement, proposals
(including director nominations that are not requested to be included in our proxy statement) must be received not less than 90 days nor more than 120 days prior to the first anniversary of this year&#146;s Annual Meeting; provided, however, that in
the event that the date of the 2023 Annual Meeting is advanced by more than 30 days, or delayed by more than 60 days, from the first anniversary of the this year&#146;s Annual Meeting, a stockholder&#146;s notice must be received not earlier than
the 120th day prior to such annual meeting and not later than the close of business on the later of (A)&nbsp;the 90th day prior to such annual meeting and (B)&nbsp;the tenth day following the day on which notice of the date of such annual meeting
was mailed or public disclosure of the date of such annual meeting was made, whichever first occurs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Proposals that are
not received in a timely manner will not be voted on at the 2023 Annual Meeting. If a proposal is received on time, the proxies that management solicits for the meeting may still exercise discretionary voting authority on the proposal under
circumstances consistent with the proxy rules of the SEC. All stockholder proposals should be marked for the attention of Secretary, Spero Therapeutics, Inc., 675 Massachusetts Avenue, 14th Floor, Cambridge, Massachusetts 02139. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cambridge, Massachusetts </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August&nbsp;5, 2022 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><A NAME="rom341851_14"></A>APPENDIX A </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED 2017 STOCK INCENTIVE PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(As Amended on ____, 2022) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><U>DEFINITIONS</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Spero Therapeutics,
Inc. 2017 Stock Incentive Plan, have the following meanings: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><U>Administrator</U> means the Board of Directors, unless it
has delegated power to act on its behalf to the Committee, in which case the term Administrator means the Committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><U>Affiliate</U> means a corporation or other entity which, for purposes of Section&nbsp;424 of the Code, is a parent or
subsidiary of the Company, direct or indirect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><U>Agreement</U> means a written or electronic document setting forth the
terms of a Stock Right delivered pursuant to the Plan, in such form as the Administrator shall approve. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><U>Board of
Directors</U> means the Board of Directors of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><U>Cause</U> means, with respect to a Participant
(a)&nbsp;dishonesty with respect to the Company or any Affiliate, (b)&nbsp;insubordination, substantial malfeasance or <FONT STYLE="white-space:nowrap">non-feasance</FONT> of duty, (c)&nbsp;unauthorized disclosure of confidential information,
(d)&nbsp;breach by the Participant of any provision of any employment, consulting, advisory, nondisclosure, <FONT STYLE="white-space:nowrap">non-competition</FONT> or similar agreement between the Participant and the Company or any Affiliate, and
(e)&nbsp;conduct substantially prejudicial to the business of the Company or any Affiliate; provided, however, that any provision in an agreement between the Participant and the Company or an Affiliate, which contains a conflicting definition of
Cause for termination and which is in effect at the time of such termination, shall supersede this definition with respect to that Participant. The determination of the Administrator as to the existence of Cause will be conclusive on the Participant
and the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><U>Code</U> means the United States Internal Revenue Code of 1986, as amended including any successor
statute, regulation and guidance thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><U>Committee</U> means the committee of the Board of Directors to which the
Board of Directors has delegated power to act under or pursuant to the provisions of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><U>Common Stock</U> means
shares of the Company&#146;s common stock, $0.001<B> </B>par value per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><U>Company</U> means Spero Therapeutics,
Inc., a Delaware corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><U>Consultant</U> means any natural person who is an advisor or consultant who provides
bona fide services to the Company or its Affiliates, provided that such services are not in connection with the offer or sale of securities in a capital raising transaction, and do not directly or indirectly promote or maintain a market for the
Company&#146;s or its Affiliates&#146; securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><U>Corporate Transaction</U> means a merger, consolidation, or sale of
all or substantially all of the Company&#146;s assets or the acquisition of all of the outstanding voting stock of the Company (or similar transaction) in a single transaction or a series of related transactions by a single entity other than a
transaction merely to change the state of incorporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><U>Disability</U> or <U>Disabled</U> means permanent and total disability as
defined in Section&nbsp;22(e)(3) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><U>Employee</U> means any employee of the Company or of an Affiliate
(including, without limitation, an employee who is also serving as an officer or director of the Company or of an Affiliate), designated by the Administrator to be eligible to be granted one or more Stock Rights under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><U>Exchange Act</U> means the United States Securities Exchange Act of 1934, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><U>Fair Market Value</U> of a Share of Common Stock means: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(1)&nbsp;&nbsp;&nbsp;&nbsp;If the Common Stock is listed on a national securities exchange or traded in the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market and sales prices are regularly reported for the Common Stock, the closing or, if not applicable, the last price of the Common Stock on the consolidated
tape or other comparable reporting system for the trading day on the applicable date and if such applicable date is not a trading day, the last market trading day prior to such date; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(2)&nbsp;&nbsp;&nbsp;&nbsp;If the Common Stock is not traded on a national securities exchange but is traded
on the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market, if sales prices are not regularly reported for the Common Stock for the trading day referred to in clause (1), and if bid and asked
prices for the Common Stock are regularly reported, the mean between the bid and the asked price for the Common Stock at the close of trading in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT>
market for the most recent trading day on which Common Stock was traded on the applicable date and if such applicable date is not a trading day, the last market trading day prior to such date; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(3)&nbsp;&nbsp;&nbsp;&nbsp;If the Common Stock is neither listed on a national securities exchange nor traded
in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market, such value as the Administrator, in good faith, shall determine in compliance with applicable laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><U>ISO</U> means an option intended to qualify as an incentive stock option under Section&nbsp;422 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><U><FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Option</U> means an option which is not intended to qualify as an
ISO. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><U>Option</U> means an ISO or <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Option granted under the Plan.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><U>Participant</U> means an Employee, director or Consultant of the Company or an Affiliate to whom one or more Stock
Rights are granted under the Plan. As used herein, &#147;Participant&#148; shall include &#147;Participant&#146;s Survivors&#148; where the context requires. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><U>Performance-Based Award</U> means a Stock Grant or Stock-Based Award which vests based on the attainment of written
Performance Goals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><U>Performance Goals</U> means performance goals determined by the Committee in its sole discretion
and set forth in an Agreement. The satisfaction of Performance Goals shall be subject to certification by the Committee. The Committee has the authority to take appropriate action with respect to the Performance Goals (including, without limitation,
making adjustments to the Performance Goals or determining the satisfaction of the Performance Goals in connection with a Corporate Transaction) provided that any such action does not otherwise violate the terms of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><U>Plan</U> means this Amended and Restated Spero Therapeutics, Inc.<B> </B>2017 Stock Incentive Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><U>Securities Act</U> means the Securities Act of 1933, as amended. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><U>Shares</U> means shares of the Common Stock as to which Stock Rights have
been or may be granted under the Plan or any shares of capital stock into which the Shares are changed or for which they are exchanged within the provisions of Paragraph 3 of the Plan. The Shares issued under the Plan may be authorized and unissued
shares or shares held by the Company in its treasury, or both. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><U>Stock-Based Award</U> means a grant by the Company
under the Plan of an equity award or an equity based award which is not an Option or a Stock Grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><U>Stock Grant</U>
means a grant by the Company of Shares under the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><U>Stock Right</U> means an ISO, a
<FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Option, a Stock Grant or a Stock-Based Award or a right to Shares or the value of Shares of the Company granted pursuant to the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><U>Survivor</U> means a deceased Participant&#146;s legal representatives and/or any person or persons who acquired the
Participant&#146;s rights to a Stock Right by will or by the laws of descent and distribution. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><U>PURPOSES OF THE PLAN</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Plan is intended to encourage ownership of Shares by Employees and directors of and certain Consultants to the Company and
its Affiliates in order to attract and retain such people, to induce them to work for the benefit of the Company or of an Affiliate and to provide additional incentive for them to promote the success of the Company or of an Affiliate. The Plan
provides for the granting of ISOs, <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Options, Stock Grants and Stock-Based Awards. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><U>SHARES SUBJECT TO THE PLAN</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;The number of Shares which may be issued from time to time pursuant to this Plan shall be
[4,619,690]<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> of shares of Common Stock for new awards, plus the shares underlying awards already outstanding under the existing Plan, or the equivalent of such number of Shares after the
Administrator, in its sole discretion, has interpreted the effect of any stock split, stock dividend, combination, recapitalization or similar transaction in accordance with Paragraph 24 of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;If an Option ceases to be &#147;outstanding&#148;, in whole or in part (other than by exercise), or
if the Company shall reacquire at not more than its original issuance price any Shares issued pursuant to a Stock Grant or Stock-Based Award, or if any Stock Right expires or is forfeited, cancelled, or otherwise terminated or results in any Shares
not being issued, the unissued or reacquired Shares which were subject to such Stock Right shall again be available for issuance from time to time pursuant to this Plan. Notwithstanding the foregoing, if a Stock Right is exercised, in whole or in
part, by tender of Shares or if the Company or an Affiliate&#146;s tax withholding obligation is satisfied by withholding Shares, the number of Shares deemed to have been issued under the Plan for purposes of the limitation set forth in Paragraph
3(a) above shall be the number of Shares that were subject to the Stock Right or portion thereof, and not the net number of Shares actually issued. However, in the case of ISOs, the foregoing provisions shall be subject to any limitations under the
Code. In addition, any Shares repurchased using exercise price proceeds will not be available for issuance under the Plan. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><U>ADMINISTRATION OF THE PLAN</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Administrator of the Plan will be the Board of Directors, except to the extent the Board of Directors delegates its
authority to the Committee, in which case the Committee shall be the Administrator. Subject to the provisions of the Plan, the Administrator is authorized to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;Interpret the provisions of the Plan and all Stock Rights and to make all rules and determinations
which it deems necessary or advisable for the administration of the Plan; </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">2,000,000 additional shares, plus the number of shares remaining available for grant under the existing Plan
as of the 2022 annual meeting, including shares that are expected to be forfeited and returned to the existing Plan by such time. The bracketed number shall not exceed 4,619,690 shares. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;Determine which Employees, directors and
Consultants shall be granted Stock Rights; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c)&nbsp;&nbsp;&nbsp;&nbsp;Determine the number of Shares for which a Stock
Right or Stock Rights shall: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) Stock Rights with respect to more than 1,000,000 Shares (after taking
into consideration the reverse stock split in connection with the Company&#146;s initial public offering) be granted to any Participant in any fiscal year; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii) the aggregate grant date fair value of Shares to be granted to any
<FONT STYLE="white-space:nowrap">non-employee</FONT> director under the Plan in any calendar year may not exceed $750,000 dollars; provided however that the foregoing limitation shall not apply to Stock Rights made pursuant to an election to receive
the Stock Right in lieu of cash for all or a portion of fees received for service on the Board of Directors or any Committee thereof; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d)&nbsp;&nbsp;&nbsp;&nbsp;Amend any term or condition of any outstanding Stock Right, including, without limitation, (other
than to reduce the exercise price or purchase price without stockholder approval)<B> </B>to<B> </B>accelerate the vesting schedule or extend the expiration date, provided that (i)&nbsp;such term or condition as amended is permitted by the Plan;
(ii)&nbsp;any such amendment shall not impair the rights of a Participant under any Stock Right previously granted without such Participant&#146;s consent or in the event of death of the Participant the Participant&#146;s Survivors; and
(iii)&nbsp;any such amendment shall be made only after the Administrator determines whether such amendment would cause any adverse tax consequences to the Participant, including, but not limited to, the annual vesting limitation contained in
Section&nbsp;422(d) of the Code and described in Paragraph 6(b)(iv) below with respect to ISOs and pursuant to Section&nbsp;409A of the Code; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e)&nbsp;&nbsp;&nbsp;&nbsp;Determine and make any adjustments in the Performance Goals included in any Performance-Based
Awards; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(f)&nbsp;&nbsp;&nbsp;&nbsp;Adopt any <FONT STYLE="white-space:nowrap">sub-plans</FONT> applicable to
residents of any specified jurisdiction as it deems necessary or appropriate in order to comply with or take advantage of any tax or other laws applicable to the Company, any Affiliate or to Participants or to otherwise facilitate the administration
of the Plan, which <FONT STYLE="white-space:nowrap">sub-plans</FONT> may include additional restrictions or conditions applicable to Stock Rights or Shares issuable pursuant to a Stock Right; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">provided, however, that all such interpretations, rules, determinations, terms and conditions shall be made and prescribed in the context of
not causing any adverse tax consequences under Section&nbsp;409A of the Code and preserving the tax status under Section&nbsp;422 of the Code of those Options which are designated as ISOs. Subject to the foregoing, the interpretation and
construction by the Administrator of any provisions of the Plan or of any Stock Right granted under it shall be final, unless otherwise determined by the Board of Directors, if the Administrator is the Committee. In addition, if the Administrator is
the Committee, the Board of Directors may take any action under the Plan that would otherwise be the responsibility of the Committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To the extent permitted under applicable law, the Board of Directors or the Committee may allocate all or any portion of its
responsibilities and powers to any one or more of its members and may delegate all or any portion of its responsibilities and powers to any other person selected by it. The Board of Directors or the Committee may revoke any such allocation or
delegation at any time. Notwithstanding the foregoing, only the Board of Directors or the Committee shall be authorized to grant a Stock Right to any director of the Company or to any &#147;officer&#148; of the Company as defined by Rule <FONT
STYLE="white-space:nowrap">16a-1</FONT> under the Exchange Act. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><U>ELIGIBILITY FOR PARTICIPATION</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Administrator will, in its sole discretion, name the Participants in the Plan; provided, however, that each Participant
must be an Employee, director or Consultant of the Company or of an Affiliate at the time a Stock Right is granted. Notwithstanding the foregoing, the Administrator may authorize the grant of a Stock
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Right to a person in anticipation of such person becoming an Employee, director or Consultant of the Company or of an Affiliate; provided, however, that the actual grant of such Stock Right shall
be conditioned upon such person becoming eligible to become a Participant at or prior to the time of the execution of the Agreement evidencing such Stock Right. ISOs may be granted only to Employees.
<FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Options, Stock Grants and Stock-Based Awards may be granted to any Employee, director or Consultant of the Company or an Affiliate. The granting of any Stock Right to any individual shall neither
entitle that individual to, nor disqualify that individual from, participation in any other grant of Stock Rights or any grant under any other benefit plan established by the Company or any Affiliate for Employees, directors or Consultants. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><U>TERMS AND CONDITIONS OF OPTIONS</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each Option shall be set forth in an Option Agreement, duly executed by the Company and, to the extent required by law or
requested by the Company, by the Participant. The Administrator may provide that Options be granted subject to such terms and conditions, consistent with the terms and conditions specifically required under this Plan, as the Administrator may deem
appropriate including, without limitation, subsequent approval by the shareholders of the Company of this Plan or any amendments thereto. The Option Agreements shall be subject to at least the following terms and conditions: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U><FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Options</U>: Each Option intended to be a <FONT
STYLE="white-space:nowrap">Non-Qualified</FONT> Option shall be subject to the terms and conditions which the Administrator determines to be appropriate and in the best interest of the Company, subject to the following minimum standards for any such
<FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Option: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><U>Exercise Price</U>: Each Option Agreement shall state the exercise price (per share) of the Shares
covered by each Option, which exercise price shall be determined by the Administrator and shall be at least equal to the Fair Market Value per share of the Common Stock on the date of grant of the Option. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><U>Number of Shares</U>: Each Option Agreement shall state the number of Shares to which it pertains.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><U>Vesting Periods</U>: Each Option Agreement shall state the date or dates on which it first is exercisable
and the date after which it may no longer be exercised, and may provide that the Option rights accrue or become exercisable in installments over a period of months or years, or upon the occurrence of certain performance conditions or the attainment
of stated performance goals or events. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><U>Additional Conditions</U>: Exercise of any Option may be conditioned upon the Participant&#146;s
execution of a shareholders agreement in a form satisfactory to the Administrator providing for certain protections for the Company and its other shareholders, including requirements that: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The Participant&#146;s or the Participant&#146;s Survivors&#146; right to sell or transfer the Shares may be
restricted; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The Participant or the Participant&#146;s Survivors may be required to execute letters of investment intent
and must also acknowledge that the Shares will bear legends noting any applicable restrictions. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><U>Term of Option</U>: Each Option shall terminate not more than ten years from the date of the grant or at
such earlier time as the Option Agreement may provide. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>ISOs</U>: Each
Option intended to be an ISO shall be issued only to an Employee who is deemed to be a resident of the United States for tax purposes, and shall be subject to the following terms and conditions, with
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
such additional restrictions or changes as the Administrator determines are appropriate but not in conflict with Section&nbsp;422 of the Code and relevant regulations and rulings of the Internal
Revenue Service: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><U>Minimum standards</U>: The ISO shall meet the minimum standards required of <FONT
STYLE="white-space:nowrap">Non-Qualified</FONT> Options, as described in Paragraph 6(a) above, except subsections (i)&nbsp;and (v) thereunder. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><U>Exercise Price</U>: Immediately before the ISO is granted, if the Participant owns, directly or by reason
of the applicable attribution rules in Section&nbsp;424(d) of the Code: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Ten percent (10%) <U>or less</U> of the total combined voting power of all classes of stock of the Company
or an Affiliate, the exercise price per share of the Shares covered by each ISO shall not be less than one hundred percent (100%) of the Fair Market Value per share of the Common Stock on the date of grant of the Option; or </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">More than ten percent (10%) of the total combined voting power of all classes of stock of the Company or an
Affiliate, the exercise price per share of the Shares covered by each ISO shall not be less than one hundred ten percent (110%) of the Fair Market Value per share of the Common Stock on the date of grant of the Option. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><U>Term of Option</U>: For Participants who own: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Ten percent (10%) <U>or less</U> of the total combined voting power of all classes of stock of the Company
or an Affiliate, each ISO shall terminate not more than ten years from the date of the grant or at such earlier time as the Option Agreement may provide; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">More than ten percent (10%) of the total combined voting power of all classes of stock of the Company or an
Affiliate, each ISO shall terminate not more than five (5)&nbsp;years from the date of the grant or at such earlier time as the Option Agreement may provide. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><U>Limitation on Yearly Exercise</U>: The Option Agreements shall restrict the amount of ISOs which may
become exercisable in any calendar year </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(under this or any other ISO plan of the Company or an
Affiliate) so that the aggregate Fair Market Value (determined on the date each ISO is granted) of the stock with respect to which ISOs are exercisable for the first time by the Participant in any calendar year does not exceed one hundred thousand
dollars ($100,000). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><U>TERMS AND CONDITIONS OF STOCK GRANTS</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each Stock Grant to a Participant shall state the principal terms in an Agreement duly executed by the Company and, to the
extent required by law or requested by the Company, by the Participant. The Agreement shall be in a form approved by the Administrator and shall contain terms and conditions which the Administrator determines to be appropriate and in the best
interest of the Company, subject to the following minimum standards: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;Each Agreement shall
state the purchase price per share, if any, of the Shares covered by each Stock Grant, which purchase price shall be determined by the Administrator but shall not be less than the minimum consideration required by the<B> </B>Delaware General
Corporation Law on the date of the grant of the Stock Grant; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;Each Agreement shall state the
number of Shares to which the Stock Grant pertains; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c)&nbsp;&nbsp;&nbsp;&nbsp;Each Agreement shall include the terms of any
right of the Company to restrict or reacquire the Shares subject to the Stock Grant, including the time and events or such other performance criteria upon which such rights shall accrue and the purchase price therefor, if any; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d)&nbsp;&nbsp;&nbsp;&nbsp;Dividends (other than stock dividends to be issued pursuant to Paragraph 24 of the Plan) may accrue
but shall not be paid prior to the time, and only to the extent that, the restrictions or rights to reacquire the Shares subject to the Stock Grant lapse. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><U>TERMS AND CONDITIONS OF OTHER STOCK-BASED AWARDS</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Administrator shall have the right to grant other Stock-Based Awards based upon the Common Stock having such terms and
conditions as the Administrator may determine, including, without limitation, the grant of Shares based upon certain conditions, the grant of securities convertible into Shares and the grant of stock appreciation rights, phantom stock awards or
stock units. The principal terms of each Stock-Based Award shall be set forth in an Agreement, duly executed by the Company and, to the extent required by law or requested by the Company, by the Participant. The Agreement shall be in a form approved
by the Administrator and shall contain terms and conditions which the Administrator determines to be appropriate and in the best interest of the Company. Each Agreement shall include the terms of any right of the Company including the right to
terminate the Stock-Based Award without the issuance of Shares, the terms of any vesting conditions, Performance Goals or events upon which Shares shall be issued; provided that dividends (other than stock dividends to be issued pursuant to
Paragraph 24 of the Plan) or dividend equivalents may accrue but shall not be paid prior to and only to the extent that, the Shares subject to the Stock-Based Award vest. Under no circumstances may the Agreement covering stock appreciation rights
(a)&nbsp;have an exercise price (per share) that is less than the Fair Market Value per share of Common Stock on the date of grant or (b)&nbsp;expire more than ten years following the date of grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company intends that the Plan and any Stock-Based Awards granted hereunder be exempt from the application of
Section&nbsp;409A of the Code or meet the requirements of paragraphs (2), (3) and (4)&nbsp;of subsection (a)&nbsp;of Section&nbsp;409A of the Code, to the extent applicable, and be operated in accordance with Section&nbsp;409A so that any
compensation deferred under any Stock-Based Award (and applicable investment earnings) shall not be included in income under Section&nbsp;409A of the Code. Any ambiguities in the Plan shall be construed to effect the intent as described in this
Paragraph 8. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><U>EXERCISE OF OPTIONS AND ISSUE OF SHARES</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">An Option (or any part or installment thereof) shall be exercised by giving written notice to the Company or its designee (in
a form acceptable to the Administrator, which may include electronic notice), together with provision for payment of the aggregate exercise price in accordance with this Paragraph for the Shares as to which the Option is being exercised, and upon
compliance with any other condition(s) set forth in the Option Agreement. Such notice shall be signed by the person exercising the Option (which signature may be provided electronically in a form acceptable to the Administrator), shall state the
number of Shares with respect to which the Option is being exercised and shall contain any representation required by the Plan or the Option Agreement. Payment of the exercise price for the Shares as to which such Option is being exercised shall be
made (a)&nbsp;in United States dollars in cash or by check, or (b)&nbsp;at the discretion of the Administrator, through delivery of shares of Common Stock held for at least six months (if required to avoid negative accounting treatment) having a
Fair Market Value equal as of the date of the exercise to the aggregate cash exercise price for the number of Shares as to which the Option is being exercised, or (c)&nbsp;at the discretion of the Administrator, by having the Company retain from the
Shares otherwise issuable upon exercise of the Option, a number of Shares having a Fair Market Value equal as of the date of exercise to the aggregate exercise price for the number of Shares as to which the Option is being exercised, or (d)&nbsp;at
the discretion of the Administrator, in accordance with a cashless exercise program established with a securities brokerage firm, and approved by the Administrator, or (e)&nbsp;at the discretion of the Administrator, by any combination of (a), (b),
(c) and (d)&nbsp;above or (f)&nbsp;at the discretion of the Administrator, by payment of such other lawful consideration as the Administrator may determine. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Notwithstanding the foregoing, the Administrator shall accept only such payment on exercise of an ISO as is permitted by Section&nbsp;422 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company shall then reasonably promptly deliver the Shares as to which such Option was exercised to the Participant (or to
the Participant&#146;s Survivors, as the case may be). In determining what constitutes &#147;reasonably promptly,&#148; it is expressly understood that the issuance and delivery of the Shares may be delayed by the Company in order to comply with any
law or regulation (including, without limitation, state securities or &#147;blue sky&#148; laws) which requires the Company to take any action with respect to the Shares prior to their issuance. The Shares shall, upon delivery, be fully paid, <FONT
STYLE="white-space:nowrap">non-assessable</FONT> Shares. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><U>PAYMENT IN CONNECTION WITH THE ISSUANCE OF STOCK GRANTS AND STOCK-BASED AWARDS AND ISSUE OF SHARES</U>.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any Stock Grant or Stock-Based Award requiring payment of a purchase price for the Shares as to which
such Stock Grant or Stock-Based Award is being granted shall be made (a)&nbsp;in United States dollars in cash or by check, or (b)&nbsp;at the discretion of the Administrator, through delivery of shares of Common Stock held for at least six months
(if required to avoid negative accounting treatment) and having a Fair Market Value equal as of the date of payment to the purchase price of the Stock Grant or Stock-Based Award, or (c)&nbsp;at the discretion of the Administrator, by any combination
of (a)&nbsp;and (b) above; or (d)&nbsp;at the discretion of the Administrator, by payment of such other lawful consideration as the Administrator may determine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company shall, when required by the applicable Agreement, reasonably promptly deliver the Shares as to which such Stock
Grant or Stock-Based Award was made to the Participant (or to the Participant&#146;s Survivors, as the case may be), subject to any escrow provision set forth in the applicable Agreement. In determining what constitutes &#147;reasonably
promptly,&#148; it is expressly understood that the issuance and delivery of the Shares may be delayed by the Company in order to comply with any law or regulation (including, without limitation, state securities or &#147;blue sky&#148; laws) which
requires the Company to take any action with respect to the Shares prior to their issuance. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><U>RIGHTS AS A SHAREHOLDER</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">No Participant to whom a Stock Right has been granted shall have rights as a shareholder with respect to any Shares covered by
such Stock Right except after due exercise of an Option or issuance of Shares as set forth in any Agreement, tender of the aggregate exercise or purchase price, if any, for the Shares being purchased and registration of the Shares in the
Company&#146;s share register in the name of the Participant. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><U>ASSIGNABILITY AND TRANSFERABILITY OF STOCK RIGHTS</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">By its terms, a Stock Right granted to a Participant shall not be transferable by the Participant other than (i)&nbsp;by will
or by the laws of descent and distribution, or (ii)&nbsp;as approved by the Administrator in its discretion and set forth in the applicable Agreement provided that no Stock Right may be transferred by a Participant for value. Notwithstanding the
foregoing, an ISO transferred except in compliance with clause (i)&nbsp;above shall no longer qualify as an ISO. The designation of a beneficiary of a Stock Right by a Participant, with the prior approval of the Administrator and in such form as the
Administrator shall prescribe, shall not be deemed a transfer prohibited by this Paragraph. Except as provided above during the Participant&#146;s lifetime a Stock Right shall only be exercisable by or issued to such Participant (or such
Participant&#146;s legal representative) and shall not be assigned, pledged or hypothecated in any way (whether by operation of law or otherwise) and shall not be subject to execution, attachment or similar process. Any attempted transfer,
assignment, pledge, hypothecation or other disposition of any Stock Right or of any rights granted thereunder contrary to the provisions of this Plan, or the levy of any attachment or similar process upon a Stock Right, shall be null and void. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><U>EFFECT ON OPTIONS OF TERMINATION OF SERVICE OTHER THAN FOR CAUSE OR DEATH OR DISABILITY</U>.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Except as otherwise provided in a Participant&#146;s Option Agreement, in the event of a termination of
service (whether as an Employee, director or Consultant) with the Company or an Affiliate before the Participant has exercised an Option, the following rules apply: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;A Participant who ceases to be an Employee, director or Consultant of the Company or of an
Affiliate (for any reason other than termination for Cause, Disability, or death for which events there are special rules in Paragraphs 14, 15, and 16, respectively), may exercise any Option granted to such Participant to the extent that the Option
is exercisable on the date of such termination of service, but only within such term as the Administrator has designated in a Participant&#146;s Option Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;Except as provided in Subparagraph (c)&nbsp;below, or Paragraph 15 or 16, in no event may an Option
intended to be an ISO be exercised later than three months after the Participant&#146;s termination of employment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c)&nbsp;&nbsp;&nbsp;&nbsp;The provisions of this Paragraph, and not the provisions of Paragraph 15 or 16, shall apply to a
Participant who subsequently becomes Disabled or dies after the termination of employment, director status or consultancy; provided, however, in the case of a Participant&#146;s Disability or death within three months after the termination of
employment, director status or consultancy, the Participant or the Participant&#146;s Survivors may exercise the Option within one year after the date of the Participant&#146;s termination of service, but in no event after the date of expiration of
the term of the Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything herein to the contrary, if subsequent to a
Participant&#146;s termination of employment, termination of director status or termination of consultancy, but prior to the exercise of an Option, the Administrator or the Board of Directors determines that, either prior or subsequent to the
Participant&#146;s termination, the Participant engaged in conduct which would constitute Cause, then such Participant shall forthwith cease to have any right to exercise any Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e)&nbsp;&nbsp;&nbsp;&nbsp;A Participant to whom an Option has been granted under the Plan who is absent from the Company or
an Affiliate because of temporary disability (any disability other than a Disability as defined in Paragraph 1 hereof), or who is on leave of absence for any purpose, shall not, during the period of any such absence, be deemed, by virtue of such
absence alone, to have terminated such Participant&#146;s employment, director status or consultancy with the Company or with an Affiliate, except as the Administrator may otherwise expressly provide; provided, however, that, for ISOs, any leave of
absence granted by the Administrator of greater than three (3)&nbsp;months, unless pursuant to a contract or statute that guarantees the right to reemployment, shall cause such ISO to become a <FONT STYLE="white-space:nowrap">Non-Qualified</FONT>
Option on the date that is six (6)&nbsp;months following the commencement of such leave of absence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(f)&nbsp;&nbsp;&nbsp;&nbsp;Except as required by law or as set forth in a Participant&#146;s Option Agreement, Options granted
under the Plan shall not be affected by any change of a Participant&#146;s status within or among the Company and any Affiliates, so long as the Participant continues to be an Employee, director or Consultant of the Company or any Affiliate. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><U>EFFECT ON OPTIONS OF TERMINATION OF SERVICE FOR CAUSE</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Except as otherwise provided in a Participant&#146;s Option Agreement, the following rules apply if the Participant&#146;s
service (whether as an Employee, director or Consultant) with the Company or an Affiliate is terminated for Cause prior to the time that all of such Participant&#146;s outstanding Options have been exercised: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;All outstanding and unexercised Options as of the time the Participant is notified such
Participant&#146;s service is terminated for Cause will immediately be forfeited. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;Cause is not limited to events which have
occurred prior to a Participant&#146;s termination of service, nor is it necessary that the Administrator&#146;s finding of Cause occur prior to termination. If the Administrator determines, subsequent to a Participant&#146;s termination of service
but prior to the exercise of an Option, that either prior or subsequent to the Participant&#146;s termination the Participant engaged in conduct which would constitute Cause, then the right to exercise any Option is forfeited. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><U>EFFECT ON OPTIONS OF TERMINATION OF SERVICE FOR DISABILITY</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Except as otherwise provided in a Participant&#146;s Option Agreement, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;A Participant who ceases to be an Employee, director or Consultant of the Company or of an
Affiliate by reason of Disability may exercise any Option granted to such Participant: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">To the extent that the Option has become exercisable but has not been exercised on the date of the
Participant&#146;s termination of service due to Disability; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">In the event rights to exercise the Option accrue periodically, to the extent of a pro rata portion through
the date of the Participant&#146;s termination of service due to Disability of any additional vesting rights that would have accrued on the next vesting date had the Participant not become Disabled. The proration shall be based upon the number of
days accrued in the current vesting period prior to the date of the Participant&#146;s termination of service due to Disability. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;A Disabled Participant may exercise the Option only within the period ending one year after the
date of the Participant&#146;s termination of service due to Disability, notwithstanding that the Participant might have been able to exercise the Option as to some or all of the Shares on a later date if the Participant had not been terminated due
to Disability and had continued to be an Employee, director or Consultant or, if earlier, within the originally prescribed term of the Option. The Administrator shall make the determination both of whether Disability has occurred and the date of its
occurrence (unless a procedure for such determination is set forth in another agreement between the Company and such Participant, in which case such procedure shall be used for such determination). If requested, the Participant shall be examined by
a physician selected or approved by the Administrator, the cost of which examination shall be paid for by the Company. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">16.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><U>EFFECT ON OPTIONS OF DEATH WHILE AN EMPLOYEE, DIRECTOR OR CONSULTANT</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Except as otherwise provided in a Participant&#146;s Option Agreement, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;In the event of the death of a Participant while the Participant is an Employee, director or
Consultant of the Company or of an Affiliate, such Option may be exercised by the Participant&#146;s Survivors: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">To the extent that the Option has become exercisable but has not been exercised on the date of death; and
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">In the event rights to exercise the Option accrue periodically, to the extent of a pro rata portion through
the date of death of any additional vesting rights that would have accrued on the next vesting date had the Participant not died. The proration shall be based upon the number of days accrued in the current vesting period prior to the
Participant&#146;s date of death. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;If the Participant&#146;s Survivors wish
to exercise the Option, they must take all necessary steps to exercise the Option within one year after the date of death of such Participant, notwithstanding that the decedent might have been able to exercise the Option as to some or all of the
Shares on a later date if he or she had not died and had continued to be an Employee, director or Consultant or, if earlier, within the originally prescribed term of the Option. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">17.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><U>EFFECT OF TERMINATION OF SERVICE ON STOCK GRANTS AND STOCK-BASED AWARDS</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event of a termination of service (whether as an Employee, director or Consultant) with the Company or an Affiliate for
any reason before the Participant has accepted a Stock Grant or a Stock-Based Award and paid the purchase price, if required at the time, such grant shall terminate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For purposes of this Paragraph 17 and Paragraph 18 below, a Participant to whom a Stock Grant or a Stock-Based Award has been
issued under the Plan who is absent from work with the Company or with an Affiliate because of temporary disability (any disability other than a Disability as defined in Paragraph 1 hereof), or who is on leave of absence for any purpose, shall not,
during the period of any such absence, be deemed, by virtue of such absence alone, to have terminated such Participant&#146;s employment, director status or consultancy with the Company or with an Affiliate, except as the Administrator may otherwise
expressly provide. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, for purposes of this Paragraph 17 and Paragraph 18 below, any change of employment or
other service within or among the Company and any Affiliates shall not be treated as a termination of employment, director status or consultancy so long as the Participant continues to be an Employee, director or Consultant of the Company or any
Affiliate. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">18.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><U>EFFECT ON STOCK GRANTS AND STOCK-BASED AWARDS OF TERMINATION OF SERVICE OTHER THAN FOR CAUSE OR DEATH OR
DISABILITY</U>. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Except as otherwise provided in a Participant&#146;s Agreement, in the event of a
termination of service (whether as an Employee, director or Consultant), other than termination for Cause, death or Disability for which events there are special rules in Paragraphs 19, 20, and 21, respectively, before all forfeiture provisions or
Company rights of repurchase (other than rights to repurchase at then fair market value following termination of service as an Employee, director or Consultant) shall have lapsed, then the Company shall have the right to cancel or repurchase that
number of Shares subject to a Stock Grant or Stock-Based Award as to which the Company&#146;s forfeiture or repurchase rights have not lapsed. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">19.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><U>EFFECT ON STOCK GRANTS AND STOCK-BASED AWARDS OF TERMINATION OF SERVICE FOR CAUSE</U>.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Except as otherwise provided in a Participant&#146;s Agreement, the following rules apply if the
Participant&#146;s service (whether as an Employee, director or Consultant) with the Company or an Affiliate is terminated for Cause: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;All Shares subject to any Stock Grant or Stock-Based Award that remain subject to forfeiture
provisions or as to which the Company shall have a repurchase right shall be immediately forfeited to the Company as of the time the Participant is notified that such Participant&#146;s service is terminated for Cause. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;Cause is not limited to events which have occurred prior to a Participant&#146;s termination of
service, nor is it necessary that the Administrator&#146;s finding of Cause occur prior to termination. If the Administrator determines, subsequent to a Participant&#146;s termination of service, that either prior or subsequent to the
Participant&#146;s termination the Participant engaged in conduct which would constitute Cause, then all Shares subject to any Stock Grant or Stock-Based Award that remained subject to forfeiture provisions or as to which the Company had a
repurchase right on the date of termination shall be immediately forfeited to the Company. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">20.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><U>EFFECT ON STOCK GRANTS AND STOCK-BASED AWARDS OF TERMINATION OF SERVICE FOR DISABILITY</U>.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Except as otherwise provided in a Participant&#146;s Agreement, the following rules apply if a
Participant ceases to be an Employee, director or Consultant of the Company or of an Affiliate by reason of Disability: to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
extent the forfeiture provisions or the Company&#146;s rights of repurchase have not lapsed on the date of Disability, they shall be exercisable; provided, however, that in the event such
forfeiture provisions or rights of repurchase lapse periodically, such provisions or rights shall lapse to the extent of a pro rata portion of the Shares subject to such Stock Grant or Stock-Based Award through the date of Disability as would have
lapsed had the Participant not become Disabled. The proration shall be based upon the number of days accrued prior to the date of Disability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Administrator shall make the determination both as to whether Disability has occurred and the date of its occurrence
(unless a procedure for such determination is set forth in another agreement between the Company and such Participant, in which case such procedure shall be used for such determination). If requested, the Participant shall be examined by a physician
selected or approved by the Administrator, the cost of which examination shall be paid for by the Company. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">21.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><U>EFFECT ON STOCK GRANTS AND STOCK-BASED AWARDS OF DEATH WHILE AN EMPLOYEE, DIRECTOR OR CONSULTANT</U>.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Except as otherwise provided in a Participant&#146;s Agreement, the following rules apply in the event
of the death of a Participant while the Participant is an Employee, director or Consultant of the Company or of an Affiliate: to the extent the forfeiture provisions or the Company&#146;s rights of repurchase have not lapsed on the date of death,
they shall be exercisable; provided, however, that in the event such forfeiture provisions or rights of repurchase lapse periodically, such provisions or rights shall lapse to the extent of a pro rata portion of the Shares subject to such Stock
Grant or Stock-Based Award through the date of death as would have lapsed had the Participant not died. The proration shall be based upon the number of days accrued prior to the Participant&#146;s date of death. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">22.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><U>PURCHASE FOR INVESTMENT</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unless the offering and sale of the Shares shall have been effectively registered under the Securities Act, the Company shall
be under no obligation to issue Shares under the Plan unless and until the following conditions have been fulfilled: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;The person who receives a Stock Right shall warrant to the Company, prior to the receipt of Shares,
that such person is acquiring such Shares for such person&#146;s own account, for investment, and not with a view to, or for sale in connection with, the distribution of any such Shares, in which event the person acquiring such Shares shall be bound
by the provisions of the following legend (or a legend in substantially similar form) which shall be endorsed upon the certificate evidencing the Shares issued pursuant to such exercise or such grant: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;The shares represented by this certificate have been taken for investment and they may not be sold or otherwise
transferred by any person, including a pledgee, unless (1)&nbsp;either (a) a Registration Statement with respect to such shares shall be effective under the Securities Act of 1933, as amended, or (b)&nbsp;the Company shall have received an opinion
of counsel satisfactory to it that an exemption from registration under such Act is then available, and (2)&nbsp;there shall have been compliance with all applicable state securities laws.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;At the discretion of the Administrator, the Company shall have received an opinion of its counsel
that the Shares may be issued in compliance with the Securities Act without registration thereunder. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">23.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><U>DISSOLUTION OR LIQUIDATION OF THE COMPANY</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the dissolution or liquidation of the Company, all Options granted under this Plan which as of such date shall not have
been exercised and all Stock Grants and Stock-Based Awards which have not been accepted, to the extent required under the applicable Agreement, will terminate and become null and void; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
provided, however, that if the rights of a Participant or a Participant&#146;s Survivors have not otherwise terminated and expired, the Participant or the Participant&#146;s Survivors will have
the right immediately prior to such dissolution or liquidation to exercise or accept any Stock Right to the extent that the Stock Right is exercisable or subject to acceptance as of the date immediately prior to such dissolution or liquidation. Upon
the dissolution or liquidation of the Company, any outstanding Stock-Based Awards shall immediately terminate unless otherwise determined by the Administrator or specifically provided in the applicable Agreement. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">24.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><U>ADJUSTMENTS</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the occurrence of any of the following events, a Participant&#146;s rights with respect to any Stock Right granted to
such Participant hereunder shall be adjusted as hereinafter provided, unless otherwise specifically provided in a Participant&#146;s Agreement: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Stock Dividends and Stock Splits</U>. If (i)&nbsp;the shares of Common Stock shall be subdivided
or combined into a greater or smaller number of shares or if the Company shall issue any shares of Common Stock as a stock dividend on its outstanding Common Stock, or (ii)&nbsp;additional shares or new or different shares or other securities of the
Company or other <FONT STYLE="white-space:nowrap">non-cash</FONT> assets are distributed with respect to such shares of Common Stock, each Stock Right and the number of shares of Common Stock deliverable thereunder shall be appropriately increased
or decreased proportionately, and appropriate adjustments shall be made including, in the exercise or purchase price per share, and in the Performance Goals applicable to outstanding Performance-Based Awards to reflect such events. The number of
Shares subject to the limitations in Paragraphs 3(a), 3(b) and 4(c) shall also be proportionately adjusted upon the occurrence of such events. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Corporate Transactions</U>. If the Company is to be consolidated with or acquired by another
entity in a Corporate Transaction, the Administrator or the board of directors of any entity assuming the obligations of the Company hereunder (the &#147;Successor Board&#148;), may, as to outstanding Options, take any of the following actions
(i)&nbsp;make appropriate provision for the continuation of such Options by substituting on an equitable basis for the Shares then subject to such Options either the consideration payable with respect to the outstanding shares of Common Stock in
connection with the Corporate Transaction or securities of any successor or acquiring entity; or (ii)&nbsp;upon written notice to the Participants, provide that such Options must be exercised (either (A)&nbsp;to the extent then exercisable or,
(B)&nbsp;at the discretion of the Administrator, any such Options being made partially or fully exercisable for purposes of this Subparagraph), within a specified number of days of the date of such notice, at the end of which period such Options
which have not been exercised shall terminate; or (iii)&nbsp;terminate such Options in exchange for payment of an amount equal to the consideration payable upon consummation of such Corporate Transaction to a holder of the number of shares of Common
Stock into which such Option would have been exercisable (either (A)&nbsp;to the extent then exercisable or, (B)&nbsp;at the discretion of the Administrator, any such Options being made partially or fully exercisable for purposes of this
Subparagraph) <U>less</U> the aggregate exercise price thereof. For purposes of determining the payments to be made pursuant to Subparagraph (iii)&nbsp;above, in the case of a Corporate Transaction the consideration for which, in whole or in part,
is other than cash, the consideration other than cash shall be valued at the fair value thereof as determined in good faith by the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">With respect to outstanding Stock Grants or other Stock-Based Awards, the Administrator or the Successor Board, shall make
appropriate provision for the continuation of such Stock Grants or other Stock-Based Awards on the same terms and conditions by substituting on an equitable basis for the Shares then subject to such Stock Grants or other Stock-Based Awards either
the consideration payable with respect to the outstanding Shares of Common Stock in connection with the Corporate Transaction or securities of any successor or acquiring entity. In lieu of the foregoing, in connection with any Corporate Transaction,
the Administrator may provide that, upon consummation of the Corporate Transaction, each outstanding Stock Grant or other Stock-Based Award shall be terminated in exchange for payment of an amount equal to the consideration payable upon consummation
of such Corporate Transaction to a holder of the number of shares of Common Stock comprising such Stock Grant or other Stock-Based Award (to the extent such Stock Grant or other Stock-Based </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Awards is no longer subject to any forfeiture or repurchase rights then in effect or, at the discretion of the Administrator, all forfeiture and repurchase rights being waived upon such Corporate
Transaction). For purposes of determining such payments, in the case of a Corporate Transaction the consideration for which, in whole or in part, is other than cash, the consideration other than cash shall be valued at the fair value thereof as
determined in good faith by the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In taking any of the actions permitted under this Paragraph 24(b),
the Administrator shall not be obligated by the Plan to treat all Stock Rights, all Stock Rights held by a Participant, or all Stock Rights of the same type, identically. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Recapitalization or Reorganization</U>. In the event of a recapitalization or reorganization of
the Company other than a Corporate Transaction pursuant to which securities of the Company or of another corporation, limited liability company or other entity are issued with respect to the outstanding shares of Common Stock, a Participant upon
exercising an Option or accepting a Stock Grant after the recapitalization or reorganization shall be entitled to receive for the price paid upon such exercise or acceptance if any, the number of replacement securities which would have been received
if such Option had been exercised or Stock Grant accepted prior to such recapitalization or reorganization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Adjustments to Stock-Based Awards</U>. Upon the happening of any of the events described in
Subparagraphs (a), (b) or (c)&nbsp;above, any outstanding Stock-Based Award shall be appropriately adjusted to reflect the events described in such Subparagraphs. The Administrator or the Successor Board shall determine the specific adjustments to
be made under this Paragraph 24, including, but not limited to, the effect of any Corporate Transaction and, subject to Paragraph 4, its determination shall be conclusive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Modification of Options</U>. Notwithstanding the foregoing, any adjustments made pursuant to
Subparagraph (a), (b) or (c)&nbsp;above with respect to Options shall be made only after the Administrator determines whether such adjustments would (i)&nbsp;constitute a &#147;modification&#148; of any ISOs (as that term is defined in
Section&nbsp;424(h) of the Code) or (ii)&nbsp;cause any adverse tax consequences for the holders of Options, including, but not limited to, pursuant to Section&nbsp;409A of the Code. If the Administrator determines that such adjustments made with
respect to Options would constitute a modification or other adverse tax consequence, it may in its discretion, refrain from making such adjustments, unless the holder of an Option specifically agrees in writing that such adjustment be made and such
writing indicates that the holder has full knowledge of the consequences of such &#147;modification&#148; on such holder&#146;s income tax treatment with respect to the Option. This paragraph shall not apply to the acceleration of the vesting of any
ISO that would cause any portion of the ISO to violate the annual vesting limitation contained in Section&nbsp;422(d) of the Code, as described in Paragraph 6(b)(iv). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">25.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><U>ISSUANCES OF SECURITIES</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Except as expressly provided herein, no issuance by the Company of shares of stock of any class, or securities convertible
into shares of stock of any class, shall affect, and no adjustment by reason thereof shall be made with respect to, the number or price of shares subject to Stock Rights. Except as expressly provided herein, no adjustments shall be made for
dividends paid in cash or in property (including without limitation, securities) of the Company prior to any issuance of Shares pursuant to a Stock Right. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">26.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><U>FRACTIONAL SHARES</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">No fractional shares shall be issued under the Plan and the person exercising a Stock Right shall receive from the Company
cash in lieu of such fractional shares equal to the Fair Market Value thereof. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">27.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><U>CONVERSION OF ISOs INTO <FONT STYLE="white-space:nowrap">NON-QUALIFIED</FONT> OPTIONS; TERMINATION OF
ISOs</U>. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Administrator, at the written request of any Participant, may in its discretion take such
actions as may be necessary to convert such Participant&#146;s ISOs (or any portions thereof) that have not been exercised on the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
date of conversion into <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Options at any time prior to the expiration of such ISOs, regardless of whether the Participant is an Employee of the
Company or an Affiliate at the time of such conversion. At the time of such conversion, the Administrator (with the consent of the Participant) may impose such conditions on the exercise of the resulting
<FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Options as the Administrator in its discretion may determine, provided that such conditions shall not be inconsistent with this Plan. Nothing in the Plan shall be deemed to give any Participant
the right to have such Participant&#146;s ISOs converted into <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Options, and no such conversion shall occur until and unless the Administrator takes appropriate action. The Administrator, with the
consent of the Participant, may also terminate any portion of any ISO that has not been exercised at the time of such conversion. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">28.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><U>WITHHOLDING</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event that any federal, state, or local income taxes, employment taxes, Federal Insurance Contributions Act
(&#147;F.I.C.A.&#148;) withholdings or other amounts are required by applicable law or governmental regulation to be withheld from the Participant&#146;s salary, wages or other remuneration in connection with the issuance of a Stock Right or Shares
under the Plan or upon the lapsing of any forfeiture provision or right of repurchase or for any other reason required by law, the Company may withhold from the Participant&#146;s compensation, if any, or may require that the Participant advance in
cash to the Company, or to any Affiliate of the Company which employs or employed the Participant, the statutory minimum amount of such withholdings unless a different withholding arrangement, including the use of shares of the Company&#146;s Common
Stock or a promissory note, is authorized by the Administrator (and permitted by law). For purposes hereof, the fair market value of the shares withheld for purposes of payroll withholding shall be determined in the manner set forth under the
definition of Fair Market Value provided in Paragraph 1 above, as of the most recent practicable date prior to the date of exercise. If the Fair Market Value of the shares withheld is less than the amount of payroll withholdings required, the
Participant may be required to advance the difference in cash to the Company or the Affiliate employer. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">29.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><U>NOTICE TO COMPANY OF DISQUALIFYING DISPOSITION</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each Employee who receives an ISO shall notify the Company in writing immediately after the Employee makes a Disqualifying
Disposition of any Shares acquired pursuant to the exercise of an ISO. A Disqualifying Disposition is defined in Section&nbsp;424(c) of the Code and includes any disposition (including any sale or gift) of such Shares before the later of
(a)&nbsp;two years after the date the Employee was granted the ISO, or (b)&nbsp;one year after the date the Employee acquired Shares by exercising the ISO, except as otherwise provided in Section&nbsp;424(c) of the Code. If the Employee has died
before such Shares are sold, these holding period requirements do not apply and no Disqualifying Disposition can occur thereafter. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">30.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><U>TERMINATION OF THE PLAN</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Plan will terminate on June&nbsp;30, 2027, the date which is ten years from the <U>earlier</U> of the date of its adoption
by the Board of Directors and the date of its approval by the shareholders of the Company. The Plan may be terminated at an earlier date by vote of the shareholders or the Board of Directors of the Company; provided, however, that any such earlier
termination shall not affect any Agreements executed prior to the effective date of such termination. Termination of the Plan shall not affect any Stock Rights theretofore granted. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">31.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><U>AMENDMENT OF THE PLAN AND AGREEMENTS</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Plan may be amended by the shareholders of the Company. The Plan may also be amended by the Administrator, including,
without limitation, to the extent necessary to qualify any or all outstanding Stock Rights granted under the Plan or Stock Rights to be granted under the Plan for favorable federal income tax treatment as may be afforded incentive stock options
under Section&nbsp;422 of the Code (including deferral of taxation upon exercise), and to the extent necessary to qualify the Shares issuable under the Plan for listing on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
any national securities exchange or quotation in any national automated quotation system of securities dealers. Any amendment approved by the Administrator which the Administrator determines is
of a scope that requires shareholder approval shall be subject to obtaining such shareholder approval. Any modification or amendment of the Plan shall not, without the consent of a Participant, adversely affect such Participant&#146;s rights under a
Stock Right previously granted to such Participant. With the consent of the Participant affected, the Administrator may amend outstanding Agreements in a manner which may be adverse to the Participant but which is not inconsistent with the Plan. In
the discretion of the Administrator, outstanding Agreements may be amended by the Administrator in a manner which is not adverse to the Participant. Nothing in this Paragraph 31 shall limit the Administrator&#146;s authority to take any action
permitted pursuant to Paragraph 24. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">32.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><U>EMPLOYMENT OR OTHER RELATIONSHIP</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Nothing in this Plan or any Agreement shall be deemed to prevent the Company or an Affiliate from terminating the employment,
consultancy or director status of a Participant, nor to prevent a Participant from terminating such Participant&#146;s own employment, consultancy or director status or to give any Participant a right to be retained in employment or other service by
the Company or any Affiliate for any period of time. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">33.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><U>SECTION 409A</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If a Participant is a &#147;specified employee&#148; as defined in Section&nbsp;409A of the Code (and as applied according to
procedures of the Company and its Affiliates) as of such Participant&#146;s separation from service, to the extent any payment under this Plan or pursuant to the grant of a Stock-Based Award constitutes deferred compensation (after taking into
account any applicable exemptions from Section&nbsp;409A of the Code), and to the extent required by Section&nbsp;409A of the Code, no payments due under this Plan or pursuant to a Stock-Based Right may be made until the earlier of: (i)&nbsp;the
first day of the seventh month following the Participant&#146;s separation from service, or (ii)&nbsp;the Participant&#146;s date of death; provided, however, that any payments delayed during this <FONT STYLE="white-space:nowrap">six-month</FONT>
period shall be paid in the aggregate in a lump sum, without interest, on the first day of the seventh month following the Participant&#146;s separation from service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Administrator shall administer the Plan with a view toward ensuring that Stock Rights under the Plan that are subject to
Section&nbsp;409A of the Code comply with the requirements thereof and that Options under the Plan be exempt from the requirements of Section&nbsp;409A of the Code, but neither the Administrator nor any member of the Board of Directors, nor the
Company nor any of its Affiliates, nor any other person acting hereunder on behalf of the Company, the Administrator or the Board of Directors shall be liable to a Participant or any Survivor by reason of the acceleration of any income, or the
imposition of any additional tax or penalty, with respect to a Stock Right, whether by reason of a failure to satisfy the requirements of Section&nbsp;409A of the Code or otherwise. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">34.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><U>INDEMNITY</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Neither the Board of Directors nor the Administrator, nor any members of either, nor any employees of the Company or any
parent, subsidiary, or other Affiliate, shall be liable for any act, omission, interpretation, construction or determination made in good faith in connection with their responsibilities with respect to this Plan, and the Company hereby agrees to
indemnify the members of the Board of Directors, the members of the Committee, and the employees of the Company and its parent or subsidiaries in respect of any claim, loss, damage, or expense (including reasonable counsel fees) arising from any
such act, omission, interpretation, construction or determination to the full extent permitted by law. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">35.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><U>CLAWBACK</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Notwithstanding anything to the contrary contained in this Plan, the Company may recover from a Participant any compensation
received from any Stock Right (whether or not settled) or cause a Participant to forfeit any Stock Right (whether or not vested) in the event that the Company&#146;s Clawback Policy then in effect is triggered. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">36.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><U>GOVERNING LAW</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This Plan shall be construed and enforced in accordance with the law of the State of Delaware. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g341851g75s04.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">your vote counts! </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">SPERO THERAPEUTICS, INC.
</FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">675 MASSACHUSETTS AVE., 14th FLOOR </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">CAMBRIDGE, MA 02139 </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">VOTE BY INTERNET - www.proxyvote.com or scan the QR Barcode above Use the Internet to transmit your voting instructions and for electronic delivery of information. Vote by 11:59
P.M. ET on September 14, 2022. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an electronic voting instruction form. </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">During The Meeting - Go to www.virtualshareholdermeeting.com/SPRO2022 </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">You may attend the
meeting via the Internet and vote during the meeting. Have the information that is printed in the box marked by the arrow available and follow the instructions.
</FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">VOTE BY PHONE - 1-800-690-6903 </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Use any touch-tone telephone to transmit your
voting instructions. Vote by 11:59 P.M. ET </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">on September 14, 2022. Have your proxy card in hand when you call and then follow the instructions. </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">VOTE BY MAIL </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Mark, sign and date your proxy card and return it in the postage-paid envelope we
have </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717. </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">KEEP THIS PORTION FOR YOUR RECORDS
</FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. DETACH AND RETURN THIS PORTION ONLY </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">The Board of Directors recommends you vote FOR </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">the following: </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">1. Election of Directors </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Nominees </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">1 a. Frank E. Thomas </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">1b. Patrick Vink, M.D. </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">The Board of Directors recommends you vote FOR proposals 2 and 3: </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">2. To ratify the appointment
of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as the independent auditors of Spero Therapeutics, Inc. for the fiscal year ending December 31, 2022. </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">3. To approve an amendment to the 2017 Stock Incentive Plan. </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">NOTE: To transact such other
business as may properly come before the meeting or any adjournment thereof. </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">For Withhold </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">For Against Abstain </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Please sign exactly as your name(s) appear(s) hereon. When signing as
attorney, executor, administrator, or other fiduciary, please give full title as such. Joint owners should each sign personally. All holders must sign. If a corporation or partnership, please sign in full corporate or partnership name by authorized
officer. </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Signature [PLEASE SIGN WITHIN BOX] DATE Signature (Joint Owners) DATE </FONT></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g341851g76s05.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting: </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">The Notice&nbsp;&amp; Proxy Statement and Form <FONT STYLE="white-space:nowrap">10-K</FONT> are available at www.proxyvote.com </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">SPERO THERAPEUTICS, INC. Annual Meeting of Stockholders September 15, 2022, 9:00 AM </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">This proxy
is solicited by the Board of Directors </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">The stockholder(s) hereby appoint(s) Ankit Mahadevia, M.D. and Satyavrat Shukla, or either of them, as proxies, each with
the power to appoint his substitute, and hereby authorize(s) them to represent and to vote, as designated on the reverse side of this ballot, all of the shares of Common Stock of SPERO THERAPEUTICS, INC. that the stockholder(s) is/are entitled to
vote at the Annual Meeting of Stockholders to be held at 9:00 AM, EDT on Thursday, September 15, 2022, virtually at www.virtualshareholdermeeting.com/SPRO2022, and any adjournment or postponement thereof. </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">This proxy, when properly executed, will be voted in the manner directed herein. If no such direction is made, this proxy will be voted in accordance with the Board of
Directors&#146; recommendations. </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Continued and to be signed on reverse side </FONT></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g341851g46n24.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g341851g46n24.jpg
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M 1$  A$! Q$!_\0 '  !  (" P$               <(!08#! H)_\0 *!
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M9KFE08?*3M][M;TAFL-"L" 4J:;J4E'4;!QLI*L14F[-<%>\"K=2YJT3J-Y
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4P!X \ > / '@#P!X \ > / /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g341851g50v17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g341851g50v17.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1KT4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &MB^:'(X0DE-! 0      %8< 5H  QLE1QP"   "AD@< E  "')R,CDS
M-S0W' (% #5-:6-R;W-O9G0@5V]R9" M(%-P97)O("T@4')O>'D@4W1A=&5M
M96YT(#0N,C0N,3@N9&]C>#A"24T$)0      $+U]P?V8U@YZV.^WT6@[IL4X
M0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T    !0    !0
M<W138F]O; $     26YT965N=6T     26YT90    !#;')M    #W!R:6YT
M4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $       ]P
M<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M      IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O
M;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I
M;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M     %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB
M;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!O
MX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M      !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M          !2<VQT56YT1B-0>&Q :T            IV96-T;W)$871A8F]O
M; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L
M=                %1O<"!5;G1&(U)L=                %-C;"!5;G1&
M(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P
M4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M#6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M #A"24T#[0      $ .__C4  @ ! [_^-0 "  $X0DE-!"8       X
M        /X   #A"24T#\@      "@  ________   X0DE-! T       0
M  !X.$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         ".$))30/T       2 #4    ! "T    &
M   !.$))30/W       <  #_____________________________ ^@  #A"
M24T$"       $     $   )    "0      X0DE-!!X       0     .$))
M300:      -!    !@              J0   ;@    & %, 5 !? #  ,  S
M     0                         !              &X    J0
M               !                         !     !        ;G5L
M;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG    J0    !2
M9VAT;&]N9P   ;@    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L
M:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M    !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T
M960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD
M<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE
M9G1L;VYG          !"=&]M;&]N9P   *D     4F=H=&QO;F<   &X
M W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G951%6%0
M   !       &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O
M;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M
M#T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T
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M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  X )$# 2(  A$! Q$!_]T
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M7L]JZ;_&_P#T[I/_ !.1_P!5C+H/\5T_\T:9_P!/D1_VZ])3YY1];/KETC+
MMS<MMH <[&SVN<'-G\ZK*:V[8[_24OK_ .,7JWU3^LU'UCZ6,MC?2R*G>EE4
M3.RP .]A_.JL8[U*G_\ ?V+GO\;5W3OV/C46EIZCZ[7XK=/4:S49-G[WH.K_
M $?_ !OHK$_Q;YMO3<'ZR]3#=]>)
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M?4V!"F&VKE=\NFYP)ZS/:)]-)XD[?U8I8G$=.K<DU3Z 3 S"<KD5$S<>L4@
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M-)-FL "JBY;1ENF"HJ)F(HGW1$#=/44ULN%LC)90PYB;)9TA0/D3&=$O1D#
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MVLLT1,9K.5R2%.N <\19X%U)5Z72*.ZL;).DPV$P"&H9C.Y!DC'=(OHUVS5
M;E5("S*52YPC^N6VM+S,8W?KP%F@91!L_BIV&57/'RC%T@FHV>-UDQ 0* C5
MCJFY;&24[W<-1?+PS,PTT9SO9W#S+6+[9$EM>EG48\61.@Y>91QJX8R["'ML
M@W.=L]O5>A7$B\(<ZSUBI)N%Y@1K-26F6Z0\U(GU=^C\/Y:V!W%'F7N7KDW(
M58I$^L1;NKRA:50([*%/B"2@KBL8)J+93F_X,[5JJBY3+$.N8K;IS94],?(+
MSU9KF*J)8B9U1R6H[+=8AGQCG:F.]H\35<0T:39$.IU*C<7DC'-U$@5<I)HH
MJ]=GF&.1IS!]>MOH^0.9]E!GA?"U.*V)3-..-U*HS>P%;W35&LTNBX_;!B/#
ML4]; FV=R+89NXG,14)J)"1(+S@P+!N"\4Z;<6U'#&%*9$T'&](C0C:_6X=(
MQ44"&4.NZ>O'2QUGLI+R;M19_+R\BX=2,H_77>/G*[A4YQ=KB--ZU8XCQW9I
MRJ61:WI2=?5(G)G84BRR<>D95J@^ Z,DSCU6*Z16[A,RBB:QB)FZTSF Z9BE
MZ6N:SL(6N4A(B#=7-RYL$G'Q<:J:A6E)@LYDWB3)H*C\\>#1% 5UR HY45*@
MB03J*&*0IQX?%IDBJ/<BRF*T'3@UQAZTTMCYF+%P1H2$>NR,6ZY7XI@U56,X
M.4IVZ:HJE#<QB](&'CWY&R%6,5T^3O5P=.&5=A5(Y-\X:,W#]=,TI)-(AF!&
M;5-594#O7S9,W0F()D,90VQ"&$.LR9E>FXEJ9+K=7CQI "^81Q5V<<\DG(NI
M/K]3(5HR25<#W!((&,4FQ1VWV 1X8PVM_!@>:F0-O[V]QWVZ1#R&+WV\PV#S
M'QV\MW8?9WQ]%8F)FE^[EVE$,4AQ=.8*41E2%5F/82?<AE6Y9),3R'N@!T $
M41!P'X$P&X:4=<6!DR]QR^N[- H"*SIWCJX(M6Y WZEW"OLD022)^R,<0Z2E
M#J,.P#Q)ZJVNNW>"86:J3+&=@91'OQ\I'+ LV<D YB'][;J(JDH0Z*Z"A"+(
M*D4262(H0Q02ETRW1*%9Z+4+1,!'SV1)%2*JS0&RZX.W:1VR/2X613,DR34<
M/&K9%9T=-)5RL5(HB8#;.2(E -Q\O$=P OEY?+;_  [CMQ$=;6Y@=)T]:$>7
M-TI'OGD<Y59T"TO&Q';!8[=RD1PVC5$E.A5,P=13" @(& >D0X>#&&;L99B;
MR"U#L9)-Q$G*E+Q+EH]B)N,,H)R$%[$R3=H_134.0Y$W H&;F4*8A5!.42@W
M%IU>X6IUIL%+EWEJ5G:R]*PFF\12['+MVKHZ*:Y2B\8,7#<X'34*(& PE-L8
M"[B4>.XH&J'%>2[0RI]9-;C3$@D\6;!+4NQP['H8-%7CCO2$DQ0:HCV4%.V"
MJ@&64Z4R *AB@+F5?)55MUHO-.@W3I>;QP]BH^U-UF+ELDU<3+5P\CR-G*R9
M$'I5&[94YSMCJ%3$ *<0,8H#X7_)=2QHSK[ZV.W35M9;3$TZ).V8N7QEIR;,
MX&/;JD;)G,@@J+983N50(@CL7N&#J#ANLD:D\78RL2E2MAK:6639M'YO8U/L
M<RS!N\*<R/Z>BF*K<RFR9A.EUB=,0*!P+U>+8(:TM/,L0BC-_?GB"IQ(59G2
M+F=$5 /T&*"C=B9,PD/N4P ;<@AL.PAP\TQ-8Z;9!K>+Y"1L"=NML-(ST*S;
MO9]-LO'195C/5%7[=<K9LHF#=;I154(HH(>Z4>H %'Y:3PABZ)1FLCVRV0B#
MYP9I'-F=YOQI26=  &,VBHN%F/7GBA-R=P$$130$Z8K'2[B?4W>,[OINOMB3
MJL#9LFQ5J<)G7CX"YVO*,-(RB!4SJF4C$Y^:[+\01345%!NJ=<$DU#@@)"&,
M#SW^<Q-AB#3GKO9):'8KN2L8]%>=L<M)2CXQ>LC.,C4G+Q_(.1+[QR-T#E3*
M8#*F(00'A%4S4Y@RR6&,JI):TUB<FE4V\(UO,+9*RG,+K&(5NBP>RB1&2R[D
M52$;H*+D5744(FB0ZBA"&E2#!OL&QC^7^Z%O_OPA\M 'Z%^3/ /Z@;@/D'F,
M!);C_#\>&OTC!^MLQ"  &_T2; 'A\WKO\NP;_/;AA+#E3'^)M:]UF<@V1K68
MJ1P?6HQD[=-W[@B\@:P%=@V*1@U=*@?U=LLKU'3!,"D$.OK$ %,ZM]36"\B8
M#N50IF08V=LDH\J!X^,;Q\VBJX+'W. DGABJO(MNW*"+%HY7-W%B]14Q(0#G
M,4AG0US+H,\!0CMRH"*#7(&/'"ZI@$P$20=**J*B  81Z"E,80(!C;A[NX]/
M"]#6;IB GCEB(   -]XFS^0;#[P>Q  =_ !\_#8-O#Q3^N55%SI:OCA(0517
M-4U43% 0 R2MHA3D'I$H&V,4P&V$H& !\@$!X53K5YIH29+G<96J[I(J!^ZV
M03D'SA8@$V,DDT1CE5'!CA[@)$3,*@B!=MAX1^BF%D(W'MXF#PSVMUJZ96MU
MOH,"^1.T<,:;)EC$XLY61P*+!!V9JNHW:$(5(J)2.4143=%5/'_)=)D-2-NU
M'7Z'46,IA6)CJ'B5RV$QA^FM*D&]VM"[(Q#=@SQR_;#!%<%ZSE92B @(]!0"
MP#$-_992QE2;^R,D!+- LGCM-+<2-95,#-9MA[P ;JCY=N]8F,(;"9OU (E,
M!AB1I!R9C>K8VLT39\@4BMRI,KY%<GC)^UU^&D?5EIO\ N9G(OVSD$5A(;L*
MF3Z#@0>@1Z1X\X6?JV1=:L+9\3O&,W%5C&4S&94MD 8B\')+/5C)5R(5E6P&
M8R[YNX(Q<D4157ZF[/MD6.6,5323./,V8MQ'G[58AD6W,:NM-W2JK1*;MG*.
M_7$H^$?$>&)[.8O (")G38I@6[>XJE[8& #"69F.<WXJRVYEFF.[>RL[F%0:
MN)5)HTE&IFJ#TZJ;913VBP9%.*AVZI0!$5! 4QZ@* E$6)T]  :BM8H>'A;<
M:E\@\AK\T A^\(> @'@(>'EQQK5 /HWA/P#QU%XTW\ \?":\^)FB >]X!^Q^
M0?$# /VAX?O<0RT$%*.G6(W !VMMWVW !V_5 Z_^1^WCU7L ^[@P5\OT++[]
MO1)_E 3?PCX\>AC$M;5KILKJ=13DDL=8:@E*JB] %D8>2G)E-5U),4C;%1>*
M(+ND1<=)U.E4NRA.TB!'TS#A2O9BCH!*0?/:_.U:Q1EFJ]LA$VGMV#DHU=-Q
M^DUG22J?JSKM)D<H'(9,YD6ZP%!=LD<L>M1*ZU#SMAG-%KK\O8<6U."LT++/
M(F-<31J/89(1%M:748@111-NJW%!$[UN0RR18\W2(N4F"+AZZEGK3UEN2BHB
M NE/LTVB\0DX:(E&@LY=&3;$.9%W$L+ R9NQDVI.X8BK!,SQ!,%#D$$P,8)!
M[C\Q^T>&^RT(!B_)G]P%Q'^ *_)"/V!X\-?I%W^YMQ#MX_J3;;?$-P>O/MV^
M/#=1#!@_USY 2?,VCU(N ZVH5)VW2<)%4"T-B]94UBJ%*?I$Q>H WVW !VX]
M^N*#A6>F7(+AG$1C-PF\HX$<-6#1!<@'O]73.!%4D2'+UIG,0P%,'40QBCN
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MB$5*Q;H'"&J3-\9DA^WJ\5F;Z(6FCV>84!E79$T%&NX^1B3RJXD9,Y%%T\.
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MB>L0AF<E,D.H<LN_:F8B@\DRG$3E?N"*.BG$3 J B(\.GT$V .DNP> !TAL
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)=?8/D'V!Q__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g341851g75s04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g341851g75s04.jpg
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M  (#  ,! 0$           <(!08) P0* @$+ 0$! 0$!
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MD;9$A:)M;$)&MB'L!)!6O.88(9IQFQ&&"&8(0MAON P& P& P& P& P& P&
MP& P& P& P/FRZE__2>_:_\ ^@EU'_[S9&!])N P/G<_Q1W_ &2<Z_Z0?+'_
M *;XG@?1 7_YLO\ \@/_ +G6!^\!@:O-V)GE$+E\:D*LU P2*+O[$^+R%86\
M]$SNS2K0.:LE>/6P(C4R)0,83M_<+V'S;_<P1\#J:C/<*]A"LIY-8O5?(/N)
M^UW+).VRM]ECM'X5(C'&.RDYIBL<=7QV$2?+8XH=T($"/1A(9?$BEAVC"P%_
M$#\T>G.OLO>;MJ[-MWG+LGW1O9*77>RHJ\]M&RN7:RFU6U9)O@XU6$;=9"KL
M%H4P22HD@T46;&]!.HM$XRZ^GZ2/Y.4G+WL*(_6Q$UEFFV/RR^SZPZ%XR;8;
M&Q6=47-['!8:^1-7#54KA=<,$>B,C0/3<="3XHO7-Z%)'GHA^)2_+=HC"3_B
M-%A)\1;UK=<)=NV7R:_XB+KN@K-]Q_A?A:_[+;H!RE14QB][==OJQ+(75 8L
MD@#7!EA:UHBS:]O:]>=6K6>F)"G2&C*^MX31:T$O8@QW]6MFEVG-X>O_ (=W
MLRAJE]PWM'@"C[406/R?>,[E=V<<R@A-(&E&!T94A;F]0A.TRIM8GI Y'UF<
M00:%0D*$<=$!F T()^A")[=;=9M>>[F3S/Q5TU>?0WNG=A\-S=_C?97!G;$H
MGE6Q-K^'-2VG$Y79%\FS^#%HSM  XO[B@C!0$[<>(2%\3&*&TX&AJ23BC=VD
MDUV_&Q;OASNUO]QC_$3\5=(AACC74M-Y@EM=6K!UQ)Y:>-6O!:>O!-,T+$:K
M%M<ICAJE>4<D^*"6L( ;M.H!H\DS>W=-M?'U6=LOO8>H^PR1*!%(F1H?D11X
M5)21Z;43HE+4@ ,L"@"=<2>4 \)9H@Z'K7FUH6]>/AO>5YGR(\ P^(KO\3O[
MJ3$MBT<6,:"C1GH694R-BAJ1'"5<O^8Y(W&I1I$YN_B#/$0 :WOU!?\ LM^,
M=MK?U:HU=X;5-H?XJN2UMV>QQ9;7\&I"/$<<US.D;?NLE[N7 H5((B@8H\YA
M^KC@<K?W6:.2=)HL8#Y"EWX%B4$%A#>Z\>G.O/=)/^*^K3FBO^8:!M*'L$*K
M[L=KOJ+I:6>X"W-<9L]VBS>TO3C)-%_5\A&[NC+%GM$S*41QGGTW.PDP4X@#
M4C"9*GIMNV+^+ZM:/73ASI:H'*SDQB.R7"KH NL)(:5H@U+.%<3:3Y8F,(#H
M.B3"'XQ0'8-:UH.]>&5RN,].$HX0P.,_O2_H'[?7_P"+3P?_ /OG3YK#IZ^;
M]JS=\>TU%_M(?>G> +6?. .LW<P3C))'6+2D=*!O%85O9X6[HGG=28F@\V*7
M'Z\#'=$6WOA S!'^N<9H.L)-^F-NNK2(-[JD[YOES!1WNY4TCY)FSTY$QV$=
M7PI8YRWA.ZW,PW9"0399ZLC3G1\E=/$(_D<Q"F]+6][TM%K8=;+X>773K/EW
M=IVUR;GEN0N[.X(G5I=$:9P;'1M5$+FYQ0+"0*$BY"M2F&IE:-408$99I8A
M& 6MAWO6_'#F]W 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M]GNFY3<-V=*GK-S3[<W.$SN*11*M=TCKMLKV-#AC7J-HDR9K0-Y'K'*SBFU
M22$?AZ@C#-WVNLU[1_+W]I;CV\^F^;.KDQ<II6Z^7'I&[0)=0J^$0%ID(D$@
M2R-,UV#'C84]IY,V:&6J2C+#\,8:WN2L@8Q ,#Y!-]I+KVK>^*?;AYVX2L'J
MBT*4D-CNSYUK8X;1M,F>2IA?V9HD 'R;R$*>($-,98#V5HTMGBT/I*CEIGI
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ME\5K'7!)LTQ,M<'5MC:D[83 HQ%EZ2C.NUF/[XN_T_E]76'$P& P& P& P&
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MGQF+N#/T#3MCU-79\AA[ PKD[!7LK>33W4TH AJ!%OC=,9G"ZO5O!/1,F]P
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M4]N:V*<+T6ZEF#)5"F5SI2#16O(&W18C/J_#=+E"@.O#XHO81!P33'7?I/\
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M6Q#WL0O$6][V9SGK6ZX# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MA#>ZY]QSAVVBH2.O.E*YD9MB*[=;H<W%*W) ].SK0L9:9K<#*-A=FU ]-C[
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MF0UW>]?72E9GNW;;M^9=3MSXK-BBI$%8VR=,H9_6($VC2B)"((1I /9SD15
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MZDX>JHBGAA+9X\YS=+SVK#,@W]=1\N=F6K'M(6UD.$5@CDUGNBPI&A^'/$
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MM1EHL:]II<I9"$85"% 71+\\&KGI0=M7I4B+) 6%R3@2A)T/ZJLFZ.->L+?
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MC'8E/0^V]A5">BY'"]/3D^U0_0R3:;7+X$R2M-\6+5Q80E%@!]6UT@4[\=H
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M8H<%VT2#9JL02!&NPN&U+S74=0TP?'IWN2R1LKR%J:AA2.2,D\232*QYW:6
MUN7JF5L?GJS$:M 0I1K?AG)RACL<4H-);0J!AZ5J-_&'#O3]?W2Y065EV9;[
M<T5##D<,W!=1:N6%_D%,4\A):(@K>XM(4C [/.XNVA(;27A*U$DFC)3(23%
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M(51I(_, P0=A'$@Y2YFE<B'+9-0E2OTF,4J5ISZZP..+7-0M5K5#B>N4JCT
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MY;U9O\)8WMY8RW!S12^05U6^E#\L3HS2'&6N:M08$9(P# %6"O;>['A\0J.
MUAU&]16%P:/U4D=H\T7/93:8FG<=JF$PV66!'7J20JPA@C[9*(JJ6-D-"D1,
M2TMS&8/3>87LLT.ZN P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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MYL%I<V$RRN%QZQN3E*5+2L5[)4D&.",19IX5]C/N/G&KI6NDM3UBLCJ9#([
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MGKJDT2O"?N EQAC^@L.4Q 4:7QA6T@($Z.TC/"N$G):SC%(3/=4^<$=E]'5
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M6_$(8FG#W+LZ<:\7.531YF35E+Q3N.1Z&%CA$342K;G&WH+R_P 5BHFEB?W
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MK$V!JP-$#;7:3.NT8D#PZNJC;'KUT24I:$Y,'OO?N1RYL<.>U9M#QV+PCHA
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MQL0%<U#LD5:97UYT9RFHD4+MU?-&6(ZH-IDJ-+9LK.>ZH@AZ".SBRF="Q:)
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MDN>-,;9'RT4D#LM2UIW9.T.X]^NE/1$K42P@D+*8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MTJ3Q!;$!I/GV&"X4]ROH;J.^H!7<FCD!"T2IID\AEK"SU+8L%+B$$C5+U=+
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MGD*92!2C0'D! <'0C 8# 8# UZ7*Y,WQ23KX6R-DEF**//2N)QQZ>S8RS/\
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M?D-Q):3E;E*_J^Z *(2>I&&[Y@48(T7PVP^F(*L_;E[O?_=Z\@?[1"9?]2?
MM.KG'79?-B69H^?*@4]4C)3"5T2=T.\IJJ3G#E?P"HHJ^=4H>[* $0W_ (1
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M_P"[UY _VB$R_P"I/@6G.G'78>:RIF1SY4!O5(B21'409T.\E546<*6:0'E
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M >ZI[8<FC<%C^UY#2DBD1D/*[&4N8H0F=57R6,IG5G9T7Q1P4VDVC1[$'9'
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M!1S5;T@.F+&O:MGC-2KFM0O4Z\@&E9X!T295+FL9FE8]MA3(\JFQ I=V8EP
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M"%_5';R"2'/HP;!'=J-J?1%YMJ/'6]8%5JO]\93:?*[IU''N:H,\H%IO++7
M*QA/9E-6!9#E)NL;=B]1P..VLP1QC-5T0J;7.5DGJQ/98]^8A0G"'U23/*'4
M?CKJ]OZS@4[>U-=R>G;*INWYK05X5%+G)@?G:N[8@9+,XNK0GD\56N$;ET>=
MXY)6MW:G5$9HI:VN)(Q%DF^H26%M<!@5C[88Y;)^-NLXW 6U]>)S(.:;T9(:
MT1<M6=)764NM8RA"P-L>);]Z7G/:YU/**2@(_AA'B#H'X6]8'SZ.U#3+^\;7
MDF;*&MABX@2GVV?6E=6WR+TST4W1"7GP+E=+*GAMH*&2^'6-2[5.I>P/>XT>
M] (0IEJ!Z5DMNBG,LTX+B73R8\M%L=N.%$\]K$$GZ*8>7:?KZ=H$,BBK4QM-
MW/5AM?6\R(FC:V/:R!#0U\J&I=W9$A/5IG7Y?OTAJ-DAV&@497=GHYZ7'^N.
M>>AIS9]412FJ)Y5G<$362^11C^Q6:V=&I79;?;A'U*9HL@F45U&Y!)G60":S
MYTS&Z;"TKF:G-:0!:'VU8%U#593TY]+FOD@^&X-]OEI80H:UEL..:W^#QGH+
M=AUTM:'R=3]3+;=BZER;P/RU.-O-6G*T@1H2-Z!H04"2T-[BSCN'M:V/SV&S
M.Y^GJD]PMED31)YO+(G6%G:B=YK9Q25O*5L;CA->0H:ANKE@<8L7MS:])%;J
M,A08;H6]!^.'ZEZ',L6FI=(*%Z0JCHI=>E*SV:S";LT_9X=$^6#>6XTFMJI)
M[-W(TFOIR,%AC6-*2.DC<')-*/1=0$)RB!K !-':?/?24F[/LRX8G 92X5>C
M.YF8T\UKZ)2Y7?C*<BAEP"&.GY4@EJ1D%4#M/W!F8;0:BV-R5ZC[P>N#O_-M
M^D&BTMQU'Y_P_043EO.6G*VH;<?!^K%2#Y%O?G"0I&-7-J.;>@@R<RV9=)U=
MKF%Q-E>2Y7(FHY.TJD03/53@#O8AA@^E:)Z4E*B?<_5W5=KEDQ3IFY9XD7J(
M-.W6DUE&6B]<[M%8MS<Z-BY@C]@,"1$\.9+C%6EW+<FULC[M\4!O(]$\T(?:
MN:>\8)-I0]L$!MS1;/)J4I^U:KAZ*9LM# CTP[VE,R?)WR4UN[T]FCJFI8NP
M1F2D)_C#UR.+RV0)E@2#B-(DP=N>Y.7X=>=B<<R9VJ!'8JJ-]),3=/7032I<
M?E=/?9;="]>DDPR!A*U"]STQF,- HT).)?M-L6MB\F!QZM6@.N#.?;^:K,A%
ME63%GKD7W"HS45=0>F+26SR-6=*^ZF.34,B>E33,)HMFDL<60M&[L#BB:& #
M2Q(C3MA$GT8<$+HS2OUK;VM0D]K6E+D?&XE-RG'X:P3"F;?CD;K.I"&V3-$O
MD=47S#I:S,5%(H!&I >;/*RLAE]67*T"8@@G9QR898;-UEQO>_1O9D_E\!>F
MFKVN(<\\OJZZNAQC<P7SEALF%W%T9.'R/TA)VZ:1R(1AP?TR=B;I<)S0O))S
M*YIPG)#R]Z)&',ITY3Z;GAU.)Z#YYDJ=I::=A:FZH!UE!K:^S:=]KQWF_I=/
M;<J?D3K+H0O4R>4O4@C+2"Q4BXY@<I-\&J).<=I!'%ATNYAY)K*)VZ;;<EI*
MSGB/;]N[GDISF-PP21+;AE=HN([^8+V+G<>1EN2MWOV40(UG32I(B*5+5IAY
M!0-GA,)V,.?\ H:U2^8N88WJA>D&:8-?'PHMSTB!7=K19YIGOK5^I'22618O
MQ;>A6UJYK6P;.X%3&1[3LZF.-SPE*6&%JC4:L+F>UU5G6=5W,FBUZ1VS3*X;
M.87^3P>;S33QLM'([?Z0D\TDM+R#YH+UBY55SDWK%#7ZWG,U$'MK( +RI1@"
M%1K,YEZ@L*5Q)IK./]$5A>AO0<[<>K[Q3,MA-T;D:[??=8SSE";M+TN]*(VI
M#ZZK".JUP LHE22/0C:AF<-I?B=HMA97C=YN5GL'2OKGG[HV-(^AN=I5#9/#
M&ZK+?LZ&1>?2_O/LQ]D\1?))!6)_:8DSDU]8[(>C=' Y 2=&CDJ@)H22]>F%
MZ/;[HRRZR37&_75*;!FTR:Y\[<_5:]V&2J1KB>6J">7F/46800<H.)?7V6MC
MFJ>G^3[T!5*'%7H\[6BR$Q10=&\!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@41L/A>/6#>74=X*+!>VMRZ?XMC7&;LQ)F9">DB3%&GJ[7DF<M
MBTQ6 ]Q>%)EU* "2&@+)#I 7O0]^H+RA4HCV;8?%Z*ZCI2J;I4UD'JCB_F?B
MV6R5HJ6&JM-43H6'V#7TKG)$= X-S:ZS.X(=9*],L./'H38>$H\H9PP!UH/8
MZ,]I^>=*4!6'/$T[.DPX.S<^$\W70RNE#53+8C9\93"3$M]HP"'242Y%0_0[
M(T%F(F^6-I[EI(48$?P0SB"#"P["1]E21MA9(Z@,6'(6!H;65$:X*SE[@:D:
MD1*%,8N7*!"4+5@R2 [--'O8S![V(6_'>\"F$CX H>=]LK>W+-B,&M";I:3J
MNHJ_8K!K2&RX-5.576)9EAIK&K^2R!"Y.\;ECVLL4*<XQ$%,86!L('HT0ON
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MX],C6SIN]4MH7+5W:=7=!SUZ=GJ7QNSV[MU0ODMBN+#4,BF"NOZD4,]EA:Y
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MWHS\D5[](7?CN ^-Z,_)%>_2%WX[@/C>C/R17OTA=^.X#XWHS\D5[](7?CN
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M8FMN/D(#=L+RR'F&-ZA23K8A(CP&G*!!-%]P.M^(=Z%L/B'>A:%H)RP& P&
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M>?\ T<HK_P#&W/ ZXX$"VQ^GE)_M8L_>;<">L!@,!@,#6YE^B$J_9M\_-BK
MTZD/[*X=_(%/YS78$JX# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MLMX<CW(5<>2I4J./+7$UN2E!2IB=["Z& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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MAT&O]XHK#4]-\_FP)+>1TM(@*T50**U#:X($EM4/0W/XW<RTU4/\M:D1;[)
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MH-ZP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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MMM:UJOXGX=(H,+"T 1!$'0@[T((M:$$0=ZV$0=Z\=;UO7W-ZWK _N P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M@,#6YE^B$J_9M\_-BK TZD/[*X=_(%/YS78$JX%9;MH\NQ+>Y,M1NC\>6/\
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M<,;G0"1L<A[3>JC3% ^#(W^"$+3X# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MG*$%/5K#ZZ321Q;R#$J!:_%Q-H:M.ZE F.&60-1ZFR0#%H'ET(7B$]X# 8#
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M*OV;?/S8JP-.I#^RN'?R!3^<UV!*N P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M#JXCU@;5+3<9#O 8,V3BHY)1T.N&'2Z#DU4BD]?3*2/1DEVH01M,K3.;3'5
M"'=6:Z-JHY<'6# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M+X.PG$!K4,*Z<)/0!Z3L;H2\OR!\INO#6!O+DRLSUMOV\-+8[;:'-*]-.W)
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M]XK: NRZ>,*&*SE:YPZ.KU<SC#8%0!MCDK4*FXTZ1,+<!6;HA&LV<G)T8/0
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MG1(DBT?8ZQE+A(;.8U9=CJ/KU6+46ET=+8(G15!)U!KB7Y !3LXAZ#O2IO\
MBP]1Y]R#EEA)E2]SE$@2,$=1MI[7*U46<D,4GZ]W;ZE<VYAKY^<?@T,@>5*6
M](KORB$02#;H+S&ATC7[2AF8UW]SW,0:6Q4VQI''TE/F7E)I<Q5C,'F)0N!!
M2V082=*'YK;5B-.]K7"H9&WD-Z;:I4:O;?1"'_.$@E 3Q15WPCHBM&*UZ[$Z
MCB<B&N VFNZ$M&>?IO6&HS3TYJ52O:G- <,KS$JD2I4E-#O\$S8M""$(5KKJ
ME=.H?Q_*386D;3.HIA)XNM1%OARH$-!'JFN*RP+$IXFL@3V-4=5H$>P#"FT
M*T1GCO9>@#".>:.U)/?/2=ZTDJAD**CM5/\ ;[&7(X9)I:_/L56U1;!%8M[+
M;J%T@S-%([(;31&GOK"F;7AP.^7-RKUR@:"6:,+TS26M4"B,FFSZ!R,9HFQN
M<@="V=K7/;J- TI#5JD#>T-A"A>X*Q%$[T644 0A"\-?^K@4]A?N(<ZSUWA;
M/'S9Z>;,7)G8S7#4(<E;!#Y!(;:GE$L3%,I$U&.+&W+GBVJX<V9.),H5IC3
ME*-&_"&A48$[W!<I54O]*L1[*L6EW!:C;6A;WM,L,96%4X-#NZIPN2EO)6*4
MK@[?*A$H/4)TD,.T()QY/X&QA7M7[BE$#:9B>PMEHOTCCS@J:(Y#T5:R<R16
M0N2O5PQQ0J@+<4E-4/S&W.]!R[:M7K0 DI&8Q3K0B3T8U(:9#/='YQ?FMC;G
MA6^EV<HKRJ)4^UY$&9;,' B76>@IHW5=1X",M.YO,@87"^(V6HV:D2%>FN$+
MS>9(N E#;'CW,>2F!V:6%WFKN@>G&!R">KF=1'%Q;S&BHTAM!:YQ62,@MZ>4
M,U .EI2GT@+3G>56T;*&8 2I#I4&#L/W(:NCD,*=8A#[&D<[.ES1&%=>/4)D
MD==HDA62NF&-PEL_-^7+P1.*$-%[QU<G6&Z& \+@$(M%_#K]I \B?W2N1G*/
M/$FCDEETP;F:0.3.H+A\,=)(M.:&NOYY:9\X)2M>SQEPPV U@_.!9YVR50M-
MVR=I]*3DQ)X6$I/HU#=D^OR$ME>SN,(J-G4?A9<RD:1N)C%B D5;PBR43W$C
MTJX]7\)MJFZ<6BSR@#$F&0?O>MG;)*#"SKLFEZXF5KQ"6F39N(HR CLBW9QJ
M!R4^N(''!Q=;,&P#S-2T6V@QX?6-K5"1HTPCSC#R/0%H!QR8!X:#&_<1YQE_
MU U&54Z?QSN4M4,5[8H0Z/R2NY _VHFI2/)K-=V,3DR1=+(+,4;;42K2E0E4
M>B:> S:8&SL#^(>]JH;F.#N4^12>+NUF7Y9E#0^+E1EY6/Q,BK>9.T5=")"F
M$06G3NJ,#;H\Y*A.7FJ@"&-O"M**-& ,8;[AM4QN+7/,;1B,]JUEJ;HQTYJ:
MC)&D93#;2FB G2HA1!-D.X49J18A)4*]_&')@%(R-F;,WO>PA#-K?<-YL1MD
MSDOS6;J(% :_A5BR6S2J]E)%<)6VRXK"IG6S&3+EZ%$VJ99.V"P6LQ @#OS^
MJH](\1)O@'8:MOW%ZCE#Y0K'4C9(K#'<E@1*(OCHG9W0B/U@BD[M:D;"*8R%
M&D<F1%)12>GGM$E0Z/$2K$CV8!1Z2A$-4%A[AZ9K2CI3"XG.0RO2R:-;S(0.
M3'%G)[8(M%H]*8!#'F535X1@VEC; WR*SF8DPXWQ%HM08=Y?03*3"@KS/_<4
MJJ*F50KC4:GL^9IXI:G.2!C,/D#E)HO!)#6W2DW998CC:%O4J7G9:_FAW3KT
MWG)&D2BT=XC,$00<&:<.PG-E(ZN?SHLS2N$4=3E77O7+] EKR\KIQ7UH1V>.
MR1:_-"EM2&H-L8H$>L4#;QK1&M1VAE%"4 ]$P)JBW2,'E5C-U5-+?,7F2"C<
M?>9#(F"%29RK:*.DEB6YPS1B13?Y<4WL;X[Q4'QZ8I7HH/H')@&B+4+$A!X+
MCZ=JRB9;6$/L14^-JRV)*SQ..NR=D4*(XB>)%)6&&Q\A[>AC(3)AN\IDR)(
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M?SBT[!8 N/1<4ME$_,+E:RYYAS".T:XDJ:J*BC<1EK@^1^2SA[@K(C5N<=3
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MK >6VNSG7D"8(BO<VXM4 M4!"O5- S2=&!"9HL>M"UK?CK G' @6V/T\I/\
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M31X<:7/4[)1#:^FVGUDCLR 5A3]6VTS7+8I@1FQTXGUVJ4L9)31O8-A3(MB
M?I29O1N@B"5>U_1LQV_:>IC9*].>],SQ 6MX35-*8_48&:57'+2VJ'1N7U8_
ML3\W*EE\R1,/ZT)Y">6C/3 ),*&B3&EAK;)[8%>N:"V8]9\ODLBADCD+P&HX
M8@%#SHU5<95(:$,1.R)K=:\$!UF9DAH)J5*DSL-ZCNP:-)*0@)5JR3 DIM]M
MZ@$<>#%UBJ8N3*H)C13VW%F0Z,MKYJ/L=X,*@)K/"(;&&=C3OZ;H%^&J(:4[
M>248%+\(%,$D03 P"3VRJ;'/(K:,LGMG6-8L<F2&5K9?/D%-OSK(TC2"G/DL
M54:^R-,DBS.TG48R#+61TIF?#-&+0&KS *MA &\).!ZN9V%D:HU-[/CKM%F_
MGU'%9:C<8<O>V%3S<YSMQ@[H2D>X4YQMQ5NA=C.:9U M0*4R@@P&R2DYH-&X
M%@[TIAGOJO#ZZ?I'*(TWG/L4D G.,&,8U2A3$9"VR-(VO#1)V.21*3QIV4MH
M2'%K=&Y8@6I3!EF%?[W80IBT^UC133'H_"2K ND^OX_#BHP&$F/T'(:G)V34
M,_<W(IXO7H*^1R$F6(*O>@$D 1K$K04N0D*@H=&>MZH6#KSDB(0-;!GM9/+(
MG<IA%OVK=^I1+U</+<9'.+@B\FB4H^>(HG#8NQ$LB1JE)^F](WI$(4NRB=;$
M, !!&$=.OM^UR[0-FKDVS;@2QMA+N:+MP4#E!$Z_[%[]5-2RSJ'5K10 T2N!
MO)S*F]%Q%KZV)-$A])X#OQWL-[GO&M:S^EIK1C@\R9)%)U:DQMUW4#0P&2J-
M2*<6(\66[MWR6;PB40U?'T[Z]F@2$K&M2>D++),+."K)+4A"29/0D1E5%H*"
M<'B8AC;/'(.Q,LH$_C<I^W+ZV5,#I"9>9)'Q,ZA>)<S/\70N(E+@0K*6+"=[
M5%' ,,+&&$K3FB%UB]022M[],'Z1P>-7>Q#>9$N9C5$L<NB+/B=PVE+I,0TL
M30B^L+Q/(D!20! 4@;D92HX@I*$K1 20]"_N8(_T.MC'UHL2T8[&&DQ$3+*^
MBKQ'?J+9K2VRN-S1M;I<S2F+2<UI<6M^BY DCY'#F*2)2#U!)3@ !FM "G#)
M[5D"D];,S+><^E$ULAJ=52EJEA+;5TB9X5'0.5YA;(/#8W.:D=8VKCR=AO\
M?R_B7QL=7HA6>4:2N#M$BV2%N%G(M=#A4WAC,^3*,ZEUJU_=#9(&=5'37J!V
M#5K+5C+!7*(D/$:=8^- S%5 TF"1.B%S2JMC4%G &0;HH 3'4E81NF*XB581
M(;F>PQ%LV@3+7I6%>].JI0I4.+L]O*PLE*0H=WUW6'K%0BB22?7/'Z919?E
M$*V@X-IG49A$2.=)VJ9H)5M.U"W$GO#/ZCC$Z4M:+V_&?FYA,>)V<XNLBB:=
M,XF$Z( :@,- 2 @T03@!CZ%]ORDN=A0/<$6R7RUO-!S"+E&MU<L1(2R*<>Z,
M98^]%0: 1(,B1,<(?U @KUWKOJUPW\0M7J=[$'81+./;7:CYP^VC6ER63&[&
MF5M5W,GV4/"BOW%QC<2C%]CO5X:HHM65:\+)$\$.*Q2VM'UK$_)DC+LEMUH"
M4@G0 R"+VI^:6=2_GL"V:L>G^!MD1$<B)K<]_;WYHB<$AJ&QD<W<JZ73PZ3E
MM=<-9HV]4YJ(N:M">>-J$-0=Y@GVN^1X]6DDKN8,EG6>OD\)6W\H?7=Z'7RH
MRS4G2%GD7+835,DB6 H6]M1$6*B3+&P4?)9#T9)&DNS#$XAEB#Q#X[AR1SB#
MU%;%MB"O$6D=T.JMUB;Y&D;C*HW?EV);]L2OGQ:MB3@I0QA9/&]-I,I:1-KX
ME;RA)P+_  /4"-#U(%Q\R5(JNU[JZR)Q&Y5><YC$UD3P:DA&D;48QS1QE;DF
M;F)@B,=:G-UDZ%]7-3D^NQ;A(G!O^$+4KSMH4PBPG.[JN37=3]F4ZOE,EA39
M:,)D<"=Y1#@1P<H:665-BAE>36/ZW1^51TM>>UK#B@#5-ZH!?J><(//H(M!7
M63<&5%.DZXF>2&P9::^(8BCE*I8Z1YK-DXXG0=D\[Z6+RX[&&=.WJ7R'6HYK
M%?R\",L#J$@U,%.27M.()U@-2O,(;H\D7W3;L_6M$G=I*\/$V<(:>KF('*-J
MHTDCCXB8(4P,C7&&(LQ.M2)65(TBVY) *#QG"-5:4!G;+JV/6HEAB21*79*7
M!K)@]I-&VE0F3C.D,!>"WMF3+]JD:W1K2>K+T%06#19HR_N!,!O[N!7/7"U7
M"ECM*%<MLE>2?-@3F)QE2[1H,>KIP<.DH3UA-V^)!310AW/:K$NBOVY:Y!=E
M;F<G2 $E;C$)(M!T%LIA%6>=1*4PB0DFJ&"8QQ[BKX00>-,>>SR%L5-#F22I
M*WHU.:8B6#"$8?P@;WXZ^[K JL3Q)7JMN84<MF]D3A8RQ>@8<<[OBJ&-ZQ\8
M>;[,EUFU^E=TL6A<>:?44K9B>W.9B9,F$K;R"O)Z2GU%)@;3RKR36?(4.=X3
M61SDJ:W=:RG"/=6> LRM,VQB,-$/C3/L%>PN$-[IIJ8F4H(W!>0K>%Z@9ARQ
M6>8/QT&1?N7*]D4'O* +G.5ELW0%@BLF9GIG!L X(7T:"#-VT\=.,9S4Z)L]
M" (M^F>4I,\QAV_4_"#H 1I.^#ZMG]LV+<SC+K$:)E8+'&6S2B-J(4T:C+M"
MY)6<QALH1+2H2-ZESC#I74S2O9T<J52!H:CC5X$J,HE>I*&'KG<'P=SN*H[Q
ME%L71-9O4"AB=6DZ7.\'>2'F1,B*T6X3TM/-@('>-D/2*W'("YKCBID95&DK
M=_F>M("-:"SE1U;'J8@;;7D54NRMD:W26.Z=0]J$JIR$IF,O?9HZ!./1HV].
M(DIUD)X"=:*#L) 0!%L0M;&(.>C#[7-9R.G1PFV3BD<M<.@;HZ &KA08W-F&
M)*;>322&[KR+I[CKV2LRV)1BI75&QMYQ[&G5MYJ I2@VB$  =!)Q?MOTOJSY
M?:9\PM%:[RM4TF@;53C"S$3"W,MTU1>[8P-SMJ#!F#DQ-DOI]L1($SJYN &M
MA&:WHOARM$[*"W]P57$+RJRP:=GZ10NA5F1%]A<F3)#@IU8VA_0'-ZL:,\PI
M044K) =YRMF%FEZ,#KS@&'Q#L*K1#V]*4B37IM+=I8O^(4UXM>#"$-;Q%"]+
M*WZ 7=&-)AT9KVOHA$&HESEZWX!:2W-Z(HQH+ 6 ):GS*A![M><%5K7R%(@#
M8%LRPEIGE%36/BE3M#C#8^BYQ94T<JJ$(!,<(8@J(LU,B0LI68KTI=G SS''
MK1'&#,V$9V_P$+<?T_<^RUU8;C:7IU=8E))=*4;2CC9THM&ZK/DCDU+T=93E
M*2Z;67V_-Y0%S([)#6<P*?912OR.9(6%4\NH'ODF"<L/4[E#8"%U]3$2(LB(
M$1]/*"'ZEC86Z1^6-:*7,DOC?Q!DBA*92-,O0KDPRQ"*, /6][P(/+]L#G(R
M6LTS>5,PE+V!@>F>?.$H)KUX>;8<9 Z6R_.TJE<K-@ )A&7YP?[ND*L\,2<(
MV@.V>F($FVE1)2"@RDD]NBKYT&KU5C61:EE2"J5B\ABDT^3U%)G,Z&N(JR$H
M@!:%PJ@R/1=G$*H64S;BP(FB1;4:6'[<?67JS#0T:/>U-24,2:+A%J7S$',)
MZ(87]K?Z\5NFD9$"MBM'!L]-\K-V:MI7F)7,\%G#VF^()4!3*$QA!I&A"#<F
M3VS><HP_3MWC&I)'$,Z%'S#6-H25^G^2&,DZJVQ%6D,N,@AUD/*-\D=/M C4
MKT].B1(4)2!$6E];Q %ZY?'"YA%))%#GB0QXN2L3JQ#?XB\*8]*F33JA/1?-
MXV^H_P#.6=];?6]9(I!K>R3P!%X;\/#80!!^4H3"_J&N-E,XE4GA5USKH%;+
M9 IC!#I-K,L. SFMY"YR=NC46C\82-WU:GB@)"-G0-1)1R5.9O0A>OZX3I#F
M)\CZ%W3/\K7R]2OELN?4"QP2(DAC0QOTA<'5BBB<*$HD!Z"*-2HI 0:9K9YI
M1 1&"$/>Q;"G .#&/4KMN:F7W=RF2V?;;+=[4^*DU*J7RKK C"@:6)FPA^/I
MXQY=8K%(8>=&FYADI[^SIF-2>$*?XH\U6,-6/]M^*)#YH"&]$=$5\SR_G>-\
MR(6N,+*?-7P"MXQ'261/]F\UD%0OE@Q)Y>'+XA[=32'793H^*MJE)0]D(P)@
MMG4]-CJ>*5E#4%ARY\8ZPBCQ#F]M4LE81=F>VE6H:/JV%UCM=5]#(^W"K]H9
MPMS.6TIFU.%(>;\46J.V T 35@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,"!;8_3RD_VL6?O-N!/6 P& P&!K<R_1"5?LV^?FQ5@:=2']E<._
MD"G\YKL"5<""++Z9H^GK#JRJK'G9$;G=SN7RBO&8;')W,AT7&/#)'$07A[96
M5QC\,3/,HDC>TMRA[5-R=S=UQ"%(,Y6: D03O@1'=]XUUSM7KK:EK+9(U09B
M,)"]N\9KZP;(4-!!P31[<7)CK6+RZ0(V9.$G?KKC$H4B?Q#HTP&QA\0WN,R=
MJEC*S/K7IT3)GUH1OB)OD3"^Q&2$-ZX 1D;>(E*FYFE,>6!\WD-2KT:9209K
M8#"P#UL.@S1BI,2:00<H(*/4^K\,28<6 U1Z /5.] L0M#-]$O\ "%Y=;\H?
MN[^Y@>'3DW""4,*]$(!YXDI(]*B-A.5!,]$28H6C/ P\)WX&P:\1:%]SP\<#
M]F+D).CQ'+$I04OI[4B,4$@TF];?@3Z^Q#UHGU=_<#YO#S?Y,#]"5I0:%L:E
M.'0/6\^Q'%AT#X?7F4>;>Q:T'T _='X_[W7[OA@>4LPLXL!I0P&E&@"8686(
M(RS"QAT( P##O81@&'>MZWK?AO6!ZI;DW&A3B*7HC JS#"4@BU1 PJ32MF!-
M*3["9O1QA8B1Z$$/CO6P;\?W-X'F4*4R0O1JI00F*V843HQ0:627LT\P))!6
MAF""'9AQH]! ']T0MZUK[N\#QB7H :4"&M2 "D"8-5L2DD.DP"=:V:-1O8]:
M)"5K>O-L7AH/C]W _6EB01WPVE2;:CT=J/0T>5L[X</IZ$?Z6A>?T=;-#XB\
M/+^%K[OW=8&IQ&Q85.RWLZ)R!([EQR72""/ @%JDNDLLBRL"%_: :7)TNUAC
M>K,"#9I'J$#WO6P#%K[N!M/S!!Y0#^.1^0Q1M&6+XDGRC5A.^&$E +S^ E 5
M'\'L&OPM#_!\/'[F!@8S.(?,SI,GB<E99$?#)*OALK*:%Z=<./2MK)2J'&/N
MP2!CVC=4)*XH1I(_ 8//KQUXX'\;YU#7632J%MLG9%TL@Z5D6S"/)G%,:[1I
M))$JE:PJ'I&$>S6\IV1HS32-F:#YRP>;7W/#>PV8)Y(B=*0G%"3B*T>$\)@-
MDB)V#U-':-UOR;*V#\+S>/AX?=P(OC%XU)-5\*;8C/6"2'V-"WNPX,<S*#'!
MMD\,CCM&F-Y?&IX3E#:3R$;K+VXKT_7T>9M3H18!! 8( 2@4>0?LW1!Q1VR#
M1$'Z*, 9LD\ 0B$2;H&]^F:$(P[V'?AO6MZ_W<"MDC["YWB<GF,->YZI)DD&
M\"'AM10J?O&W)WTY0=E.BD*5L\67H;&G*-YLV.HU##'S7-Y3*WM$2:F 8H+#
ML,RT=24'(G!M98U8[5*)$\4DMZ,:HI%T+Y))@OII"N;VH<R3Q)D:UTC&!4[N
M92)(A^%TYK5H34Z=.:<0> L,[3U]5C>T.>9Y7;L^G1J.RB4PQ_/F4%GM7N;+
M)H2JVAEC6YQZSHS#Y"B&PK@#(4&#2Z) <487Y_.49H(:E777'/%J-[:Y1&QT
MNB'N8-$%8"98P2RO'*12.11!18$7)C;/8+#%W:0M4N@R0UX9W)$0>VNS:4-0
MD/.+"(6@L*->A*"J$:L2%A0:#M<(:@D 4>A%A-#M5L0]:3Z$4+0M>?P\0[UO
M]S UR/SN)2IUF#&PO2=P=H%*/J7+$.BE2<YIDWU5B\VVU[^+(3@6C#%YHUJ]
MF)MG$A"K"'8]&!& (:I(KMKR*VS7](/:Z0I[%M%@E\GA2!- YXZ1YQ9($!O,
MEJMPGC7&EL"C8V?3NCT(ES<T9YHUA 2P#$<7H028%P;QA*&!<C& ]2)&2,*D
MD03E8-F:&E*%H>]&*0[*%K8->(M>7?W/N;P W%O+ <88N1EEICOAU QJ20 3
MJ/* ?H'"$/02CO(8'?E%X"\!:WX?=P-+/M6NR%%A(OK<SJ7&J$R158K2W'B=
M'J)EN+(5(VTMT9FT"MU"L<V0\M0E3@)&>I 8#10!B&'6PW!"ZH'%(C6I3_$A
M>0D4)PJ"CD2G8%J8"M, ]"M+3K4BDQ./0MDFE@-!]W0@ZWK>M![9"@A24 ],
M<2H(,\=@.(, :4/01;"+8#"Q" +RB#O6_#?W-ZP*CPONSF2P6MH>8K-)4L;7
MN9UI!4![A3USQXS3I<ZH;?4CTM22*OFE:VU_9+F#:1EE*@LJ-."S6R"EPCM;
M!H+8C<6\K:O1BY&7M!H EVAJB ;1Z-+]4K:O0AZ^'T85KS!\_AXA^[K[F![8
M1:%K0@[T((M:$$0=ZWH6MZ\=;UO7W-ZWK _N P& P& P& P& P& P& P& P&
M P& P& P& P& P& P& P& P& P& P& P& P&!4SJ/LFK^4!5PT2V,6]9EA6^
MZR%LK*H:%K"1VW:DQ+AK22^39[;HM'BM:21F&-2M.:Y."P],E3B5IRO.(Y02
M6,,%S/W-5_34TFE7M\ ORDK;@L98)TZU1TG3TEIJ=.->R=S=F)FL&,-S[H]!
M)X@?(6%8W'*42DX2-:1Z2@!6S"?4"Z& P(?OV]JUYFJ";WE;SPL8Z^@#<D6O
M2IL97>2/2Q4ZNK?'H\P1Z-L"-P?)%)Y3)G=&V-C>D(-4K7!6226'8QZP*>UO
M[G%536S:ZJR<4#V=S@Z6Y(C836LHZ6YHF555]+K!TQ/$G15ZBFJDYT94,R>V
M".N"EO2+1I=+O@C2B1C/\A0@Z18# 8')UX]X6@D::62J-4%W-9E,PMUF*!XZ
M+J_DJR)E11[?73PZ,-@2Q@F"$H"Z40Z(.C"X%J7%N0*B#](3AI/B"] $,.H,
M1ED;GL4C$YAKRAD<0FD>999%9"V&^NVOL;D;:F>&-Y;S_ /K(71L6%'E#\->
M8L>MX&PX$"VQ^GE)_M8L_>;<">L!@,!@,#6YE^B$J_9M\_-BK TZD/[*X=_(
M%/YS78$JX%$^O^:+@Z*F_-ID0L& 1*MJGN2!7#+DS]&)0X6"ADU9S:.RMA?J
MS=V>4-L6-6O<<0O$87H)$V.+>6D?MN)&M+$))1H7'B_UP^%=/KIN-;7?662?
M)?JOITTE^I_SE9]4-.GS7>SMR74>^'^9;*_S7XSU/0_@O+@1OTE5;A>%#6Q4
M+2ZHF-RL2$O461/#B2>H0MRAT3[)+5*B$V]*#22M[\1!!^%O7[F! J?E*4%=
MGJNE!2*&ACQJY6_!4DLKJ"V%)"NG&&H@TPO?_C=,YM)M[JRBFA*70-F?6=1L
M?H!V$2DT(Z[%X]M"][JJJVHA)X4V,M5)X@[%MRMC""P1.<1G*V52!JCLG+:E
M2[2"Q8XI TB) X-25*(D8E13F6J"!$%#(5[<=_#A7,L1<HG3\24N];2DJ>#;
MV-V%'>:'D^CN6:S0RVND);B!6'H98[UJZO('$ O@P.GFT)5L96UJP+S2[V_$
M*BOG]+&&"CGJPY-U#:%^SH%B0M4X0NZHW,IW>#]#*[M\]N*$_OS=6K5;Z=:U
MA- L2(WIB3[()+*WH981>[^V!,U<9LN,E7P<X)'^D:DA<.&X-;@G5:LUGW4"
M?H>52U<)>\&J&#HEFYUB2):0$*HU&!<^C,TLTO$68%VZ@Y_DM7<DE<_HY&QI
MY85"+%9&U]$E=Y-%HZ]3EPE3PV$$M[JL;7!ZB\/52,M*2E#ML(-1) E)T[>1
MLI,0'.NKO:HGL6-2/$FFE6[>F.6-LO@Q$?CZ@*&N'#5G\ASU]W#1(HY$FQD5
MNJ7G5Y)&H;&MJT,R0^&RM!$IV:%T_<"Y7GG7-1-M:0>20./"TOEHW4Z>1P#X
M23J15C.(.S/["J$UOAC6^1!\E!#D#X=.F6*BR!D$.+<,>E&!0)Q]H.Q5,SMJ
M=D6U#M.5ER);*7AM+0O*,$ZV*]Z^N,$,L-V5-KZ!=&7M-#CD*TTUO<@A..*-
M$C5%%C3F!**7VKWM-$E#:DL2,-4W61Y/$#;$3-DD<I*1#RN(W3F<,,^=.CL9
M)5T.*L!6G>MMXW L!C<E  (B50"1E!%A?M"3Q?94!LOZXTU5ZJ)31^EZ"/5'
M&9 V-5>CD5_N%OJ$]8FJB4/RY2WM2[X<L[9"0HQP#L[1!!.PE%AL4/\ :1DK
M15@8*_SB!NCPU1>W6^-.JA&_O"1LL&64Y4-6PNXT29:F0IF"=$NU:*'U><A3
M 6$*UP/\]7K"C'$\.C_.G/ J%G?3#FWLU:I(U=UR++D;'6),6V"9K'*3,S:1
M(FF?%$-Y2!SVT/B$\] M+5'&*"UYNS2B#-"V<$'6MQ"YS"R.JIE$05*S Z:K
MFH&QU?7*+J2Y:=*:@D!"TZ$38YH2DF3"G;5CJ(EM?@"7$+ )O.4$A2#8/(%G
MN=Z:45)2#/5,IW%G?05M@N#DQ1UJ-3U^QMMA3F53(-<1%F==GF@KV#MLG"PM
M1!X0!VUH2@^B2#P(+#GC'/;#<6R"<_1(W=(LJ[F:&OL+K5WBD/5(0DKC.@.<
M;7:;30H_EJ7ZG6&]QFDUJ)V&A&<,*IRUZ:LT@1VMA8WASC>2<GKKC4R.;IIN
M;83LRB3/!:IX-=I"!C?)\]#F\T3JRD;41.I("< (<!$%K%!GR\ C7%25M*F0
M!H-D\H]+V?>EBVC(Y-2ZYLCC[6L@Y4+.7STHZO4=:V'5MFN$,EL83,86C8[D
MDL'5;DTE2+53D6G):"$R39#>,M2$P4GR>\TZ]4M(B9-'W=YK?GFX:LDBS32K
M1?62;6M9%76;MY2!T<>H31%C>(:Y$ID9QQAY*9:4$(O$)F]A-5$4\?3G/T!I
MX3NE<7^.P@MLDTJTC$L(D=@/!*ATG<W4(7$>QK3)7.'1>ZGEJ!;$:8J%HS?C
MO>\#G)!O;FM!B8Z^.E:KGF2+J?Z$K^VJPJH3+83M2<3;(Y74SKF;*:_2S]PG
M#[32R=&S(M_31IA+'&6!>Q(B$H1B-4+]AD'WVY+!6RBQY*3(::?DSO82N:DQ
M:51A^-9NB$3I?#_=)#'U>,K2LJ1_9VV/@8]&C2$KD4F(1EGC)TGV%L*"7.<^
M()E0_14DO0V=15_13V-M$0D4%2M#XABL#:(Q3=%P=D5T:TNCD_J:_&[RBK%N
MG](8N6_.V@;+H]3L]D)T:$KW]15KVI=%=RF,.U?M5=L-$]*U9*!/2B2_7C;Y
M=[1#$S$ZQU(W-QC&8V,3C TNU6E"DLXPE4;LO6A%@T,*E0[VTY!7,H@;G&#Z
M'?8E%E4**)K^<P9_<8A"US/6O+<5?K@KYF:'!I"CN3;[STO,2J]FI!FIY"(P
MY8$PM22N#68E[4SNB.E2.>3:)6&S/EJ/,W6?6U([2(Z=%GP'K1@9I3.V9:C2
MQT4]32'HUM-.-]%>>(J.^IM>,(D*)N"98I[?REE9.G(P_(Z8E9'3/.=>5W*9
MJZ0\:B:JK.A-.,U3J%TJ$M;%I<OAK@M82) 6>I5!<"7$0M;)&+03\#(V%P)(
MIU+4;NBMPR&LRGEEXJI](86Y?\Z#T"AJ^7TM6M^-#CIR2>D?#:WMB4)S$V]E
MJ%"D+4:$X D6MX$Y\3<WO/+U.+:]?'%B5N#I-GR7"0Q=2[JHPPEN;>R-1;6R
M?-4K240F/^2;7'%HVUL2Z6+3M^@8=LY6I"(JJ]OYAJ3GNLZNC[\J6V(R2SD&
M3V58<HE5@3DV5E\Q61!9P&.QT<UD#\OB4.+21YQ3L#&@VC9F@;D,128OU#MC
M"$U_MLSR4]!6/9TWE=3.T!G=EQ*5N<.30_9/UPCT0Z;C5[,J*=-A+,C;WMU;
M8JU'1[SN2AZ&I-$-3ZY"55MM2A?[FVK[ I2L*NJ20OT6D4<K:H(3"BG5O3O9
M3\NE<>^.;G%1YER@:$N)Z8"&\M"3HO2DHT!VABV7Z80A8K 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# XZ]\6M6G/7N ^
MV9?%ZSN*U#2<?A?=]?2&V[%>T$1K>.S6P(=0[I!8S(9H]G(X\Q.TP1P1WVV%
M*U!.UIB PHKSF^4&PPW/-\TKU5[MMC6US1:L"ORJX-[=< K:6V74<H:)_ 8_
M8;]TE.Y8V05PF$:5.,?*ERF,(!N F[2C:LI'Y#3"P ,*V,.T> P.7?O,%'Z]
MN^WG8"58I01"R.3[$DIR)&J7B9X/6G7]#6#/Y0L3HB3U(6>(0B-.#HO-" 6B
M$2,TT7X(-[P*O]6]J\A==V[[;]6<J]-T7TC8S1[A]46:]0JC;/B%IR)CKF!5
M3=ZR8SQ^;84[/)[)$(X4N3Z4N*O1*0!J@HKU-FFE@$'>3 8# ^7GEGN_BZA?
M:/F/,EU=3T1572$#K?LZNI;0,\LV*QFZ62>J;&O$INAY]7NCDFFYTC>A.:7;
M<D)0F'N051 DH3@G%;$'=KA".OL0X>XUB<I9W"/2:+\I\\1V1L#NE-0NK&^L
ME11!M=V=S1'A >C<&UP3&$G%#UH99@!!WK6]8%K,"!;8_3RD_P!K%G[S;@3U
M@,!@,!@:W,OT0E7[-OGYL58&G4A_97#OY I_.:[ E7 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# ])P;6YW2F(75O1.:$W8-FHW
M!*0M2F;+%H9>S$ZDLTD>P##K>O'6_#>O'6!XVMG:&1.)(RM3:T)1FB/$F:T*
M9 G$<,(0C.$2D**+V:((-:V+>O'>M:_W,#(X# _(@A&$0!A", P["((M:$$0
M1:\!!$'?CH01:WX;UO\ =P,(UQ>,L9YBEECK$SJ32O1-4-;0WMYYI/F"/TC#
M4B<DP97G#K?EWO>O'6MX&=P& P, HBD75N.GA7&V!4[!,)."Z*&=N.<0G)]!
MTG-TM,3B4Z,(T#7D%YO$/AKP\/# S^ P(%MC]/*3_:Q9^\VX$]8# 8# 8&MS
M+]$)5^S;Y^;%6!IU(?V5P[^0*?SFNP)5P& P& P& P& P& P& P& P& P& P
M& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P
M& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P(%MC]/*3_:Q9^\V
MX$]8# 8# 8&MS+]$)5^S;Y^;%6!IU(?V5P[^0*?SFNP)5P/GD]U>M.[G[K&M
M)[R>V6<[PU%55!5Q/&:.ER+<34BEO<E:R99.$XF\(VT<HJ ,';G%W#H.S=0A
MP>-G_P":>IK85&J;BRQ;>JV.)['H_K MC:[^]MM'+H_;T@OMKF*JXG)]9F/W
M.K&;"7.8;?U=/SMNVVZ<7E*/ZJN T*Y>V"]'8E PNMQ#!IE5UF>Y.]/T?MFO
M9T?9'2JN#S9'RCU6_34NM$U]6&JJ]9$IS94AF//G19?U).9SXVR0J/)%A3<6
M62J^,WYQ[#MW;,&CUEUI-X)*V0$C8)+'')O<&,P2H&G'7H"/3$!&A.3JPF?&
M$EB!Z8PB\^M>&\#E=2:3H^A([PS4-=02:1>&J*=YN7V#&C:T=I2WR6?S1X$1
MU<9<5BO8ECI4T@K"(Z*D#4%2K;C'Q^5GH_*N$7M(6%R.I$]G);,X[D\.FUO1
MB ,=^.:.Y6BJX@EFR.11=_J*QV^,%6 SD0B:R$N&ZL#36B/6)@)TK;MQTM/.
M3C3)UJ0*V6E.NW(?3%E3Q"^V0[S.5]$V3 :_AL/HME7*:KK"&V/<K57\L])O
M@%G2I\:+%BL;CFE#NI8'\DTQQ3F$$MJ14<XHPBM'<_N1K(2_2]P:Y3'GJ2P*
M7'H8T?0"Y8V5F^L47Y-<FE:WHF6)R>?.+D]/4WL)/_#HY-Z86\(DS,X&M)Z5
MP#]*ND?<)V]\]$Q>I;.6NCO5@5$^C4XJL"&)2"5N,+Z*$WO#_+F*O6Y-&%A4
MWA,+ :6O=H"<D3/Q.SF ?QAP6<)$A<@Z-D5F\>S606?U2JKU-,;;B-D$.?-J
M*LDTM=I# :^<X419T"2P)VD3'"6>9?/VI))CT<<1I])M!$>+0BGAS"QG>L]Z
M)KJJHN_\W(7]TE6I\G*D+5%X"OGD@>HT3$I:X%,32!%#+$2QY8]2A$VIP+'!
MH"V';'\&I=6(*K3PC"L\ZZ"[/+FTMAC7#;8CK#&Y?89<RG++0#A*QQ:K'6_Z
M);Z[DM9GDQ>01RV9LQT3(I.J&WM)<@& U,<<J1JU"'2,T,Q0AG62+H\,U?G&
MSUU6VQ.:Z8IC&9M4*"(I4S0AX9:Y*JM@PLA2]+Z[=UMR11&R*VE.Y#9T;@N4
MHS2=N PB("<^@Y[TLQ="5%%JR0R@NN'OZ@E+38_69<R8).K?;501ZXRK G)Z
M-:FJ<BJZ6.,DL>..,0EO;SK:7>U_I;;S0H$WM7;[-5%!O\?G71LIN:CHUVXM
ML-9852D.;A-)<PN,+<*ZJ]Q0:A$;8Y5%9R0GT!G>FL"U2L(VH+:W((P[] );
M9;2]QJ5R>YXXM2.$#2[ONO(7%W-NJ%SD)M>UV^=)RN%/3]&'*45K%H9-&T?.
MB-MD)SB!?,DC4Z'Z4JE!!)@F4@+=]HL=G:X\E+-$'Z=OME-AE,B-EM>0L;_/
M%AK#:M=K)=+V2OHV2(MU7@9D"UP-:DQ(TYI01D^D,G>R]A51FZ"[>3N\.C2^
M%V0Y_6IR@XHM*E/.ST$ASK]#/.J6V2S2STJ- R,U;RU^K^-5JXKH\X+F!84M
M>-DHR4?JJ@(@R-"RKKNR8YRS*+?06&8_1KJF41VQ"G6LB8PRR2OEW.DV<FZR
M]MSO5-6S^*,4:L)1ID0F+&AD"%2J.1J=/( H7=4$,RZY_<_CE:H5B!KDKF^2
M1+7\K>I IHY?ITK8^0H.K0+H"QQ*#U/9+Q)$!$DK>NTJ[9[*M<$9$E.-/7-R
M=:G7-H2!-KK]P)')NDFA T2- 2T1*KW:O'AEI&4N$0AZ]3(*<0SQD;1D5/8$
MAE3PZ-<BDIR1W9?M/)0ID(E*Z/MYK?\ +70+V,-B6^9QD1:#O"9P5>9//ZR5
MJ(*9%F918"BQT4*4KBFL$+3KFIH52%P?2 [+;/.A]4TP)(B4H][(+#GE6G0'
MN!KY'SV3*8U8Z^,.%Y3V&3<H='OS+();6N["@B*(3Z2OSW14+865D9X+(')2
MI"K;JO4'IT6U:0QU5IS68\+">XO8?:<$*J4/'S;(5IKBGL97/C&*JTUG:T-J
M!""HB@6 4H%WR7XWYJYF%"!Y!GC3_=\X"Q@V%79AV/V_7#OT!8KS7<Z45O6
MHO(V6$2RK0Q+<I6[O%UJE?4L"DRZ(L+8X+9A"Y"TR)H&FD,N6+SDQ'E4H1K%
M+.E"_O2]AV_17$4AG:F5EF73#X)7:>1S*/0M))='R]P?(C'ID^1F Z3[2O!J
M@]Q6&MS8$H6S!B**"$0O#6PAVL95V[,Y80L6.TF;(;#JJG<KCK3+:?9H4OO>
M2IKJNZ)U<UV*YO[&TJZU=I+4;#%7ES:V]&S+D2Q>$XTE&4,UNT%7$'4'<J5W
MJF)K5%HJI/+T]@/</:W?F'; ^V=(XFU<;"?898C*9&4Y]4U%#; MF<,NI9Y6
MXD]N0)COF2KT27!T"08)9WN0SU5*XW)OF=8+'7HB"1#;VT4RO?3*O@3F^WV1
M.OJTX3:LHK"Y3'FR*Q:&GH7P)TQ0)UCH(TYS5A5!;402I;Y]C\TR#M/H&*H5
M9A,7YYY-M>0/*MK3MS!;SY44ROA?>[ RE. _JTAL&;5(T-[2#:899J-2N:MB
M%Y0D^(6I:9#T&DY$5S-4SM\CZ8-I21S9LB!K:2VMN[1<8RYR6,5\:@)4MX!I
MV5Y4I640A'D#4Z3[,,- ,P1F@HTZ73VBE)J?4 '=$];%SNX 3/<]Y8U7[Q9K
MSJRJI:W6*6FR%LB,ZFX1'*R?I4XMDA4(HN-T6M)8=?$Z3ED/H578^B?=\)KC
M1[Y#Y*-_.>V<_<C=^>GIK=6\\Z&VZ<RQ3ZG0VL)\N>6"2S:+,)3LKTVHOEY+
M@ DQV9P+"5Y =3NXD]C*J/@BR'++#89$TWSS>_REYJ"%N=DR^-11JM:)K9^\
M-4);&F2*I,WM4? J&H)$W.9>DP1&#2*M V08%-JYMCW(YW/Q0^QF-YK://=
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MS+]$)5^S;Y^;%6!IU(?V5P[^0*?SFNP)5P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M%>!'LAN2!="D/[*X=_(%/YS78$JX# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M\VNZB$63,(.0ZD,?Q[H%K&Y(HZ4>:2$\P #3!:#OR^&M!9; 8# 8# 8# 8#
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M\+#X# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M-$\?+AEUH2!HL>'V(%7*&=N"<O60>BKEH-H*<%!JUR4"6K8Y<1Z]:>2(E/\
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MX# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8$"VQ^GE)_M8L_>;<">L!@,!
M@54[8"P&<V3HF2&*PH5#M7"5$G);XP[-SK(U5G0U/$F"5M<V>8Y#'* R*4FH
MT$A(=G!"@.9%*H!R@D._4"%0.:&MW9;7NY)9,+KBL+54\\IE2>'4)&8;'*I=
MX&4^OY)$FE XQ.9J].=@IGH8DR/;L!O(3MQAX6WXKS.(R0Z*TA_97#OY I_.
M:[ E7 UF63*-0=L*=Y2Z :T"A>D:DQFTZQ8<K<EXA 1H4:)O3JUJM4?L MZ
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M_LKAW\@4_G-=@2K@0_;7_P +J3_G@C7YEDV!,& P& P& P& P& P& P& P&
MP& P& P& P(JO3^Q:V?^;B9_\7G# E7 8# 8# BA]_MJK7_F\MW\^U!@2O@,
M!@,!@,!@,!@,!@,!@,"([E_^08E_SN4[_P"DF-8$N8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# CVV_[*;-_YO9I_Q;<L#9(K^C$<_P#F%G_-Z? SV P& P(>
MF?\ :U2W_@L?_BVCP)AP& P& P& P& P& P& P&! ML?IY2?[6+/WFW GK 8
M# 8# UN9?HA*OV;?/S8JP-.I#^RN'?R!3^<UV!*N!#]M?_"ZD_YX(U^99-@3
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"*KT_L5MK_FXFG_ !><,"5<!@,!
M@,"*'W^VJM?^;RW?S[4&!*^ P& P& P& P& P& P& P(CN7_ .08E_SN4[_Z
M28U@2Y@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"/;<_LIL[_ )O9I_Q;<L#9
M(K^C$<_^86?\WI\#/8# 8# AZ9_VM4M_X+'_ .+:/ F' 8# 8# 8# 8# 8#
M8# 8$"VQ^GE)_M8L_>;<">L!@,!@,#6YE^B$J_9M\_-BK TZD/[*X=_(%/YS
M78$JX$/VU_\ "ZD_YX(U^99-@3!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"
M*[TUO=+6SK6M[WNN)GX:U]W?Z/.&!*F P& P&!%#[_;56O\ S>6[^?*@P)7P
M& P& P& P& P& P& P&!$=R__(,2_P"=RG?_ $DQK ES 8# 8# 8# 8# 8#
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M]=(U_/"+^.P'VE5]^ND:_GA%_'8#[2J^_72-?SPB_CL!]I5??KI&OYX1?QV
M^TJOOUTC7\\(OX[ ?:57WZZ1K^>$7\=@/M*K[]=(U_/"+^.P'VE5]^ND:_GA
M%_'8#[2J^_72-?SPB_CL!]I5??KI&OYX1?QV ^TJOOUTC7\\(OX[ B&6R)GG
M%G58V11<0^&,#JM>W=2WCTH1(T6@)!>)BHOQ*V/P3;UX:WO6A""'?W1:U@65
MP& P& P&!ISM7T(?5@W!WBS*O7&>'JJSD)7KG>'W-;.,!H(C1:U]SQ%X[\,#
M&?9+6OZEL/T,/W\!]DM:_J6P_0P_?P'V2UK^I;#]##]_ ?9+6OZEL/T,/W\!
M]DM:_J6P_0P_?P'V2UK^I;#]##]_ ?9+6OZEL/T,/W\!]DM:_J6P_0P_?P'V
M2UK^I;#]##]_ ?9+6OZEL/T,/W\!]DM:_J6P_0P_?P'V2UK^I;#]##]_ ?9+
M6OZEL/T,/W\!]DM:_J6P_0P_?P'V2UK^I;#]##]_ ?9+6OZEL/T,/W\!]DM:
M_J6P_0P_?P'V2UK^I;#]##]_ ?9+6OZEL/T,/W\!]DM:_J6P_0P_?P'V2UK^
MI;#]##]_ ?9+6OZEL/T,/W\!]DM:_J6P_0P_?P'V2UK^I;#]##]_ ?9+6OZE
ML/T,/W\!]DM:_J6P_0P_?P'V2UK^I;#]##]_ ?9+6OZEL/T,/W\!]DM:_J6P
M_0P_?P'V2UK^I;#]##]_ ?9+6OZEL/T,/W\!]DM:_J6P_0P_?P'V2UK^I;#]
M##]_ ?9+6OZEL/T,/W\!]DM:_J6P_0P_?P'V2UK^I;#]##]_ ?9+6OZEL/T,
M/W\!]DM:_J6P_0P_?P'V2UK^I;#]##]_ ?9+6OZEL/T,/W\!]DM:_J6P_0P_
M?P'V2UK^I;#]##]_ ?9+6OZEL/T,/W\!]DM:_J6P_0P_?P'V2UK^I;#]##]_
M ?9+6OZEL/T,/W\!]DM:_J6P_0P_?P'V2UK^I;#]##]_ ?9+6OZEL/T,/W\!
M]DM:_J6P_0P_?P'V2UK^I;#]##]_ ?9+6OZEL/T,/W\!]DM:_J6P_0P_?P'V
M2UK^I;#]##]_ ?9+6OZEL/T,/W\!]DM:_J6P_0P_?P'V2UK^I;#]##]_ ?9+
M6OZEL/T,/W\!]DM:_J6P_0P_?P'V2UK^I;#]##]_ ?9+6OZEL/T,/W\!]DM:
M_J6P_0P_?P'V2UK^I;#]##]_ ?9+6OZEL/T,/W\!]DM:_J6P_0P_?P'V2UK^
MI;#]##]_ ?9+6OZEL/T,/W\!]DM:_J6P_0P_?P'V2UK^I;#]##]_ ?9+6OZE
ML/T,/W\!]DM:_J6P_0P_?P'V2UK^I;#]##]_ ?9+6OZEL/T,/W\!]DM:_J6P
M_0P_?P'V2UK^I;#]##]_ ?9+6OZEL/T,/W\!]DM:_J6P_0P_?P'V2UK^I;#]
M##]_ ?9+6OZEL/T,/W\!]DM:_J6P_0P_?P'V2UK^I;#]##]_ ?9+6OZEL/T,
M/W\!]DM:_J6P_0P_?P'V2UK^I;#]##]_ ?9+6OZEL/T,/W\!]DM:_J6P_0P_
M?P'V2UK^I;#]##]_ ?9+6OZEL/T,/W\!]DM:_J6P_0P_?P-E8XM'(R TN/LC
M:T!/WK9^T*4H@P[P^Z'1IH0^J8$._P!S6][UK_)@9_ 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
> 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g341851g76s05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g341851g76s05.jpg
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M8B5#A*0U5747_]H # ,!  (1 Q$ /P#W\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MM^&-7)2%&^GY=],9 26
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MHJ:DLV;4Q2OX0J1R*LF\EI7J<EY,6$Z>L[.YV=C,A6.-T3X9+DZ>GMKPN/\
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MKZ]]]O\ XYR D(
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MN6[LUU11?N4TS5,S/1%7L^U/,U1Q\DS,S,?/*\@^?W5
M                                                       8S-(?
M'K"B,F@DN0F.<6F#$Z1J0MQ+@Y-)JYF>D9S>Y)2G1F6-[NW&'I#]M<')CR3R
MLY]6F^NV,9P'YA$)B-;0Z+U] 8ZT1"$0IA:HO$XLPHRF]EC\>9$1+>TM#8B(
MUU*3(D*)/H7IKC'Y,:_E]N?R@,H
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MZF?>]&8Z$8XNK7E2P$Z@E_S8V_2=N6I6)K4H*V:/FQK#M*WJ.SM'LI9J8O\
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MUC@C3F;_ )-S=,?E ;.@
M
M
M
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MX<5M<2.6,^F/?0*1(E\RGF#%ZQ884BU.+5(5:)<L0ZG(C$RXM84'I[
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M*A*7[K)FGK]/KU]H3D
M     #RK^>'&/K6/PX6?9^7_ 'H3O'M_\?9\Z>;_ ,GM_P"OL >J@      4
MT\C7V>W=_P#1IT__ *(S@!KV_#2?8@\(?X5MS_D/;H#>H
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M<$+N'V[QK4]9L%Z(MIPD%%J&"\EDCH_%0HJRI,VI)M*9=8T!FT\VTG;BZ2=
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M2C=&KW0K5:/8\G;))QA?IWR&8@
M           #RL>>'[5?\.%_6C._\T\W@/5.      *:>1K[/;N_^C3I_P#T
M1G #7M^&D^Q!X0_PK;G_ "'MT!O4
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M)TQOG8W*;;\AGIQGT9_Z^P!RP
M          !Y6//#]JO^'"_K1G?^:>;P'JG      %-/(U]GMW?_ $:=/_Z(
MS@!KV_#2?8@\(?X5MS_D/;H#>H
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M;=>]I<Y+D<CA,\3)IB^K-3I.D]*?WQP>EH
M                    >5CSP_:K_APOZT9W_FGF\!ZIP     !33R-?9[=W
M_P!&G3_^B,X :]OPTGV(/"'^%;<_Y#VZ WJ
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MKGT/:BS7)_:=)68E;:])3R%M/V=-5)QF"G)/CX?WF^2]0W6
M                                   \K'GA^U7_  X7]:,[_P T\W@/
M5.      *:>1K[/;N_\ HTZ?_P!$9P U[?AI/L0>$/\ "MN?\A[= ;U
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M[_D,PM3F;'>Q/[-M@]9X
M       /*QYX?M5_PX7]:,[_ ,T\W@/5.      *:>1K[/;N_P#HTZ?_ -$9
MP U[?AI/L0>$/\*VY_R'MT!O4
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M87-GTD3U$=Y#"I5(8XT1>QHMK)XXN09=8\L=&["M*87[[U8]@"SH
M                               /*QYX?M5_PX7]:,[_ ,T\W@/5.
M   *:>1K[/;N_P#HTZ?_ -$9P U[?AI/L0>$/\*VY_R'MT!O4
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ME>K3\M1QFB*,YM]]D]O.5*#% #:D
M       #RL>>'[5?\.%_6C._\T\W@/5.      *:>1K[/;N_^C3I_P#T1G #
M7M^&D^Q!X0_PK;G_ "'MT!O4
M
M                      'E8\\/VJ_X<+^M&=_YIYO >J<      4T\C7V>
MW=_]&G3_ /HC. &O;\-)]B#PA_A6W/\ D/;H#>H
M
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MYL]/=< 1,=<Q=H3PRW$K.ECY=CQ@MO;4^&28[L:(I(:O3^[4')],%F;;:_D
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M>82_IY0J+2*E.C^]?";X<?>%&'&X+T"JM;,E>Q>JZS?NPVB L-,M/ESM&?\
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M1#XLU,>'35\PRML?:4+3A[T7E.FCQAN2I"D?RIJYD:*<*/1[[!^FIGJ]>,9
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M13LE;DJ0I&G<RW'&%&I^FF#<'8]>-O5^4!U>)16TY?)W5.7B)2Q^BC5'\V1
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MHT^*3D:4Y<YQS0\HC.WM-+TTSC4O?.N/R!UT-DE*=*P&%VA%<P^V( [[FO\
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MA4:+CVY>?5\WD;[HXDM'N\^C5N*3X*_N\:8P&@*6O%M-U=<&VC.EEV7K=I'
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M ]4X      IIY&OL]N[_ .C3I_\ T1G #7M^&D^Q!X0_PK;G_(>W0&]0
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M+[.5+-*98F8VLYVTCM?L*J7S*0%$ZZ;Y2Q:--F<KG]PW*W]>I)'MVVTQG/\
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MWQ@+Y
M                     \K'GA^U7_#A?UHSO_-/-X#U3@     "FGD:^SV[
MO_HTZ?\ ]$9P U[?AI/L0>$/\*VY_P A[= ;U        <%2V-JU2@6K&]"K
M6-1IQ[6K4I"#U+:>H(W2GG(#S2]C49IZ8S8O?8O.N=B]LZY]N,YP YP
M      ..D2)$"8A$A2IT2-,7J2F2)"2TR9.3ICV:%$$$ZZ%%%Z8_Z:ZXQC #
MD &<8SC.,X]N,_DSC/Y<9QG_ *XS@!QTB1(@3$(D*5.B1I2M"4R1(26F3)R2
M\>G0H@@G70HDK37'LQKKC&,8 <@
M                                                          'E
M8\\/VJ_X<+^M&=_YIYO >J<      4T\C7V>W=_]&G3_ /HC. &O;\-)]B#P
MA_A6W/\ D/;H#>H
M
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MVWHUWWQC/IUVWQKOZ,;9_)G/LS[/_AD!H!C7XA?F!7,>;(+/:YG58R&[8SV
M[60FD3S'5)?.$DX^=K58Y)"++/1[^Z.>YXYTR^ELF2,Z:G>Z*SG&?>_V0I6V
M>=KJ=CM[K&]SN8II9')=<\*<0]CFTLKF]0U[+^=(%=4?DLFFK\LDJB-'26SI
MW*8ZH0."2/&'82$E(%!?Q* W&NBD+8W%^(QYDJ;I%RI_:'-;M6L*FW/E=6=8
MCI>]50ZUFJ2]%LL8?6)TK3EYZ5[6;<4 K5'-&W69O+<<FRSF;G_#)U^B8W?
M9I,/.4GBUG3IG*X]LASHRG_(BT>."X+X^D^OT6([:\K=H\S1*41.M=BU$EFD
M6,525+N[8,/;#FTA03DCX[?8TLD-@_?W<+-P55=:V6[59,[C56ET-4/.,7A$
M"<HXU2);,;E=EK)&CDZF5KFMDV*U<DNA6VARE/KG)NN<F::XVVP&MV6^=M=7
M2EWJ6<\0683V+'^T:LXD=.9XE;E<25,IG?0%0RBXJ"FS#<#DGB\3<*_L!DCG
MN%:E4F0'LANQVYY6Y9&,FAF5O>9V952X7R81PY/)S$^&8'3TJ\B4IB]TUYIC
MG:1VA"&NQ'Z!U2UNS:@,Z5=:HB#EE<^JT9T>1>X*SA-N<=MJ3D.AM?SL,]>K
M^H9A&^2+'L3F7BJS:>B?2?1+59,$9T;' ;OB\ D\0LNMZX<R=I;9&&Y)8"4]
MW:LY:C4+?Z5&IYV^^R<L.JCWXA?FV2]GM?,+;$F0^"/_ %N;PZPV61?-6'VR
MOOG7U-B9^-Y0T/Q:J+GITFFF6!+.-C\D&..=<[(M$^VIV0@JUO,WTE=E.5K;
MG.5%2GG"JU7DLYIY"-N2?RJI9J?<!KGT^Z4_>5>Q^NMV>1.49C.\;;2C,2=3
MLC5:J5)R='IH8ERJV"_5/^8& 7(]\KUXR4A8+9=O174'4?,4NJ%Q?(Z8_4&[
M<=9?S+TF4_<D65#>K8(^B2LYJ?1/Z#569&A+QG4S?TY#*_)1Y5:Z\>,AH&MG
M"-PR86UT:;8RZ$MEHWU7?,-3LD4J9E;7B9O\YNZS]%<;CRQ4<^(&YC;M4BE2
M\.:K!.N22]##M0JC./Q"E#0;G?EKJY3SU>\@HGL.MYMFF)/$$;/*W==U3#7M
MVC2?C]^C\?-<3&:=35^8EB=A?<GF,;EE*=OIO@LK?; 8[U1^(>J3D2VGRIK5
MI5O9GZE:YH.>]9,3YTG3L6LBKU]]HFQW3P.C*Q?3$[WUI,*QC[H6XRDJ.'(D
MZ%)G7*8U6;OJ5D+@UYY,K#O7HV?UUSEQA/KJYOIOI-%RC</4#/;5:QS>*V>7
M'V&03.0,%/28Q ]S*IZS*E" EZ>"79,X9-,,PWMB_!6?:& 1+S.0N=U?RK84
M2Y^GCHY=;=:WWR! (>9+XFWJT$[I#:VTVCP[/*W4EJ+9YFXU5N2G]N2\H\+]
M-SMLZE;^T->E"?B)9RBXJY'MGIRCJN8NC>P[#ZB3U@T2;HVI^;>?E]5<]R]U
M1R*</=M6$ZRA%76&A:H30YI:'/16\25_1&*=/<HU!9^H7#8_.0S]!1KF5/Q1
MS!8?0-B]'<OVIUB^Q-9/Z^K4VDZEJ2<+*@EREP>'[=[C\\G?TOH%+*S-",TA
M$[;)OB-UZ5*9J;D+<^&GHJWNM/&-R'T5?4I*FMO6G7KL^3F4DL4?C1;RZ))U
M+&0E3JQ15K98^VYU;FL@O.B5*27G.F=O3ZLYSD(5[M\TU2< R+J>)VO3U@/$
MBY\J?G.XH$T1]W8/C^BHO?\ 9CM4RDNNTJG.#D*ZLY<R*=7?13C;U)],&E_D
MSC ".[ \O<)GUFU=&:D^EQAKTGR0<6\=YMB _0]((G=<HZ0H)VOA\@3HFG4>
MDSBR5]"6%S:4TC6LV[=),.!Q6C>J*+P=[P*G\%>2?L>[+/\ #[&[*M-'(&CJ
MV=>9EGO1,7 J^:-I>V\E3Q2S4(F3GLT8;SXY\RFW3!6^[;LDW<_9ZEV5._MV
M 77[Y[1[!H7R4\"\_<UU^9>,9O6CNOY3,:&P_5Q7*&92FKFNOUL*D#[<,U87
MEW@#)%L.RS._R=@_*TY265ND49VTR4%=)Y^)&HABJGG&7Q2GTN+*O"OKTL>5
MU?>W1-0<TMM4(N<)ZZU594)46;8)RN,SFU'RQF):W1%C;2L9D&B;90:>WE?E
MP&W)A[8C%E<!IN^Z,@$NMB*OO.JKHB%U:E-;F"?RE CB2B5J($5E28O:D<U*
MRC/;_=8,/(W<"O=EF;Z[:[Y"ALX\\?,\6B<BL>/0&PK&K6)<.T%V5(I3#U#"
MI/0O?5U@-%;\V\VZ,ZE629M<5EOCB<;OJ<<0B:DB,TQ1OCV9UP%5.Y_.+U'S
MI1/1\8TXN3TGW!21'+DY,KN86W!;BK4[G_I6X$50MUKL$RCA\(UD3ZSSOVQ5
M8SF)2<-CVXIEOK<&LA28 D^Z/Q$%*4/T6ZT1852-K$55DMYZK#H]2Z=(4NWV
MK75I7\W1M6I9:JH;=:=,>C(52JJ5I$\TD;$H3)D'L.-1$KRB3-L!%W5_F1Z/
MD;E6JSE6E)-7O/:;R]4/P'(.J':255*2[2^3;=^85^1<BFW]F<9)#H&_J"5#
M:SRH@\YP.4)MLZE-^3"C-@VY^1SHY5S+55*2Q'*;&B1L^["Y:I/9?6;76+L\
M+B+9M-HBBAB>R+5C$K9$\->B56Q#J>@(3OA*3;;9O5)E'I-U"C<:\XA$@M:M
MV)1R!8K)1$_\B<\\8>;Z76= CCD?2D9D4D88XH:ZM1$'R-YKB3:QW8Q2['*F
M\QM-WV)U3JLEYWV";_+-W/TCQ1MPDDYTI5EM]9TYW!4W.DR*>))'F!24R2LI
MT==(5%39 ]LR!LF=C$LJE,C>EGOVIG*2'[*=,&GI=L!K[HKS*](0&Z>G8_T/
M2[];?/C7YJ)CX[X3>[#)JPAIU*-\U<8='::@A=8MC DDMIMD8>'#<Q]?52LA
M822Z$>[,<=RS2R GJOOQ!G.U@=J,7+".&,I$-FG4LXXU@]D);ZJMXM1?=,&P
MZ(]GZ5<K(5&;5A-$S*4,BIF8)@H-.T6K_<^_1)25!1N0OYVYW:MY&G?*U3Q6
MB91?=H]@6!.ZPJN-,,RBT%;$<KAD 7SW4^6R.4X,3M,:4)$&^JI822J/1D:&
M&Z)E.^NB<P*#<H^=%?TA8O)49DO$MD4_!.OI?T-34!L)PMZN)D<1T'S"QR%[
MLZ#?-)F3H5:J!'&1A8WM$H/5H=ECB1OJ<VI4V,*M@P**?B'X2>_]-1>PN<6Z
M/2/GWCNV^STT?J[JRC>B75=#:<E**,2:KK34U28YQ>F[MSET2K,,WRF_IBDI
MN<[K,;XUTW#)91Y]FJK6/H9YN_C:SZU.J3BVIN_JZ82;.KV7O=L<Y6S93!5;
M8J==6<HIIK2PFJ3R KW[(<K=-/<:;[95:[>S3(9),/.Y&*08.U5O47*U@T?*
M>2JXYZMI@AQ=FUQ.3K=A?4\GS!Z;(WD2 YGC5;RS>8FE)) D7*5C>R$>^587
MJR"-MLA&S+^(KJ]WKMW5M'/9UGWDP]@4#QPHJ?G/HJG+V@<FFG4$*F$MI>5U
MST,RGL=>2^+/"V&JF=UR:6W*&1S*.T4:>@GUF!MDO_LI/R-PG-.U.H*S=:_5
MU?4;;8-ETU$I0RV,],<Q<\-C:GK!BF:4AACDH<3Y@\)FDESUT3(3##,'?V2O
M;D!Y]^AO+]VI65S]CZ7["+,XZ@%->-GG3HAGJ*KW?FR[["9; L_L&/U>=8,.
ML>9URYQ=\T=8E(RV%T:GQ!LC;U2%?LD(V-PE<3@V'7#YMV2F+#[S;GOE>RW2
MBO&YH2EZ5Z!(G]>HDIDCEM<QR64W#ZTKI4<7)IK*+-EDB*8SL;[MS:P^HI8K
M5^[.U*P$/P#\113DNKNX#5%-M;_T%7\^Y@K2 4Q0_2M-]"0NZ)AV$\JXU3+'
M&>@(>:W0A@=&F1-BU),4[DE*-C>Z3;)>'#4PC)H9+V%Y0_(!1$3XRRG\?)U9
MV7>OD4@'),YA<JNNJIXR2B(O;6?)&U125@-SW%TQV]L)D*M$A>Y"SM>C'NUK
M-5:'&QR(_8/[27XA?FZZ.MHOSPCB+$S0&R+IMSG^M+++OVJ9%9RJ?T\A?%;B
M_67S SJ=[0JFI)XIC#@FBTC5FJ_E,XLG*A(BT4D[Y"(8MY@NF>F.FO$NZ5?1
MTLY]XV[9O;HYI8YE*9#54Z=.B:CK6GYVX1E1)HOHRJ)E0KVIET?*>$"-(K/,
M7-VG]\MQC!B78+@^33L?JGFOLWQ5U3S9'-;+;NF9YU=';'I'X^!Q3-JZUW1:
M25P=*ILV:,CPHKAGB$@5;N[@M;O:J-1)3"L)UFV2TVX53D_XD:H6BG^>)8BH
MQJ9;ANADZ-D,LJ:Z^GZ;H2*5@DY;L)TJVPV4N[)UI\U9_-I?-VDY'#&AO1E&
MOWN]S%&[;H7MM@+"L/F^B-JVESS7W//-%A6JP7;QG7O?DKLEZGD&KB,4?S*]
MV,]U[9\@GB9TW>'9UF-3K&([U,C.4N->E6N2$QNA>FRG 5,BGXCZE;^KR^TT
M=C+E4RTSBKJ3JV@Y?5MY<[WA<)<5Y]B[L]O*&SJDRCDS/SQ?&\=)+D+#')<E
M?6A:D*,U5'9,).29"1YOYYU55PBVE\;Y)M^_F3D/FKB_HGI>T'2S*@KQQ)K+
MJBL&.:(9(V1Q(V$H9+9R#XTXU4QMR-K:#\IE6Q*M)IJF(.#T21Q^;Y3'F&3M
M.QNS7(V9K?FW8\OW)^S>[H2'!'L<3G.V2C<IU&OJU]N?3G\@#R9^0?RL]^T%
M*?-9&Z0=43[IS+=7B]J:@UQD=J<K>@F/J^#I%5DRS!$K:R-+*=I3,%29N;B7
MC+J2U+'(I3N5J@3*- &^&[NHI!P9XY7[JCH9GGUHRRB:2B\QM9C7JJP;K%D4
MD,PQ-S^@<5U=-K-4>DA2NKMMJH-94J=F-W)VV2Z:E;: *+N_G09JRST^T]"\
MBVK5$\H^M.<+9JZNV6?5_94COF,=93@NL:384JAF-:F.O[#<9^K(0NS:J5+T
M;65DY1JN4%DY]078Y [ND=^W/>7+=[\^/'+O45"1JN+$DE;G6/&[BB$GJRV"
MG?6(3F#69%FQA2NY:9V8%C:[(U+<B/0+RL:EY4E;X. 5HL#S$)8MY")'P9&.
M?$,E>()-J8A4M=Y7TK3%-6O(RKECZ"2$SZA*!M)5'GF^ZU@3>YEZ/J]K>DRX
MM06<4D0J]B]?>!WCCYC:V;XO-I/BF)XH*A7EH;?$NH1:/L>T.<;&<I9'8F7;
M"4S;'H+A>BF1:&_!;^Q=G4O./;C.<9 9%3?DIM+HVWYLTTOQ;8,HY1AU\6]S
M*Z=;D6K6:4]LLFF2G)LF,S4T6\&-\E.I9',VPUI(>B'-2Z*3M/>:L^2MM<Y#
M7WXB_,GT-=L \:M=]ETV]KI1WM&.FB:PZP0RBLD+;9=@<YO4SD,I;'BCX,PM
M!M>1S2#-921K<LF8,<5:+?8U$3H9A1N&U_L3N]^YUNWF?F"G>?GSI;HOITNS
MI)&((BL*,U/'8S6-,-3*ZV-.)1/98A=&Y,I(Q(4:1H;=$^VSFN-R7N>E+UR:
M TL<B>8FY5-(<4VMTU)[=D<VM)L\SUB2J QV(T!&([*(GPDXO\@C<)LPY-#]
MWR/R:%Q1O(;F<^++T1*QPP:8\F.!?HW 6/DGG[2Q"B.8+CG'*C?3[CW(\+7+
MD6.W]UI2501*8TQ'JLC%E2BZ;?MQV3.D*HQI^(DY#2R-"O+H[/:L]+M@I-A1
MMJ2&:0#SI(NFX_SZCX6Y%G/3]Q7)S[9_2\OJA=;M<5.15%=4_:JVBY:WJK!<
MBY5&9G-7RW&M4U1M&@QH@>""M5QBY&E,U, 0A=OEPZKCUX>2RO)91,\Y^I3E
M#QUUUTRS32,NU#OW0=<3:=QA\D>3GEBE+M:-:/\ (ESFD/9&YO\ D]Q:6Q4P
MJ%#A\20M39P$\6'YK3ZU27!(HGRG:UZT)Q=#**=.V^A"; K2(/\ 7;A;=?1.
MPU1<$JK9$3M<;W!(;*TCK*2T"A@2(LF;DHL*-M,%@.#T5YW&>CI-UJICO)%A
M6E27#<[YB8NCKO;;.@49;6Z#]61F!2"O)K6T+=2%4HL%S3;SY/HL:=M6S4E/
MI[_*S&3-20%\?*1TSOR-P[:?0:63V/$MHD_TLWE2&IFJLWB>)=)[=]<0'W;0
MVW%&Y77YR9P+E/PZ[*U ::6@-.W2[%*]2#= JY&O,8CFOD$FO#<3Y]1*]:XO
M)/0\Q?Y'TG3%?WD2N-B*"5*+BBO*<\51Z=6%SND^4BD_SC8W1<X*/;DPAK-U
MQC&0W6@     #RL>>'[5?\.%_6C._P#-/-X#U3@     "FGD:^SV[O\ Z-.G
M_P#1&< ->WX:3[$'A#_"MN?\A[= ;U      !1>#\$UI!)]WY83;+YTK=/(6
MOCJ^T42XY@RWPPR-TX32R32 ZD,9*@G0]@)PJ,^43%^?C,^W7V%_W8"I)OA(
MYZ.KKF6MM[5N;#3RYQ'TGPM#UVJJ$8<9!7/3E>HJYF$MDN<P[9-O-6%J18/;
M=DI:=#JHSG)Z<[3^P Z&[_!K3E\U;65#2[I[J4N@X10='<[R2F-EU)RR$3*)
M4.S-3''I2P:V/3,V?*+LN5(F@K20/E?K8RJ=-,8QMZ,ZXV 3GY>^2+)ZQ\77
M27(O.S&U.5@3V$5Y$Z_87^1$LC68FBMEU\^GI5LD?#S-$_PT;C9^=3E!FQAA
MFFN,[9WV]N0@:3^#2F+/CMJ[W-T9T[;5G6WKR^QK+<GS[5R^;0>J^3[(:;7K
M.F8A\WJNC<:S%U$Q;LJ'IR7(%K\]'F;*%"W93G8W8)XZJ\5-:=,VW8MQLE^=
M&\W22_*;;.=^GT5!R* -C3T12[.<[9:XQ,BI]74^5QF0-C:_KVU-(8V<S/9+
M6N.3849TVUSH$,75X+.8[HE\<FYEF7G73[1]5T54O$.U;R5C8D7";-0[RQ/S
M6_4"A5Q]S(5RZ<K8\F(D2^38?#'!NUPDQ@LK0K!8857/CKM2<^:>6^12X:Z9
M:[K:HZ3;*MJ\LNRVV9/'1UXMZ&10))UA((''69MCM9KFBC)0NBZ5$IW/="]%
M/]C8LC3TY#9OQE5EW5!3*J+= V>]VO8"^UKIF"5]D$H/FKFQ0.96E*I%6D%.
ME9[!%?EK,*@:]O09W+;41!.Q62"=-BBM#3 U>7S^'8XBZ <>XW:32.VV-Q[L
MMRHKBG"R..D33J:V?ZP<)*[/C=59RV)K=V9HMIQFST=)-5>5AJG=R,R5N3Z=
M?8%E[6\1- 6HY=SK#9E8\10]W<R5%RK-V&+&1-.SUQ7U,,+_ !R*+*V(71E:
M<E=]VU_VU.PX;KTW]SI@LK3'MQD.B;?#W5\6NC:V*WZ3ZCJE@E3Y0LQNNH:\
MD]=,L'O&<<ZPQC@4+DLI?%%:+[.B9,GC,<1II8V1E_96R2Z$X^+(SMG;;8/U
M)/#C0TEB5WP]59ENIT-[>1V->2^2*4ZJ&?%M%N1AW@[PD@K'DR);DZ5PH.@B
M;0PM1J>Y^DXSV*\9]/I#E^8OC6WNX:'YYJNG3%*)RB'<W+=QS=]:I<W0B2Q6
MKJZER];.I9#7YR+/**F4=:UF%39IH4:=LJ+TSH7OG7TY#&&;PM4@1,H7;,SO
M"_;2O5D[EK;O.=W9.%E8Z3*V[%I^NG^J:R@,J;(?6\3A+%5L.@\@-2I&]A:F
MH_7;V[>_]FWIU#(>DO#Q2G1MI7Q/-KOZ/J"&=>M=>LG9](5'*H2SUGT\VU@@
M3LL9Q+3I#7\EG<$<5\72%,KTLB#RP*7EGTPG4;YVSL;L%)(YX1GJW^@/(]OT
M%8MLUERATMTU1$S:*$J"<UX16O0E*TI6=>)8Y$K):54+D,W@#<VSB*?"'EL+
MK'UCFTDX3*=C2,)]B@OS77B@K.HND'B[ZMZ!Z1KZMY#T!*NJ'WE.)R*OF:BW
M>]YNU_)TLD*]:DKC2WCX4^J\8=#XCF4?-G+QKJIU1ZXQ@O ="S>'BB&7EVL^
M5$]EVX;"ZN[:;>YV:0G*8;F4+[&;+O=[V)B;D9I$]&G:%&2-X,2;:%)2UWP6
MNN,*,&^TS(0OP;X]+*A_DN[L\CMVU1'J/S<YB*$T-331:*6V,,Y:]!#D%YWR
MO4M36V1B'R3H%75474F(46IBXLI&=JM-SMMKJ O#V9P!">OY;1]KI[6M3GV^
MN=#K")JB[*=UKM;)FF.VU'DD7LJ'/4<M>!63 9/&I0U-Z;?!:QJ,4(5J0E2D
M.),UVSN%7+^\(_//4D5I>O;^NGIJTZ^Y]HF9U;5S!++)2+G1NMF:ZY+/ZZD$
ML*84[_*>CXV3KKJR+51F61I]F_N&W7!IN-PY[YX=XH\V,3;2/L7KR&6'-H#0
MT"ZCE4#D-41]]ZSUYQ++2UW,;'D"BJ7620.>K&<KY-?'*#K8QL\-F^Z<W37!
MF^V0SWZJB -'1DKN^N.E>K*<@-E=$1OK.V^9:IL",1"G+-Z#CB!N;CID_O*.
M#[7*AC\V+:$ILGC;?*4C#(3DY>5278O'N\A#=?\ @[I6M[;IBP6#I#IT^ \[
M]7V1UW2G/CH[U2?4D#GMO8DRFPF5/NDJM#8+Y'71VE!YZ3#F^+%+7IZRTQA>
M%*O8\.FBW@FIRO*XI:$UCU%U! 9/R_8]^2[EZU6O-$.\SI6!=,;'J+>HQ*@E
M%)OD*G]9R%U6'.)6TE:G5[0N6VAR9>3J5H7@)EG7B-K>2J.?I/$>G.MJNN&B
MJ,EW,KE?T;G\*DEQ770]@KT[W-81;LALBNIJUN2URDQ&75$[MB%K<F9Q,R<@
M-(SH1@D.UXE\?DVX:FU-UK6MWV%(N-Z+XU645'ZYG$J;EZJ46^\7T]V;BTW*
M*L$*CS$V2"/P]<<SF.>BLS+BE6D$ZHTWP1IZT,XZK\8/-_874W*'6-M%R(^;
M<GD6(WL49;C6;$-LIDGS5HD3L=F(7!H7.#JVPMYUV=6G1(I1Y)7FF;&9,TVS
MH KM2'@YY@H+G/DGFV$3VWS(UR-VXP=X1V4NSA$%4PL6V(UF5I6EGL585$D[
M>MBR>/20AKQA$G1+O@FI)KA1ZM3-MPSSGOQ T5SE*^+I=%+)MI[7<0/_ &](
M:[32%5#MTDJ5=V2 V1601-,-L4;SCD\25&YT9/@=T6VA>/\ NLJ<_E 2-U_X
MX6#J[H'G_J!KZ,Z YQNKF>$V]#*NEU'+*VU^'+N4B.(I*ND+/9==V&Q20LIL
M8,IRT:E+LDSJIV,SI[\H@TH*XY\&?.\3@?/,=H.[^D.<[$YZK:WJB17U7[[6
M<CMBRX'T!+%%@7&ELU5:=7SV+.<BE5AK3W]&\M[6W.+&ZF^];S4^A9198;=Z
MW@3965=0JM6QUDLC:H/$V.(I7V</BJ4R^0)V-L3MGRS+9$OQ\4_R)WP1D]<K
M,QC*A29OOZ=?5Z<!J:J?P3</51S1V%RDD2V(_P!8]EV;O8TQ5.4F1(I?7!+"
MZ-KY3\.J60LS,W[QF,T&^-9:R):'E+#4:C;?W^RC3?8O(<&8>$.E[9K+I>,W
M[T=TY?-P]/1:D8-)NFI^\52DM>%0GG&P&FT:<B=>,\+JJ*U:R,['/6<MU<_?
M,"I0_KS3CEQIN^VF2PSS;Q'P\B]G"]X_UEUA"G6QI%1D_P"EHI!GVI8K'NE[
M4H2/-<:8+#FJYKJ0J6P!;.6UH*+ES7"'*,L<@*U]V8C+T_)D(WF/@UI"3V'B
M0-?1W44-J1+V]$_(4S<QQV05EBDF/I=DF**:R60-Y3A6"RP\Q6;NJ8[<]A,?
M]VIO/7*5"$A.=L5N4&P?K_D2#=EP>M8)/9)+(PVUAT)2'1C.LB!C04N7RJBI
MNAG4<9'++RU.Q&T?=W%#J2MP5H6IR3G/NC2]O9L I^B\/%$(8W6\9+LNW-T=
M9>3]X\J;.?NJAOQ*ZYWF3RN4GU\Y9Q$\%;5>4LEIY>I96I;M[LO3VK<[>K.0
MLYV_Q)#NX(744=D-C614,JH7H&N.F:CLNK-X=O*8C:=8:/:>/.'R=8$2F\0>
M6W='(E99R5:VGE[YVTV_^7V;!5IQ\.%$N46L>*G6E<.I%F^3=B\IKRX:*H3A
M>CNMA>XH^DPAN]D/PE+K92LB1/O"MR]W/&#3/2KU_L^D,MJ'Q4UW1O0RZXZV
MZ'Z6C=8*[OL[I(OE%LD\!;J++N>X25.9X]+%K=722WGN%K798:[)(HNE"B.M
M[OO\20ETQC4O 64O_CR"=#7EQ]?,IDTN99+QE9,YLV M# :S:,<G=Y[7+O6K
MD@E^CBTKUYK:C:7C<\C"(](;A1KKZM]M/;KD*1PWPF\X1&)<P0G:QKC>X_RY
M:W8=JQPA<Z15&IF"SM1DL:/V9'Y2N9HNVJT[2QMMEK<-!K9NA6$;E%;&G&YQ
MMZ@@R*_AYJ$C<270E9U+U/+H_P#[(+C\?$9;I&9125%".<K:=FE]+;(XBAU+
M1)*=,(J]-?Q6KVXZKW!V..VRXF*=-"="PFGHCPC\\=(_/WYV6I=#)]('CZK'
MQTNGS>60<OX.JJLMQBN)EFJ#Y2AKA[+"<'YA*3*C#/6VY1[[8+2:&>PS 9_>
MWA]YLZ.F?4$OLZ56HI_W3T-S]1<F;F%Z863:"Z\T3)18-6637CJ7'%#FUV"S
M3'*==[U7NM0;[I=2]DNQ.YI>X=<=XD8E)V*K$UO]6]17A,*O[:I7N5%.[!=:
MJ2*%DZHAG=&.'UVUPN"U?#:W@]7+DCJ8>YI&-H0+UR_;=48KR;OMD!?CI_FZ
MJ^O^?K9YFNUH5O=6W-#W"&RY$W+MVQU*2*]BE*)V97+30WY/?6!V2IUR$_8L
MW0I6F+VVTWUQG38-1$U\!54VP@OO>[>QNO[IF'0_-%6<KS"?3YSI3YPM%<4Y
M<T4N6$;19+%:<C# WNI#G#TZ18:>C4_*'Q*M8H]XO4F*0%NI!XIN;IPV>1F-
MV*X3N:Q#R8R"+2*ZXXM=&EN*B2^&P)A@T?/K5P:V5,O:E39O&T;J0<OW<-BW
M,G3;V9*QDK(1RH\/\!E](V)45V=6=:7B_P NFU)V/!;@E\HJZ.SB@9USD9H?
M3<OI!AKJJ8=6$7DS$L+^(=5JI@<#Y(I,,,<LJ,[_ ) ^LS\1\?L:JHO$["[)
M["G-Q0WL*$=PQ;I.62FKWN=Q2ZZ_:5T>C:*%UTLJS>@H36:)C<U!7S<:XFE0
M&'FY/.P:9^4!D-">)ZL^<KFUGM== ]():90V#;]L,'(IL@KM-037/[U+6[6,
MK<=FFMVVU)E#U#FYJG%LC3U)'!B:')28<F3:^W&N B6E_!_3%'6MRI.XWTKU
M._5[Q#8UKSKEGGR726M7.IZF:;DCTJ9)9 T)J*LFNP)+'T9LKW,:SWI[<7%L
M3IB4A!^J?)^IP7PO/C2 WUTOQCU#)I/,&B8\22.Z)-7C"Q&LND9E*R[ZSWJZ
M1$30MP:%SH<F:F;?XA%A"I1[84_E-V,T_L ->[;X*:3AT8K@FH^DNEZ7M.LG
M7J(IGO*!**;53QRKSKJPUMEVG6#VVSJI)G"%#$WR57A3'W EK(>V-63HI3K,
M'>W;(6^@GC?IR#]'H.D3IC:$ZD";A"/^/YTCMC2%OEK;+JJ8YV?/E,PFCVL:
M"Y9(K)DSDK.*<UIJ[5*I+-WSA-IOGU8"L4 \)U5P"FK<YT)ZIZWDM"3OE^W>
M1JVJ.22NLLQ"B*FN,ER(>3HMHP58P.]B3:+)7/=&P/4W5R58UMN,)=-MB_;D
M!RG3PD\].E<]DUJ;:ESEM/:O,O*/+E@+BU<'RX1:'<BUWM6\%D$.SM#LIBI-
M(VG;W[MLM+5I=U'_ -N21I_8 ;%*>H)?44YL>4XNBVIU&9M&:<C$8JN:.S,L
MKRH4U20LR'JEE:-C>R-R]J6V5OMHY2#*A0IT4.!6FY.I.F,Z9"AMZ>&ZA+[?
MNZ9#);,MYG5=\6+QE9-F$L2J&:)X@[<2G,1U>(8+APB*XPANE.6 K#SAPV7&
M[^O;X;=/^3V!=KM+E6&=O\M73RA8<AD\4A5WQ+,0D,BA9C45*&I#\J-SK\2S
M&/C8\-.JOW[;IK_?ICM/1MG^S[?9G 4\N[P\<U=#3F]IK9DJMA29?'-U"<YN
MB*/2!FCBB#%<W6"9:%5VM7C\BC^SVQV@P3;5.LT4FFJ4&<IM2]DNQ.YI9@3I
MR5P9%N7[ N&\)'<EQ],]&WNWP:.V+>]Z*H'B5GP:L42]# (!&H[5\&KBOXC%
M6+#HJ5'%H6DM2Y.*HU4L./,SI[L*]]8^'^K.R[?-GMR=$=)NE8N4ZJZQW?G0
MYUJF05RBE-2*VQ>P8K*8S.J9+>-$Q^0KV@D^0-L*E;$E>3=C-C-=<F[^T(ZF
MG@VI26VY);#2=)]1Q>"R;O.#>213S^R/U7;5*1U3%'IE>'J6ZFN%6J[%4LLS
MRQ%EJ6HY^,0I-C3#DI91^"3"0F&$^*" 5M>KI9U?=-]90BH'?H*<=5KN1HE8
M<9C=!K+ZLA"O331_<E#+"$-MO$ ?7)R/=3H2KDYT2V=C,G909*_N '1T-X=*
M&Y^:_&DTQ>R[=>"/%^JZ.5TZ8_*H9N;/=^EV>1LLNTLOY.B*#11HQIY*=LV_
M)6&W.NY>GOO?8]6,A87KG@N(]56'0=V-EP7'SI?O-RN=D5I=%&K8,5*B(?:K
M,BC]F0!^:+)@]APN01F5MS:F,UPI;-U+>N2E*4II1FNWK"D\0\#?-4+K6@JO
M;[AOYQ9N>(/Y$(%%'5]>X4ZR-_:_) TKV>UW"7NIT*URZOD,3+]MV)07H1ZC
M\>M=JK]N<9":IIXDZBD-(<,5A$+BNBJ;&\=\)00+F[HJ&?1@Z68UQ[:L6VI)
M<VRZ/6#7,UJF7-D_B+2G^4DJF/\ N]%:<HY-[C.GLR'0S7Q 05[2TN_P#K?L
M>H+UJ.B)IS([].16?0"2WA<-'V+(-I=+(G:#W9%93./J7+27&[NC,[-#:TN,
M>6[8V0&$Z%$Z%AU5F>%VEK#<+I.*OWI9D:.AN&HKPE<;.OE</L%9/H57[4[M
M$"M&13:R(1*K%76_'R'U48<XY=\)G,\SUJTYN/5KL' M'PDT+9KW8995\=-5
M_5/0D:I6,]<T/ )9 VNM>HR*%C$?AL.<9NH<ZZ>)W!G1_B\81-LE-AKS'?G
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MP'JG      %-/(U]GMW?_1IT_P#Z(S@!KV_#2?8@\(?X5MS_ )#VZ WJ
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MB*I;=J0S$S7XTL3MRR=Z5+=>+2#RF+9-B00O:]VC*U03ONLUT2J=LI\:XUR
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MTJK*2=1:&V#7<B7M"M,I6Q=_0ZNS/D_34[<S&^FV0O@
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M74G/53-#<P-!+-4VJW!6L<TCFV2]F7V?)V^_]O)>=OR@)'JWA7G6F^3I=Q3
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MZ-WTQ46C-()W3Z%>ZTQ@+_                    \K'GA^U7_#A?UHSO\
MS3S> ]4X      IIY&OL]N[_ .C3I_\ T1G #7M^&D^Q!X0_PK;G_(>W0&]0
M
M                                                          >5
MCSP_:K_APOZT9W_FGF\!ZIP     !33R-?9[=W_T:=/_ .B,X :]OPTGV(/"
M'^%;<_Y#VZ WJ
M
M           #RL>>'[5?\.%_6C._\T\W@/5.      *:>1K[/;N_^C3I_P#T
M1G #7M^&D^Q!X0_PK;G_ "'MT!O4
M
M                          'E8\\/VJ_X<+^M&=_YIYO >J<      4T\
MC7V>W=_]&G3_ /HC. &O;\-)]B#PA_A6W/\ D/;H#>H
M
M                                         /*QYX?M5_PX7]:,[_S3
MS> ]4X      IIY&OL]N[_Z-.G_]$9P U[?AI/L0>$/\*VY_R'MT!O4
M
M                                                     'E8\\/V
MJ_X<+^M&=_YIYO >J<      4T\C7V>W=_\ 1IT__HC. &O;\-)]B#PA_A6W
M/^0]N@-Z@
M
M       \K'GA^U7_  X7]:,[_P T\W@/5.      *:>1K[/;N_\ HTZ?_P!$
M9P U[?AI/L0>$/\ "MN?\A[= ;U
M
M                         !Y6//#]JO\ APOZT9W_ )IYO >J<      4
MT\C7V>W=_P#1IT__ *(S@!KV_#2?8@\(?X5MS_D/;H#>H
M
M                                           /*QYX?M5_PX7]:,[_
M ,T\W@/5.      *:>1K[/;N_P#HTZ?_ -$9P U[?AI/L0>$/\*VY_R'MT!O
M4
M                                                           '
ME8\\/VJ_X<+^M&=_YIYO >J<      4T\C7V>W=_]&G3_P#HC. &O;\-)]B#
MPA_A6W/^0]N@-Z@
M
M             \K'GA^U7_#A?UHSO_-/-X#U3@     "FGD:^SV[O_HTZ?\
M]$9P U[?AI/L0>$/\*VY_P A[= ;U
M
M                           !Y6//#]JO^'"_K1G?^:>;P'JG     1S;
M9UK)JZE"BD$<&<;3(1ISHBWV2>])86O5%."3=>B>%,?VU=4^RIHU4:)C"\XT
MT5[%9-_NL;@-5]V3_I>P.$O*P?>[7'X^PQCF*_XQ"61-4\QK60$*].4#GR6[
MG+Y!/)PQ3-@225Z5)$SFSJ5C<I-3FY(6&Z:^@L,!_#2?8@\(?X5MS_D/;H#>
MH
M                                                           /
M*QYX?M5_PX7]:,[_ ,T\W@/5.     AKH"$1&PZHDD8L"2(8K MU<7?)PY.Z
MPEOCZN'Q*6L4KDL<E*M0XM)!41ES,RG-3K@Q245NW+#M3/47G;38-3'0<2K$
MKF'R'22A[Y(M>F(]XXNGXA'X2QS.(V7&:C=WROY>]KX\W3=!.'>:D-*]*R%&
MM+(YMYZ9I3ZJ"T*_1'DAN2!Q_P -)]B#PA_A6W/^0]N@-Z@
M
M                                             \K'GA^U7_#A?UHS
MO_-/-X#U3@    (+Z39*^?J8EJ:T)EO7T/;U$6DI\U+RS;FQQ]B4P8)1#7(E
M!(FE_87U25,FA!@IL6(%Q#H;G5)LG.]]@O8-4M^+(G+>8O)#,M;??[CGJ+QQ
M]#1E:X2N#H:4>XQ%#J[L=R0(":HWKZ$29Y:WQU(/.UD"TU>C+.3;I46J;.RO
M!P?'\-)]B#PA_A6W/^0]N@-Z@
M
M                       \K'GA^U7_  X7]:,[_P T\W@/5.     BB[V2
MMI!64A06U(T\-A!1S ZK)B?+L0(R)/+)(VAXB,E;IEE<VXCSTR2Y"A4(3\G:
MX^,++USC?&V=-@U<=+LM3*.1_(G+8)T$V='OVGCWZ1CSC*7>XXU8TWBC496$
M[7D,*".P9 UQ&.11W5)_B%"OX?1P7K4Y6ANYA:<G!883^&D^Q!X0_P *VY_R
M'MT!O4
M
M    'E8\\/VJ_P"'"_K1G?\ FGF\!ZIP    %=.L,+#:&F:-%7C3:.SHMA3,
MKBC[7KW;#.6UO$\C#:\2M?6D85(9+."8 UJCG[#:WJ$RU3NVZZE'D;^P[0-9
MUGV#9]C>/WR+O-EUNEJ->7Q/U A(A*+G2T*KQOJV5K:321*UUAV$6A1R=1,T
M* IU(8$"3.8ZE6Z$*5J\[&Q^ Z?\-)]B#PA_A6W/^0]N@-Z@
M
M                                              \K'GA^U7_#A?UH
MSO\ S3S> ]4X      IIY&OL]N[_ .C3I_\ T1G #7M^&D^Q!X0_PK;G_(>W
M0&]0
M
M  >5CSP_:K_APOZT9W_FGF\!ZIP    $77+9!]3U\YS-%%7&;NI;M$HTP11K
M7MK0>^26=2]B@\:1*7MX-(:F)KV?I$GRL7*-LEI$N##?09MKJ7N&N'L7J-EL
MKDCONDW&#RNO+5C?CUZGG,]A$OV;,.D2*UK651QK^'5-*IQ99=&95NH.4-+X
MU*U3>J+2'D;Y)6IU25.$-?AI/L0>$/\ "MN?\A[= ;U
M
M                                         !Y6//#]JO\ APOZT9W_
M )IYO >J<    !BDRF+!!VMO=9(<:2A<Y7"H:DV)2F*]MWZ>RYEA49(W**UV
MVT)42%^3:;FY_LDZ;9WVSC77.0&HONNYHKT+RCU;M"T$MC'T?\A=DSQ,OF;
M:P)+@K WGB]JJS):[5(E3B8ZQY!/7!(;NG=]&M7JG,3+-4V2E*0TT,*_#2?8
M@\(?X5MS_D/;H#>H
M
M              /*QYX?M5_PX7]:,[_S3S> ]4X    "LO8I)Q_.-CZZ1:(S
M!$45&E<@:9O&(I-6))$D,QCRV82;2(3ER9XC)'V&1A.K=VI&X*2DYKHA3XSZ
M\^PO<-12B0O\E\<7=*TEZJZRJU;^#NS(]7LRA<3IR&R6KXPPQNQT,,JJ2,5.
M.!\;9R95 L-KYJU$I$)C4I2G:J]<&G%)D09W^&D^Q!X0_P *VY_R'MT!O4
M
M                                                        'E8\
M\/VJ_P"'"_K1G?\ FGF\!ZIP    %9>OT;"MH:0Z2<]U;6%-+*G<W&1M29F7
MXA&C1;4(=2+$>VN1-+['W:(UVK1EO;TE7)#4AS2@4:FY*T]1Q8:5#)C6\WXS
M\B+U##V&0NZ_Q\=GR%ZGD!L.$3)'),3 VY']2DO"-0*#Q>/U9:+7(CE^["P)
M%[RE1M*EQ+PJ.4%J5"@)Q_#2?8@\(?X5MS_D/;H#>H
M
M                                        /*QYX?M5_P .%_6C._\
M-/-X#U3@    ($Z2:C7ZM$C 7/':M]'ZSZ195<E8)'*8D_&-[G<D%2.,;9))
M#/3(&EUF:(W=H(,+W*(V,6XT4F%IMC=\!K+NRQ&IWXC\ET"8;G<+2C;/Q7T^
M]1G>;4FLK2<N:,BK[)B[O*&FP&UFA, N^"_++1NC+=VEB+.+/TTW4K5FBM,=
MN&-?AI/L0>$/\*VY_P A[= ;U
M
M                       !Y6//#]JO^'"_K1G?^:>;P'JG     5KZ\;#7
M;GV<(RH0GG_L5PI6<RJ&J4OWR4C;Y[&%Z^=I8]!GJ.3>1N-9H4QDB3-S,X(G
M5P/:]$Z0XL\PO; :GI^\H'KB+O=KAQ<6L*L*X\;O1T*AENQVE+/HTJ)9-K6;
MJ5M-)FVT99*EDY),2MR5T/7HMB]T!A&A*[<XT\G)89#^&D^Q!X0_PK;G_(>W
M0&]0
M
M  >5CSP_:K_APOZT9W_FGF\!ZIP    %5.V-6 SFR=$R0Q7JA4.U<)42<EOC
M#LW.LC56=#4\28)6US9YCD,<H#(I2:C02$AV<$* YD4JM#E!.N?>:AJ9M%K=
MV7GSR9I+)A=<5A:JGQI7TJ3PZA(S#8Y5+O RH%9I)$FE&\8G,U>G.P4SUOLF
M1Y=M&\A.W&'ZMOQ7J<=R0SW\-)]B#PA_A6W/^0]N@-Z@
M
M                                          \K'GA^U7_#A?UHSO\
MS3S> ]4X    "$>C8M/)K3$VBU;[(MI.])FI)LA7*&A#A]C.7YK,G$80ND@C
MTL8F9YE,*+<&Y"M6-JQ,C6*2CC-,:Z9WU#4Q9]#2VE^)?)3LT5HZTM3CWPET
M-KI YC,X)8$N>;(35%8>RF6(WB$)U^6>.D1TS5'LF6/*[*@_.NY"5!J29NM#
M^_AI/L0>$/\ "MN?\A[= ;U
M
M                     !Y6//#]JO\ APOZT9W_ )IYO >J<      4T\C7
MV>W=_P#1IT__ *(S@!KV_#2?8@\(?X5MS_D/;H#>H
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M<E4VO02:81&$.KE#=W\C.9"F3:8SJE-/)*V#^T%Y4.I^E_()X[X.LH28\O\
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MZIP     !33R-?9[=W_T:=/_ .B,X :]OPTGV(/"'^%;<_Y#VZ WJ
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M*^85]KN;0GAY2N$+>7H[!8]'#H&2H85"77$IT@A!SCJNU5:Z;GF8(]WKC7&
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MW-,0,*^5O3JJ:6LXQ/KL9ZO>8#:P
M     \K'GA^U7_#A?UHSO_-/-X#U3@     "FGD:^SV[O_HTZ?\ ]$9P U[?
MAI/L0>$/\*VY_P A[= ;U
M
M                   !Y6//#]JO^'"_K1G?^:>;P'JG      %:.TH!)[8X
MYZRJR$(/E6:65S1>\ B+9DS4GY1D\RJV51U@0>^W_L%?&.KB47ZL_DU]7MR
M\T/X>WRW>/6B?%S1?,71O3M9<W7SS<[VM7%G5G>S\164D0/*JWI[+DJAN2RC
MY/PZ(LMLC*)4>YSL:B7$G)U&A9FF,;!NT^NO\1WWC7(7[[87^L@#ZZ_Q'?>-
M<A?OMA?ZR /KK_$=]XUR%^^V%_K( ^NO\1WWC7(7[[87^L@#ZZ_Q'?>-<A?O
MMA?ZR /KK_$=]XUR%^^V%_K( ^NO\1WWC7(7[[87^L@#ZZ_Q'?>-<A?OMA?Z
MR /KK_$=]XUR%^^V%_K( ^NO\1WWC7(7[[87^L@#ZZ_Q'?>-<A?OMA?ZR /K
MK_$=]XUR%^^V%_K( ^NO\1WWC7(7[[87^L@#ZZ_Q'?>-<A?OMA?ZR /KK_$=
M]XUR%^^V%_K( ^NO\1WWC7(7[[87^L@#ZZ_Q'?>-<A?OMA?ZR /KK_$=]XUR
M%^^V%_K( ^NO\1WWC7(7[[87^L@#ZZ_Q'?>-<A?OMA?ZR /KK_$=]XUR%^^V
M%_K( ^NO\1WWC7(7[[87^L@#ZZ_Q'?>-<A?OMA?ZR /KK_$=]XUR%^^V%_K(
M ^NO\1WWC7(7[[87^L@#ZZ_Q'?>-<A?OMA?ZR /KK_$=]XUR%^^V%_K( ^NO
M\1WWC7(7[[87^L@#ZZ_Q'?>-<A?OMA?ZR /KK_$=]XUR%^^V%_K( ^NO\1WW
MC7(7[[87^L@#ZZ_Q'?>-<A?OMA?ZR /KK_$=]XUR%^^V%_K( ^NO\1WWC7(7
M[[87^L@#ZZ_Q'?>-<A?OMA?ZR /KK_$=]XUR%^^V%_K( ^NO\1WWC7(7[[87
M^L@#ZZ_Q'?>-<A?OMA?ZR /KK_$=]XUR%^^V%_K( ^NO\1WWC7(7[[87^L@#
MZZ_Q'?>-<A?OMA?ZR /KK_$=]XUR%^^V%_K( ^NO\1WWC7(7[[87^L@#ZZ_Q
M'?>-<A?OMA?ZR /KK_$=]XUR%^^V%_K( ^NO\1WWC7(7[[87^L@#ZZ_Q'?>-
M<A?OMA?ZR /KK_$=]XUR%^^V%_K( ^NO\1WWC7(7[[87^L@#ZZ_Q'?>-<A?O
MMA?ZR /KK_$=]XUR%^^V%_K( ^NO\1WWC7(7[[87^L@#ZZ_Q'?>-<A?OMA?Z
MR /KK_$=]XUR%^^V%_K( ^NO\1WWC7(7[[87^L@#ZZ_Q'?>-<A?OMA?ZR /K
MK_$=]XUR%^^V%_K( ^NO\1WWC7(7[[87^L@#ZZ_Q'?>-<A?OMA?ZR /KK_$=
M]XUR%^^V%_K( ^NO\1WWC7(7[[87^L@#ZZ_Q'?>-<A?OMA?ZR /KK_$=]XUR
M%^^V%_K( ^NO\1WWC7(7[[87^L@#ZZ_Q'?>-<A?OMA?ZR /KK_$=]XUR%^^V
M%_K( ^NO\1WWC7(7[[87^L@#ZZ_Q'?>-<A?OMA?ZR /KK_$=]XUR%^^V%_K(
M ^NO\1WWC7(7[[87^L@#ZZ_Q'?>-<A?OMA?ZR /KK_$=]XUR%^^V%_K( ^NO
M\1WWC7(7[[87^L@#ZZ_Q'?>-<A?OMA?ZR /KK_$=]XUR%^^V%_K( ^NO\1WW
MC7(7[[87^L@#ZZ_Q'?>-<A?OMA?ZR /KK_$=]XUR%^^V%_K( ^NO\1WWC7(7
M[[87^L@#ZZ_Q'?>-<A?OMA?ZR /KK_$=]XUR%^^V%_K( ^NO\1WWC7(7[[87
M^L@#ZZ_Q'?>-<A?OMA?ZR /KK_$=]XUR%^^V%_K( ^NO\1WWC7(7[[87^L@#
MZZ_Q'?>-<A?OMA?ZR /KK_$=]XUR%^^V%_K( ^NO\1WWC7(7[[87^L@#ZZ_Q
M'?>-<A?OMA?ZR : N]NO>?/)CYKO"#4W"MCL72RWE^XYU?UWS&KSC)'7D)@F
M'"KW\TU9,T96[(H6(VRN5>5&"C=RB%*Q$FVW^)5:%8#V?        UZ7EXFO
M&KTK83M;-Y\3<]6-9<@SIO(9P]5^U$2.1GEZXTT6R)S:]6\]^<M2M==/BE>3
ME'N]==/7Z=<8P$/_ %#WAW^[QYL_8S?\_ /J'O#O]WCS9^QF_P"?@'U#WAW^
M[QYL_8S?\_ /J'O#O]WCS9^QF_Y^ ?4/>'?[O'FS]C-_S\ ^H>\._P!WCS9^
MQF_Y^ ?4/>'?[O'FS]C-_P _ /J'O#O]WCS9^QF_Y^ ?4/>'?[O'FS]C-_S\
M ^H>\._W>/-G[&;_ )^ ?4/>'?[O'FS]C-_S\ ^H>\._W>/-G[&;_GX!]0]X
M=_N\>;/V,W_/P#ZA[P[_ '>/-G[&;_GX!]0]X=_N\>;/V,W_ #\ ^H>\._W>
M/-G[&;_GX!]0]X=_N\>;/V,W_/P#ZA[P[_=X\V?L9O\ GX!]0]X=_N\>;/V,
MW_/P#ZA[P[_=X\V?L9O^?@'U#WAW^[QYL_8S?\_ /J'O#O\ =X\V?L9O^?@'
MU#WAW^[QYL_8S?\ /P#ZA[P[_=X\V?L9O^?@'U#WAW^[QYL_8S?\_ /J'O#O
M]WCS9^QF_P"?@'U#WAW^[QYL_8S?\_ /J'O#O]WCS9^QF_Y^ ?4/>'?[O'FS
M]C-_S\ ^H>\._P!WCS9^QF_Y^ ?4/>'?[O'FS]C-_P _ /J'O#O]WCS9^QF_
MY^ ?4/>'?[O'FS]C-_S\ ^H>\._W>/-G[&;_ )^ ?4/>'?[O'FS]C-_S\ ^H
M>\._W>/-G[&;_GX!]0]X=_N\>;/V,W_/P#ZA[P[_ '>/-G[&;_GX!]0]X=_N
M\>;/V,W_ #\ ^H>\._W>/-G[&;_GX!]0]X=_N\>;/V,W_/P#ZA[P[_=X\V?L
M9O\ GX!]0]X=_N\>;/V,W_/P#ZA[P[_=X\V?L9O^?@'U#WAW^[QYL_8S?\_
M/J'O#O\ =X\V?L9O^?@'U#WAW^[QYL_8S?\ /P#ZA[P[_=X\V?L9O^?@'U#W
MAW^[QYL_8S?\_ /J'O#O]WCS9^QF_P"?@'U#WAW^[QYL_8S?\_ /J'O#O]WC
MS9^QF_Y^ ?4/>'?[O'FS]C-_S\ ^H>\._P!WCS9^QF_Y^ ?4/>'?[O'FS]C-
M_P _ /J'O#O]WCS9^QF_Y^ ?4/>'?[O'FS]C-_S\ ^H>\._W>/-G[&;_ )^
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MI8WN1%)=L[HTCT_ED[OCFWHC-MMB$QRC=.1OMMMIIKG;;.0M<
M
M
M
M
+           /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
